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Abstract 
Regulation of mtDNA content is critical to normal human health and is often abnormal 
in mitochondrial diseases. Only a proportion of a female’s mtDNA is used to populate 
the oocytes she forms during embryogenesis. This mtDNA bottleneck can cause rapid 
shifts in heteroplasmy levels between generations in families with mtDNA mutations. 
The heteroplasmy levels of several mtDNA mutations were analysed from mother-child 
pairs using previously validated pyrosequencing assays. Analysis of the shifts in 
heteroplasmy caused by the mtDNA bottleneck reveals that the inheritance of the 
pathogenic tRNA mutations m.3243A>G and m.8344A>G do not show selection bias. 
However, the distribution of m.8993T>G (in MT-ATP6) in offspring suggests this 
mutation is selected for during the mtDNA bottleneck. This finding is in agreement with 
meta-analysis performed on previously published data, which also reveals biased 
inheritance of the LHON mutations m.11778G>A and m.3460G>A, in Complex I 
genes. Selection for these mutations explains the higher prevalence of homoplasmy, as 
fixation can occur within fewer generations.  
Crucial to formation of the mtDNA bottleneck is the dramatic increase in mtDNA 
replication rate that allows primordial germ cells (PGCs) to repopulate their 
mitochondrial genomes. Gene expression analysis during pre-implantation embryonic 
development has not revealed any other biological processes associated with regulation 
of mtDNA copy number. Upregulation of Lrpprc correlates with the expression of 
transcription factors as pre-implantation development progresses at this stage. The 
limited number of PGCs in the early stages of post-implantation development prevented 
sufficient quantity of high-quality RNA to be isolated for use with gene expression 
analysis.  
The reduction of mtDNA copy number observed during the mtDNA bottleneck was 
modelled in myoblasts and fibroblasts, using ddC, a reverse transcriptase inhibitor. 
Although some gene expression changes were induced during repopulation of mtDNA, 
these were limited to below 3-fold change. Forcing reliance on oxidative 
phosphorylation through culture with galactose media could not increase the rate of 
mtDNA replication or induce greater gene expression responses.  
Ragged-red fibres (RRFs) are a common hallmark of many mitochondrial diseases, 
caused by proliferation of mitochondria in the subsarcolemmal region of muscle tissue. 
Multiplex immunohistochemistry allowed fibre typing and identification of RRFs in 
muscle tissue from a patient with the m.8344A>G mutation. A novel technique was 
iii 
established to ensure extraction of intact high-quality RNA from laser-microdissected 
muscle fibres. The RNA was used in a pilot microarray experiment to study the 
differences not only between control and patient tissue, but specifically within RRF, and 
has identified a multitude of potential signalling pathways involved in mitochondrial 
biogenesis and formation of RRFs.  
This thesis reveals the complexity of mtDNA copy number regulation and, the critical 
involvement it has to human health and the inheritance and pathogenicity of 
mitochondrial diseases.  
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1.1 An Introduction to Mitochondria 
1.1.1 The origins of mitochondria 
The prokaryotic ancestors of eukaryotes 
Mitochondria in eukaryotes are believed to be the result of an endosymbiosis between 
an oxidative bacterial cell and a primitive glycolytic cell (Margulis, 1971). 
Identification of mitochondrial heat shock protein-60 (Hsp60; HSPD1) genes in the 
nuclear genomes of seemingly amitochondriate ‘archezoa’ (Clark and Roger, 1995, 
Roger, 1999) and the identification of anaerobic homologue organelles, 
hydrogenosomes (Muller, 1993) and mitosomes (Tovar et al., 1999), disproved the 
concept of an amitochondriate lineage of eukaryotes.  
Phylogenetic analysis of both protein-coding and ribosomal RNA genes suggest the 
ancestor of mitochondria to be an α-proteobacteria (Gray, 1998). The host of the 
endosymbiotic event is more difficult to determine (Baldauf et al., 1996, Harris et al., 
2003, Woese et al., 1990). Reanalysis of phylogenetic trees, constructed from rRNA 
genes, using more appropriate models (accounting for composition heterogenetity), 
support the ‘eocyte hypothesis’, and propose Crenarchaea as the archaebacterial host of 
the endosymbiotic event (Cox et al., 2008).  
Phylogenetic sequence comparisons between endosymbiont-derived eukaryotic genes 
and eubacteria date the endosymbiotic event to approximately 1-2 billion years ago 
(Feng et al., 1997, Sicheritz-Ponten et al., 1998).  
From the endosymbiotic event to modern eukaryotic mitochondria 
The nuclear and mitochondrial genomes (nDNA and mtDNA respectively) in modern 
eukaryotes are highly diversified, and in most cases vary widely from that of the 
ancestral host or endosymbiont. This is a combination of genetic drift, reductive 
evolution, and gene transfer from the mitochondria to the nucleus.  
Due to the uniparental inheritance of mtDNA and the bottleneck created during 
embryogenesis, mtDNA transmission shares many characteristics with the genomes of 
small asexual populations of intracellular obligates. Evolution of the genome is strongly 
affected by drift, Muller’s ratchet and gene redundancy caused by the presence of the 
host genome leading to purifying selection (Andersson and Kurland, 1998).  
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The key difference between parasitic and organellar genome reduction is that organelles 
often still require the products of the genes on their genomes. However, since mtDNA 
has a high mutation rate, no recombination and is uniparentally inherited, it is 
advantageous to translocate genes to the more stable nDNA to improve cellular fitness 
(Timmis et al., 2004). This may be achieved through incorporation of nucleic acid 
fragments into the nuclear genome, as a by-product of autophagy, followed by purifying 
selection (Berg and Kurland, 2000).  
The reductive evolution of mtDNA in animals appears to have stopped, since all animal 
mtDNA contain the same 37 genes, with a few exceptions including: nematodes, 
bivalves and cnidarians (Boore, 1999). However, analysis of human nuclear DNA 
reveals fragments of mtDNA sequence (known as nuclear mitochondrial sequences, 
NUMTS) are being continually integrated into the nuclear genome, presumably by the 
same process, but without redundancy and removal of the gene encoded on the mtDNA 
(Mourier et al., 2001).  
Alongside transfer of genes to the nucleus, the nDNA evolved novel mitochondrial 
genes to complement the presence of the mitochondria. Studies of yeast mitochondrial 
proteins found that only half had prokaryotic homologues, with most mitochondrial 
regulatory and transport proteins evolving during development of eukaryotic lineages 
(Karlberg et al., 2000). 
The benefits of the endosymbiotic event 
Arguably the largest benefit of the endosymbiotic event and acquiring mitochondria is a 
200,000-fold increase in nuclear genome size compared to bacteria. Since expression of 
genes as proteins is highly energy-demanding, the development of a mitochondria 
allows cells a more diverse and highly expressed proteome in eukaryotes (Lane and 
Martin, 2010). This may explain why complex, multicellular life has been able to evolve 
in several eukaryotic groups, but never in prokaryotic lineages (Rokas, 2008).  
1.1.2  Mitochondrial morphology and structure 
The diversity of mitochondrial organelles 
Mitochondria are diverse across eukaryotic lineages. The majority are aerobic 
mitochondria which, through consumption of oxygen and oxidative phosphorylation, 
efficiently produce ATP from supplied substrates. However, many eukaryotes live in 
Chapter 1  
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low oxygen or oxygen-free environments and have evolved anaerobic mitochondria. 
These systems still have an electron transport chain (ETC), but use substrates other than 
oxygen as their final electron acceptor, and consequently do not have H2O as their end 
products. Some anaerobic mitochondria use environmentally available compounds as 
electron acceptors, such as NO3
-
, but some others use endogenously produced products 
such as fumarate. However, anaerobic respiration is much less efficient, producing only 
~5 mol ATP per 1 mol glucose (compared to 36 mol using oxygen) (Tielens et al., 
2002). Hydrogenosomes are highly reduced mitochondrial homologues, found in some 
intracellular obligate parasites, which do not undergo oxidative phosphorylation and 
usually do not contain DNA. Instead, pyruvate:ferredoxin oxidoreductase (PFO) 
metabolises pyruvate to generate electrons, which are transferred to hydrogenase by 
ferredoxin, producing hydrogen and a small amount of ATP (~4 mol) (Embley et al., 
2003). Mitosomes are even further reduced, have never been found with a genome, and 
are only 0.2-0.5 µm in diameter. The ATP generating processes in eukaryotes 
containing mitosomes are situated in the cytosol, not in the mitosome itself, and ATP 
production is very low (~2-4 mol) (Aguilera et al., 2008).  
Aerobic mitochondrial structure in mammals 
When mitochondria were first visualised by electron microscopy they were described as 
small, discrete vesicles with two membranes: the smooth outer membrane (OM) and 
invaginated inner membrane (IM), forming cristae. This compartmentalised the 
mitochondria into an intermembrane space (IMS), between the membranes, and the 
internal matrix contained by the IM (Palade, 1952). This led to the ‘Baffle’ model of 
mitochondrial structure, whereby the cristae of the inner membrane have wide openings 
into the intermembrane space, and stretch across the width of the matrix. However, the 
development of electron microscopic tomography allowed imaging of much thicker 
sections of tissue, at multiple angles. The cristae were more tubular in nature, with 
narrow joints to the inner membrane, called cristae junctions, suggesting that the cristae 
form separate pockets from the intermembrane space (Mannella et al., 1994, Perkins et 
al., 1997). Additionally, fluorescent microscope studies of human cultured cells 
revealed mitochondria as dynamic tubule networks, not discrete organelles (Bereiter-
Hahn and Voth, 1994) (Figure 1.1A-C). 
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The IM is the site of oxidative phosphorylation (OXPHOS), but is also the site of many 
other components essential for mitochondrial function, including: mtDNA-containing 
nucleoids, mitoribosomes and the protein and solute transport machinery (Gilkerson et 
al., 2003, Wang and Bogenhagen, 2006) (Figure 1.1D). 
 
Figure 1.1 Mitochondrial structure and membrane components. (A) Computer 
generated 3D tomogram of a mitochondrion from chick cerebellum and (B) a single 
cross-section through the 3D tomogram allowing measurement of membrane 
dimensions (Adapted from Frey and Mannella, 2000). (C) Mitochondrial network 
morphology in wild-type HeLa cells (Benard et al., 2007). (D) Major components of the 
mitochondrial outer membrane (OM) and inner membrane (IM) including (from left to 
right) the mitochondrial permeability transition pore (PTP), components of the 
OXPHOS system, protein import channels, nucleoids (comprising mtDNA and 
supporting proteins) and mitoribosomes involved in replication, transcription and 
translation.  
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1.1.3 An overview of mitochondrial functions 
Energy metabolism is the primary function of mitochondria, but they also play a critical 
role in a number of other cellular processes.  
Adaptive thermogenesis 
In response to certain stimuli, such as cold temperatures or overfeeding, mitochondrial 
can increase energy expenditure, in a process known as adaptive thermogenesis. This is 
achieved by uncoupling the ETC from ATP synthesis, and dissipating the excess 
cellular energy as heat (Lowell and Spiegelman, 2000). In small mammals, this is 
mainly achieved by brown fat tissue; however, in humans this can be achieved in 
skeletal muscle (Wijers et al., 2008). Adaptive thermogenesis is closely linked to the 
regulation of mitochondrial biogenesis and may present a therapeutic target to tackle 
obesity.  
Calcium homeostasis 
Cytosolic calcium ions (Ca
2+
) must be maintained at extremely low concentrations to 
avoid toxicity. This achieved by both the endoplasmic reticulum (ER) and the 
mitochondria. Inositol 1,4,5-trisphosphate (IP3) gated channels in the ER release Ca
2+ 
in 
the vicinity of mitochondria, creating microdomains of high Ca
2+
 concentration, and 
stimulating uptake by mitochondria (Rizzuto et al., 1993). Calcium homeostasis is 
important to the correct functioning of mitochondria. Intramitochondrial Ca
2+ 
levels can 
alter the activity of key enzymes in the tricarboxylic (TCA) cycle (McCormack et al., 
1990), and is essential for maintenance of cellular bioenergetics in response to nutrient 
deprivation (Cardenas et al., 2010). Apoptosis and necrosis are also regulated through 
alterations in mitochondrial Ca
2+
 concentrations (Chami et al., 2004). 
Apoptosis 
The BCL-2 family of proteins regulate apoptosis ultimately through regulation of the 
permeability of the OM (Oltvai et al., 1993). If apoptosis is triggered, OM permeability 
allows the release of intermembrane space proteins into the cytosol, including 
cytochrome c and apoptotic protease activation factor 1 (encoded by APAF1), forming 
the ‘apoptosome’. This subsequently activates the caspase cascade, responsible for the 
organised destruction of cellular content (Spierings et al., 2005). Importantly, many of 
the proteins central to apoptosis regulation also have key functional roles in 
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mitochondrial bioenergetics, such as BCL2 involvement in complex IV assembly, and 
apoptosis inducing factor 1 (AIFM1) as a protector from oxidative stress (Kilbride and 
Prehn, 2012).  
Iron-sulphur (Fe-S) cluster and haem biogenesis 
Several components of the ETC require Fe-S clusters or haem prosthetic groups to form 
redox centres within the complex structures. In addition, other mitochondrial proteins 
also require Fe-S clusters, such as mitochondrial aconitase (ACO2), participating in the 
TCA cycle, and glutaredoxin 2 (GLRX2), involved in redox signalling and oxidative 
stress. Furthermore, Fe-S clusters produced in the mitochondria are essential for many 
nuclear and cytosolic proteins such as ATP-binding cassette, sub-family E, member 1 
(ABCE1), involved in ribosome assembly and xanthine dehydrogenase (XDH), 
functioning in purine metabolism (Gille and Reichmann, 2011). Mitochondrial Fe-S 
biogenesis also functions as a sensor for intracellular iron acquisition and distribution 
(Lill et al., 2012). The importance of Fe-S cluster biogenesis can be highlighted by the 
existence of mitosomes, ancient mitochondrial homologues that have lost all major 
functions except Fe-S cluster formation (Tovar et al., 2003). 
1.2 Energy metabolism  
1.2.1  Metabolic pathways prior to oxidative phosphorylation 
OXPHOS requires specific substrates first generated by downstream metabolic 
processes. Glycolysis is a 10-step cytosolic process, which converts one molecule of 
glucose to two molecules of pyruvate (Figure 1.2). The first phase consumes ATP to 
convert glucose into two glyceraldehyde-3-phosphate (G3P) molecules. The second 
phase, converts the G3P into pyruvate, producing both a small amount of ATP and 
NADH. 
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Figure 1.2 An overview of glycolysis. The metabolic pathway converting glucose to 
pyruvate. Many other carbohydrates can enter glycolysis at alternative stages to 
contribute to the TCA cycle and ultimately oxidative phosphorylation. From each 
molecule of glucose there is a net gain of two NADH and two ATP molecules. 
The pyruvate is then transported to the mitochondria, where pyruvate dehydrogenase 
converts it to acetyl-CoA, which then partakes in the tricarboxylic acid (TCA) cycle 
(Figure 1.3). The main products of the TCA cycle are NADH, utilised by Complex I 
(NADH dehydrogenase) and FADH2, used by Complex II (Succinate dehydrogenase; 
also partaking in the TCA cycle).  
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Figure 1.3 An overview of pyruvate dehydrogenase and the TCA cycle. The 
metabolic pathway converting pyruvate generated from glycolysis into acetyl-CoA, 
which is utilised by the TCA cycle to produce a net gain of eight NADH and two 
FADH2 molecules for input into the ETC. 
Although the initial step of glycolysis requires glucose, other nutrients enter these 
pathways at various points to contribute to energy production in mitochondria. By 
various processes nutrient components can be converted to substrates of glycolysis or 
the TCA cycle (Table 1.1).  
Chapter 1  
11 
 
Table 1.1. Alternative nutrient entry points into glycolysis and the TCA cycle. The 
carbohydrate, lipid and protein components that can be metabolised into substrates of 
either glycolysis or the TCA.  
Nutrient Molecule Entry Substrate 
Carbohydrate Components Glycogen/Galactose Glucose-6-phosphate 
 
Fructose/Mannose Fructose-6-phosphate 
Lipid Components Glycerol Dihydroxyacetone phosphate 
 
Fatty Acids Acetyl-CoA 
Protein Components* L, K, F, W, Y, I, T Pyruvate 
 
A, C, G, S, T, T,W Acetyl-CoA 
 
D, N Oxaloacetate 
 
D, N, Y, F Fumarate 
 
I, M, V, T Succinyl-CoA 
 
Q, R, P, H, E a-Ketoglutarate 
*Amino acid symbols listed.  
Amino acids are an alternative source of cellular energy. Glucogenic amino acids can be 
converted to a gluconeogenic or TCA cycle intermediates and can be used to synthesise 
glucose. Ketogenic amino acids can only be converted to acetyl-CoA, acetoacetyl-CoA 
or acetoacetate but cannot be used to synthesise glucose.  
Many lipid molecules consist of a glycerol with three bound fatty acid chains 
(triglyceride). β-oxidation is the process whereby fatty acids are shortened to acetyl-
CoA to be used in the TCA cycle as a source of energy. Long-chain fatty acids are 
activated in the cytosol by conversion to acyl-CoA molecules which are reacted with 
carnitine to be transported into the mitochondria. Short-chain acyl-CoA molecules can 
diffuse across the membrane. In a 4-step process, an acetyl-coA molecule is removed 
from the acyl-CoA chain; this is repeated until the final products are two acetyl-CoA 
molecules (Wanders et al., 2010). This process produces NADH and FADH2 molecules 
used by the entry point enzymes of the electron transport chain (Figure 1.4A). Glycerol 
is phosphorylated to glycerol-3-phosphate which can be converted to DHAP by 
mitochondrial glycerol-3-phosphate dehydrogenase, producing FADH2 and ubiquinol 
(QH2) (Guo et al., 1993, MacDonald, 1981) (Figure 1.4B).  
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Figure 1.4 Lipid metabolism in mitochondria. The metabolism of lipid components 
(fatty acids and glycerol) generating NADH, FADH2 and QH2 which contribute to the 
ETC. 
1.2.2 Oxidative Phosphorylation (OXPHOS) 
The OXPHOS system uses the reducing capacity of the coenzymes NADH and FADH2, 
produced during glycolysis, the TCA cycle and β-oxidation of fatty acids, to pass 
electrons between redox centres in the ETC complexes. This translocates H
+
 ions from 
the matrix to the IMS and creates an electric potential (Δψ) and a chemical (and pH) 
potential (ΔµH
+
) gradient. This gradient is then utilised to induce conformational 
changes in Complex V (ATP synthase), catalysing the conversion of ADP and Pi to 
ATP (Figure 1.5).  
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Figure 1.5 An overview of the OXPHOS system. Glycolysis and the TCA cycle 
produce substrates utilised by the ETC to move H
+ 
ions from the matrix to the 
intermembrane space. The electrochemical gradient (potential) drives ATP synthase 
(CV) to convert ADP and Pi into ATP. 
Complex I 
The coenzyme NADH is produced at many stages during glycolysis and the TCA cycle. 
Complex I, NADH:ubiquinone reductase (or NADH dehydrogenase), oxidises NADH 
to NAD
+
 and transfers the H
+
 ions and electrons (e
-
) to the first redox prosthetic group, 
flavine mononucleotide (FMN). The electrons are then passed from FMNH2 along a 
chain of seven iron-sulphur (Fe-S) clusters and are finally used to reduce ubiquinone 
(CoQ/Q) to ubiquinol (QH2). In addition, this process is predicted to induce an indirect 
conformational change leading to the translocation of four protons (H
+
) from the matrix 
to the intermembrane space (Friedrich, 2001, Galkin et al., 1999). 
To date, the most in-depth study of complex I is from bovine heart mitochondria, which 
identified 46 protein subunits (Carroll et al., 2003). The complex core comprises 14 
subunits containing all the critical redox centres (Weidner et al., 1993). There are two 
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distinct groups of core proteins: seven hydrophobic proteins, containing transmembrane 
domains, encoded by mtDNA; and seven hydrophilic proteins, containing binding 
motifs for redox prosthetic groups, encoded by nDNA (Fearnley and Walker, 1992). 
Complex I contains an additional 32 accessory subunits. The exact function of the 
additional subunits remains unclear, though it has been proposed that some may have a 
role in the assembly of the complex, iron-sulphur cluster formation, rhodanese activity 
(cyanide detoxification), proapoptoic function and fatty acid metabolism (Brandt, 2006). 
Complex II 
Succinate dehydrogenase (SDH; complex II) is part of both the TCA cycle and the ETC. 
During the TCA cycle, SDH oxidises succinate to fumarate, and reduces FAD to 
FADH2. In the ETC, it oxidises FADH2, passing electrons through three Fe-S clusters 
and reducing Q to QH2 (Rutter et al., 2010).  
SDH is comprised of four subunits, all encoded by nDNA. The enzyme has a 
hydrophilic domain (protruding into the matrix), containing the catalytic core of the 
enzyme and a hydrophobic domain, embedded in the inner membrane (protruding 
slightly into the intermembrane space) (Sun et al., 2005).  
Alternative entry to the ETC 
Each cycle of β-oxidation of fatty acids removes two carbon units (acetyl-CoA) from 
long-chain acyl-CoA esters, ultimately resulting in two acetyl-CoA molecules. Each 
step in the process is catalysed by a FAD-containing dehydrogenase (Watmough and 
Frerman, 2010). There are nine acyl-CoA dehydrogenases and two enzymes of 
mitochondrial one-carbon metabolism (Hoskins and Mackenzie, 1961), which utilise the 
electron transfer flavoprotein (ETF) as an electron acceptor entry point to the respiratory 
chain (Crane and Beinert, 1956). ETF is then reduced by electron transfer flavoprotein-
ubiquinone oxidoreductase (ETF-QO), which transfers electrons via a FAD and Fe-S 
cluster domain to ultimately reduce Q to QH2 (Ruzicka and Beinert, 1977). 
NADH produced by glycolysis cannot be transported into the mitochondria from the 
cytosol. The glycerol phosphate shuttle is a system allowing this NADH to contribute to 
oxidative phosphorylation through a paired redox reaction (Shen et al., 2006). Cytosolic 
glycerol-3-phosphate dehydrogenase (cGPDH) converts dihydroxyacetone phosphate 
(DHAP) to glycerol-3-phosphate (glycerol-3-P) and oxidises one molecule of NADH to 
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NAD
+
. The DHAP is then converted back to glycerol-3-P by mitochondrial glycerol-3-
phosphate dehydrogenase (mGPDH), embedded in the outer surface of the inner 
mitochondrial membrane (Chowdhury et al., 2005, Klingenberg, 1970). This conversion 
also reduces a bound FAD group to FADH2, which is sequentially used to reduce Q to 
QH2.  
Complex III 
Coenzyme Q: cytochrome c - oxidoreductase is the third complex of the respiratory 
chain. It has 11 subunits of both mitochondrial and nuclear genetic origin (Iwata et al., 
1998). Initially, it binds and oxidises two QH2 molecules, produced by either Complex 
I, Complex II, ETF-QO or mGPDH, back to Q and releases two H
+
 ions into the 
intermembrane space. An electron is transferred to cytochrome c1 and then onto 
cytochrome c, and another single electron reduces a Q to ubisemiquinone (QH). After a 
further round of reactions, another cytochrome c is reduced, and the QH from the 
previous reactions is fully reduced to QH2 and released back into the pool. The overall 
reaction results in two molecules of cytochrome c reduced, to be used by Complex IV, 
two H
+ 
ions picked up from the matrix and  four H
+
 ions released into the 
intermembrane space, contributing to the proton gradient required for ATP synthase 
function (Crofts, 2004).  
Complex IV 
Cytochrome c oxidase is Complex IV of the respiratory chain. It has 13 subunits, three 
of which are encoded by mtDNA. It accepts an electron at a CuA site from each of the 
four cytochrome c molecules reduced by Complex III. These electrons are then 
transferred through a cytochrome a and an a3-CuB binuclear centre to a molecule of 
oxygen, which binds four H
+
 and forms two molecules of H2O. In the process,  four H
+
 
ions are transported across the mitochondrial membrane to contribute to generation of 
the proton gradient (Babcock and Wikstrom, 1992, Tsukihara et al., 1995). 
Supercomplexes 
The original concept of the organisation of mitochondrial complexes was the liquid state 
model, whereby each complex was free to move independently throughout the 
mitochondrial inner membrane, with reactions occurring by random collisions during 
diffusion (Hackenbrock et al., 1986). However, blue native polyacrylamide 
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electrophoresis (BN-PAGE), allowed isolation and characterisation of mitochondrial 
supercomplexes (respirasomes). These supercomplexes were found, existing in different 
combinations of Complex I, Complex III and Complex IV monomers (Cruciat et al., 
2000, Schagger et al., 2004, Schagger and Pfeiffer, 2000).  
Advancement in electron microscopy allowed mapping of first the 2D and 3D structure 
of mitochondrial supercomplexes, confirming that they were not simply an artefact of 
the solubilisation process but function in substrate channelling between complexes 
(Schafer et al., 2007, Schafer et al., 2006).  
Complex V 
Complex V utilises the electrochemical (H
+
) gradient generated by the ETC to drive 
synthesis of ATP from ADP and Pi. The complex is composed of two regions, F0, 
embedded in the inner mitochondrial membrane and F1, which protrudes in the matrix 
of the mitochondria. The F0 portion forms a ‘proton pore’, where a ring of c-subunits 
translocates H
+
 ions across the inner membrane, and rotates in the process of doing so. 
Subunit γ is an asymmetric stalk attached to the c-ring, and protrudes into the centre of 
the α1β1 subunit trimer that forms the catalytic site of the F1 portion. The catalytic core 
is stabilised by other subunits of ATP synthase. As the stalk rotates with the c-ring, it 
causes a conformational change in each of the α1β1 heterodimers. At any one time, one 
dimer will be in an “open” state, where any previously made ATP is released and ADP 
and Pi can bind, another will be in a “loose” state, and the other in a “tight” state, where 
ADP and Pi are bound tightly and ATP is produced. The cycle repeats so each dimer is 
continuously producing ATP (Gresser et al., 1982).  
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1.3 Mitochondrial Genetics 
1.3.1 Mitochondrial DNA (mtDNA) 
Human mtDNA is ~16.7 kb in length, and contains 37 genes: 13 protein coding, 22 
tRNA and two rRNA genes (Figure 1.6). mtDNA was first sequenced in 1981 and later 
revised as the ‘revised Cambridge Reference Sequence (rCRS)’ (Anderson et al., 1981, 
Andrews et al., 1999). Since the rCRS is of contemporary European origin, it has been 
recently suggested that its use results in inconsistencies, misinterpretations, and errors in 
medical, forensic, and population genetic studies.  
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Figure 1.6 Mitochondrial genome map. A map of the heavy and light strand of 
mitochondrial DNA identifies the D-loop or non-coding region (NCR), transcription 
promoters, the origins of replication and genes locations. Genes are colour coded 
depending on which OXPHOS complex they contribute to, or if they are an rRNA or 
tRNA gene.  
There are several prevailing models which attempt to explain why mtDNA has been 
retained, despite mass transfer of the majority of mitochondrial genes to the nDNA. 
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Hydrophobic membrane proteins are difficult to localise correctly and import into the 
mitochondria, with the possibility of misdirecting proteins into the membrane of the 
endoplasmic reticulum (ER) (Popot and de Vitry, 1990, von Heijne, 1986). This is 
supported by higher eukaryote mtDNA encoding only central membrane-embedded 
respiratory chain subunits, and recombinant peptide experiments showing the inability 
of the mitochondria to import proteins with more than 3-4 transmembrane helices 
(Claros et al., 1995). Further theories include the necessity for rapid expression 
regulation of particularly important genes by the redox state of the mitochondria (Allen, 
1993), or the possible cytosolic toxicity of mitochondrial translation products (Martin 
and Schnarrenberger, 1997). The disparity between the genetic codes used to translate 
nuclear and mitochondrial genes must also factor into the ability of mitochondrial genes 
to be transferred to the nDNA.  
Due to the high importance of mitochondrial function, it might be expected that 
mitochondrial genes would be under a lot of constraint; however, mtDNA appears to 
evolve 5-10 times faster than single copy nDNA (Brown et al., 1979). Mitochondrial 
DNA likely has high mutation rates due to a combination of proximity to damaging 
free-radical production (Balaban et al., 2005), continuous replication of mtDNA, 
meaning higher base misincorporation (Johnson and Johnson, 2001) and diminished 
repair systems (Mason and Lightowlers, 2003). 
1.3.2 Haplogroups 
As mtDNA mutation rate is high, there is vast variation between human mtDNA 
sequences. Analysis of European populations identified 10 major haplogroups of 
mtDNA sequences (H, I, J, K, M, T, U, V, W, and X), defined by specific sequence 
polymorphisms (Torroni et al., 1996). Updating the phylogenetic tree with the further 
analysis of ~4000 publically available mtDNA sequences revealed the complexity of 
haplogroups subtypes, and allowed the SNP definition of each haplogroup to be refined 
(van Oven and Kayser, 2009). Mitochondrial haplogroups are of particular significance 
as they can be used to track population distribution (Torroni et al., 2006), and have been 
associated with the occurrence or severity of many clinical disorders (Herrnstadt and 
Howell, 2004).  
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1.3.3 Inheritance and the mtDNA bottleneck 
Mitochondrial DNA in humans is maternally inherited (Giles et al., 1980). Despite the 
contribution of ~100 mtDNA from the sperm to the fertilised egg, the paternal mtDNA 
is tagged for destruction by ubiquitin, and is degraded before or during the third 
embryonic cleavage (Sutovsky et al., 1999). In one case, mutated mtDNA from the 
father caused myopathy in a patient (Schwartz and Vissing, 2002); however, this 
appears to be an extremely rare event (Taylor et al., 2003).  
Nucleated mammalian cells contain multiple copies of mtDNA, dependent upon cellular 
energy demand. When all of the molecules are identical, the situation is known as 
homoplasmy. However, cells can contain a mixture of mtDNA with different genotypes, 
and this is called heteroplasmy (Larsson and Clayton, 1995).  
Heteroplasmic, pathogenic mutations generally do not result in a phenotypic effect until 
a specific threshold level (Taylor and Turnbull, 2005). Heteroplasmic variants are 
heritable; however, the level of heteroplasmy can vary dramatically between a mother 
and her children. The shift in heteroplasmy levels is purportedly explained by the 
‘mitochondrial bottleneck hypothesis’ (Howell et al., 1992a). It is theorised that the 
bottleneck provides an evolutionary mechanism for the removal of deleterious mtDNA 
variants from the population, thus protecting the human species from the mutational 
meltdown predicted by Muller's Ratchet (Bergstrom and Pritchard, 1998, Felsenstein, 
1974, Muller, 1964).  
1.4 Mitochondrial Biogenesis 
Mitochondrial biogenesis is a synergistic process, requiring the simultaneous 
upregulation and coordination of both nDNA and mtDNA encoded mitochondrial 
proteins, along with replication of the mtDNA. The nuclear-encoded mitochondrial 
proteome is estimated as >1000 proteins which contribute to mitochondrial function 
(Lythgow et al., 2011, Pagliarini et al., 2008). 
1.4.1 Protein transport 
All but the 13 proteins encoded on the mtDNA must be transcribed and translated in the 
nucleus and cytosol, and transported into the mitochondria. This includes not only the 
remaining complex subunits but all structural and regulatory proteins as well (Anderson 
et al., 1981, Andrews et al., 1999).  
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Proteins in the cytosol are maintained in a precursor form, often bound by chaperone 
proteins (such as Hsp70 and Hsp90) or containing the mitochondrial signalling peptide 
sequences. The N-terminal presequence, also known as the matrix-targeting sequence 
(MTS), does not necessarily share the same primary sequence but tends to form 
conserved amphiphilic helical structures (Roise et al., 1988).  
The chaperones or presequences are recognised by components of the translocase of the 
outer membrane (TOM) complex, which activates transport of the protein into the 
intermembrane space (Abe et al., 2000, Young et al., 2003). Several β-barrel proteins 
require insertion into the outer mitochondrial membrane, and this is mediated by the 
sorting and assembly machinery (SAM) complex (Paschen et al., 2003). 
Some proteins are targeted for the IMS or integration into the IMS side of the inner 
membrane by addition of a hydrophobic sorting domain accompanying the N-terminal 
MTS. This prevents translocation into the matrix, instead causing the protein to be 
inserted into the membrane by translocase of the inner membrane (TIM) 23 (Meier et 
al., 2005, Rojo et al., 1998). A special group of cysteine-containing IMS proteins, 
which do not contain N-terminal targeting sequences, are instead transported into the 
mitochondria by the disulphide relay (Deponte and Hell, 2009).  
Carrier proteins to be integrated into the inner mitochondrial membrane are escorted 
from the TOM complex by small Tim proteins, which are thought to prevent unwanted 
interactions in the IMS (Vergnolle et al., 2005). This allows the protein to associate 
with the TIM22 complex, enabling the insertion of the carrier protein into the inner 
membrane (Sirrenberg et al., 1996).  
Proteins destined for the mitochondrial matrix are passed onto the TIM23 complex, 
which recognises the MTS and facilitates the transport of proteins across the inner 
membrane (Schulz et al., 2011). The targeting presequences are then cleaved off, 
usually by the mitochondrial processing peptidase (MPP) (Braun and Schmitz, 1997, 
Vogtle et al., 2009). 
1.4.2 Transcription 
The initiation of mitochondrial transcription was originally thought to begin with 
mitochondrial transcription factor A (TFAM) binding to mtDNA promoters, which in 
turn recruited the transcription complex, containing RNA polymerase (POLRMT) and 
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transcription factors B1 or B2 (TFB1M/2M) (Bonawitz et al., 2006). More recently, it 
was shown TFB2M is primarily responsible for transcription, with TFB1M functioning 
mainly in the methylation of 12S RNA (Cotney et al., 2009, Cotney et al., 2007).  
Recent in vitro modelling revealed that transcription can occur in the absence of TFAM 
but is enhanced at LSP and HSP1 by optimal TFAM concentrations (Shutt et al., 2010). 
This implies a two-component transcription system, also observed in lower eukaryotes, 
with TFAM providing a method of complex regulation specific to mammals (Figure 
1.7).  
The regulated, two-component transcription system 
The human RNA polymerase, POLRMT, was first identified through its homology to 
those in lower eukaryotes (Tiranti et al., 1997). Eukaryote polymerases show high 
levels of conservation to those of T3/T7 bacteriophages (Masters et al., 1987). The C-
terminal domain (CTD) contains the conserved motifs essential for the catalytic activity 
of the enzyme, and the N-terminal domain (NTD) functions in promoter binding and 
recognition. An N-terminal extension region contains the mitochondrial targeting 
sequence and novel pentatricopeptide repeat (PPR) motifs. The function of the PPR 
domain is currently unknown, but it is essential for initiation of promoter-directed 
transcription (Ringel et al., 2011). Suggested roles, based on the functional properties of 
other PPR domain proteins, include RNA processing and linking transcription to 
translation (Aphasizheva et al., 2011, Lightowlers and Chrzanowska-Lightowlers, 
2008). Unlike bacteriophage polymerase, POLRMT requires additional factors for 
initiation of transcription.  
TFB2M was identified, alongside its paralogue TFB1M, as rRNA dimethyltransferase 
homologues with the capability of interaction with POLRMT and essential for initiation 
of transcription (Falkenberg et al., 2002, McCulloch et al., 2002).  
In vitro, the use of ‘bubble templates’, created using non-complementary sequences, 
simulates ‘pre-melted’ promoter regions. POLRMT can initiate promoter-specific 
transcription from these templates without TFB2M, suggesting the main function of this 
protein is promoter melting (Sologub et al., 2009). This study also found, through 
crosslinking and catalytic autolabelling, that TFB2M interacts with the templating 
nucleotide and priming substrate (NTP), suggesting that TFB2M functions to maintain 
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the upstream edge of the open transcription site and the position of the template 
nucleotide and priming substrate for POLRMT.  
TFAM was identified as a member of the high-mobility-group (HMG) of proteins, 
capable of wrapping, bending and unwinding mtDNA, and mediating transcription from 
POLRMT (Fisher and Clayton, 1988, Fisher et al., 1992, Parisi and Clayton, 1991). The 
HMG-box motifs are known for their ability to bend DNA, whereas the C-terminal end 
of the protein has been proven essential for transcription enhancing through interaction 
with TFB2M (Dairaghi et al., 1995, McCulloch and Shadel, 2003). TFAM is unique in 
its ability to bind DNA non-specifically in addition to recognising specific sequences 
within promoter regions, known as TFAM responsive elements (TREs). Nonspecific 
binding packages mtDNA into nucleoids, facilitating mtDNA replication and 
transcription, and provides protection from DNA damage (Alam et al., 2003, Kaufman 
et al., 2007).  
TFAM functions through induction of U-turns in mtDNA structures, which have been 
shown to be distorted to a higher degree in TREs at promoter regions compared to 
nonspecific mtDNA sequences (Malarkey et al., 2012, Ngo et al., 2011). The U-turn 
bend at TREs enables the C-terminal end to approach the promoter site and interact with 
TFB2M to enhance transcription at LSP and HSP1 (Rubio-Cosials et al., 2011). 
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Figure 1.7 An overview of mitochondrial transcription initiation. Initiation at HSP1 
and LSP consists of (A) TFAM binding and (B) bending mtDNA at TREs in the 
promoter region. (C) POLRMT and TFB2M form the initiation complex (IC) and 
assemble onto promoter sequences. TFAM C-terminal domain enhances transcription 
initiation. TFB2M is responsible for promoter melting and aligning the priming 
substrate and DNA template for POLRMT processing. (D) Transcription from HPS2 
can be inhibited by TFAM due to overlapping binding sites. (E) Extended transcription 
elongation requires TEFM to increase processivity of POLRMT. 
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Regulation of transcription initiation 
Each strand is transcribed as a long, polycistronic precursor mRNA molecule. Light 
strand transcription initiates from a single promoter (LSP), but heavy strand 
transcription initiates from two promoters, HSP1 and HSP2 (Montoya et al., 1982, 
Montoya et al., 1983). Integral to regulation of transcription initiation are the varied 
gene products transcribed by each promoter. Transcription from HSP2 begins at the 5’ 
end of MT-RNR1 (12S rRNA), and transcribes all but the tRNA
Phe
 gene (meaning it 
transcribes all subunits of the OXPHOS system except MT-ND6). HSP1 transcription 
includes only the tRNA
Phe
, MT-RNR1, tRNA
Val
 and MT-RNR2 before terminating, 
meaning it can independently upregulate transcription of rRNA, essential for translation, 
without transcribing unnecessary OXPHOS components. Transcription from LSP 
produces the eight tRNA genes and MT-ND6 encoded on the light strand; however, it 
also generates the RNA primers essential for initiation of replication (Chang and 
Clayton, 1985). This enables maintenance of OXPHOS components by HSP2 and 
biogenesis by HSP1/LSP to be regulated separately. As previously stated, TFAM is not 
essential for initiation of transcription (in vitro), but conveys an additional layer of 
regulation onto expression from the independent promoters. 
Each promoter responds differently to varying concentrations of TFAM (Figure 1.8). 
HSP1 transcription has a higher basal rate of transcription, but requires higher 
concentrations of TFAM for maximal activity compared to LSP (Shutt et al., 2010). 
Despite enhancing transcription from HSP1 and LSP, transcription from HSP2 is 
actually repressed by even low concentrations of TFAM (Lodeiro et al., 2012, Zollo et 
al., 2012). This explains how previous attempts to transcribe from HSP2 using 
conditions suitable for LSP or HSP1, containing TFAM, have been unsuccessful 
(Litonin et al., 2010). DNase I footprinting at HSP2 reveals predicted TFAM binding 
sites overlapping with POLRMT/TFB2M binding sites, suggesting competitive 
repression by TFAM. This principle is supported by higher concentrations of POLRMT 
and TFB2M overcoming small concentrations of TFAM (Lodeiro et al., 2012). Overall, 
this means that an absence of TFAM favours HSP2 transcription, low TFAM 
concentration favours LSP transcription and high TFAM concentration favours HSP1 
transcription.  
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Figure 1.8 Differential promoter response to TFAM concentrations. Graphical 
representation of the response from the different promoters to variable concentrations of 
TFAM. HSP1 and HSP2 have higher transcription levels in the absence of TFAM; 
however, low levels of TFAM stimulate full activation of LSP whilst inhibiting HSP2. 
Higher concentrations of TFAM inhibit transcription from LSP whilst enhancing 
transcription from HSP1. Concentrations above 1000 nM inhibit transcription from all 
promoters. (Compiled using data from Lodeiro et al., 2012, Shutt et al., 2010) 
This may explain the heterogenic nature of nucleoids. TFAM is responsible for 
packaging the mtDNA into nucleoids, and at full capacity has 450 binding sites on 
mtDNA (Kaufman et al., 2007). It has been previously noted that the TFAM content of 
nucleoids is variable and not always co-localising with replicating mtDNA, which could 
be perceived as either coincidental or a possible regulation mechanism (Wai et al., 
2008).  
Recently, photoactivated localization microscopy (PALM/iPALM) has been used to 
obtain super-resolution images of mitochondrial nucleoids based on their TFAM 
incorporation (Brown et al., 2011). This study demonstrated not only the wide range of 
nucleoid sizes and shapes, but that TFAM distribution is not always even. 
Transcription elongation 
Independently, POLRMT can only transcribe short species of RNA (approximately 25-
75 nt in length) (Wanrooij et al., 2008). In vitro modelling has shown that transcription 
elongation factor, mitochondrial (TEFM) binds the catalytic subunit of POLRMT and 
increases the enzyme processivity, allowing generation of longer templates. In vivo, 
disruption of TEFM leads of loss of transcripts distal to the promoters, suggesting 
premature failing of mitochondrial transcription (Minczuk et al., 2011). This study also 
reveals RNA-dependent complexes formed containing TEFM, POLRMT, 
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pentatricopeptide repeat domain 3 (PTCD3) and DEAH-box polypeptide 30 (DHX30), 
but noticeably with neither initiation factors TFAM and TFB2M.  
Extensive study of PTCD3 revealed it is not essential for mitochondrial transcription, 
but is required for mitochondrial translation, suggesting a function in linking 
transcription to translation (Davies et al., 2009).  
DHX30 is a DEAH-box RNA helicase, previously shown to localise to mitochondria 
but with unknown function (Wang and Bogenhagen, 2006). Since further analysis of 
DHX30 function has not been completed to date, it is possible that this protein functions 
directly in transcription elongation; however, the typical roles of other mitochondrial 
helicases, such as SUPV3L1 (formally SUV3), would suggest a role in mtRNA 
metabolism or maintenance (Szczesny et al., 2010).  
Excision repair cross-complementing rodent repair deficiency, complementation group 
6 (ERCC6; previously CSB) has also been recently implicated in mitochondrial 
transcription elongation (Berquist et al., 2012). The major functions of this protein are 
nuclear transcription-coupled nucleotide excision repair (TC-NER) and enhancing 
transcription elongation from nuclear RNA polymerases (Orren et al., 1996, Selby and 
Sancar, 1997). ERCC6 has previously been shown to localise to the mitochondria and is 
involved with base excision repair (BER) of mtDNA (Aamann et al., 2010). Recent data 
has shown that ERCC6 assists POLRMT in transcription, through dissociating non-
specifically bound TFAM from mtDNA during elongation (Berquist et al., 2012). This 
study reveals defective ERCC6 causes loss of transcripts distal to the promoter region, 
but increasing concentrations of ERCC6, in vitro, causes a general reduction in 
transcription, presumably through loss of TFAM stimulation at promoters. What is not 
considered by this study is the separate action of HSP1 and HSP2. With evidence of 
TFAM repressing HSP2 in vitro (Lodeiro et al., 2012), decreased levels of protein-
coding transcripts in ERRC6-deficient cells could be, in part, due to increased TFAM 
repression at HSP2 and not simply deficient removal of non-specific TFAM.  
Transcription termination 
The first mitochondrial transcription termination factor identified was mitochondrial 
termination factor 1 (MTERF1) (Kruse et al., 1989). The crystal structure revealed it 
binding duplex DNA and causing duplex melting and inversion of three bases (Jimenez-
Menendez et al., 2010, Yakubovskaya et al., 2010). To date, it is the only factor 
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required for termination at the tRNA
Leu
 from both HSP1 and LSP, with a higher affinity 
for termination of light-strand transcription (Asin-Cayuela et al., 2005, Shang and 
Clayton, 1994). Additional binding sites have been found in the HSP1 promoter region, 
leading to the model whereby simultaneous binding of MTERF1 to the termination site 
at tRNA
Leu
 and HSP1 causes a looping out of the bridging DNA segment, and can 
stimulate HSP1 transcription through the ease in recycling the transcription complex 
when they are brought in close proximity (Martin et al., 2005) (Figure 1.9A). 
Manipulation of MTERF1 expression affects relative amounts of anti-sense transcripts 
around the tRNA
Leu
 site, suggesting MTERF1 also plays a crucial role in the 
termination of light-strand transcription (Hyvarinen et al., 2010) (Figure 1.9B). This is 
of critical importance as there are no genes on the light-strand downstream of the 
tRNA
Leu
 site, but generation of anti-sense rRNA transcripts could interfere with 
ribosomal biogenesis. Weaker MTERF1 binding sites have been identified in the non-
coding region (NCR), suggesting a role for MTERF1 in termination from HSP2 
transcripts also; however, there is yet to be conclusive evidence supporting the model of 
HSP2 transcription termination (Hyvarinen et al., 2007). 
As previously discussed, transcription of the light-strand is essential for generation of 
primers for heavy-strand replication (Chang and Clayton, 1985). One model for 
production of replication primers involves post-transcriptional cleavage of RNA 
transcripts through a generated ‘R-loop’ (Lee and Clayton, 1998). However, a more 
recent model predicts premature termination of transcription on the light-strand by 
formation of four-stranded G-quadruplex structures in nascent RNA transcribed from 
the conserved sequence block II (CSBII) downstream of the LSP site (Wanrooij et al., 
2010). The presence of the G-quadruplex structure in the nascent RNA and presence of 
a downstream poly-dT region, which enhances termination at CSBII, is reminiscent of 
rho-independent prokaryotic termination using hair-pin loops (d'Aubenton Carafa et al., 
1990) (Figure 1.9C). 
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Figure 1.9 An overview of predicted transcription termination mechanisms. 
Several predicted termination models have been suggested. (A) Termination at tRNA
Leu
 
from HSP1 and LSP requires looping of the promoter region to the termination site, 
joined by binding of MTERF1. (B) MTERF1 can terminate transcription from any 
promoter without looping either at the tRNA
Leu
 site or within the NCR. (C) Premature 
termination from LSP to generate replication primer oligos requires formation of G-
quadruplex structures in the conserved sequence block II (CSBII). 
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Phylogenetic analysis and similarity studies led to identification of three additional 
proteins related to MTERF1, consequently named MTERF2-4 (Linder et al., 2005). 
However, despite being structurally similar to MTERF1, they do not seem to function in 
transcription termination, although sufficiently thorough characterisation has not been 
completed and there have been conflicting reports on their functions. MTERF2 and 
MTERF3 seem to have functions relating to regulation of transcription or replication 
(Huang et al., 2011, Park et al., 2007), whereas MTERF4 deficiency impairs translation 
despite an increase in mitochondrial transcripts (Camara et al., 2011).  
Post-transcriptional modification 
Perhaps the first and most important post-transcriptional modification is processing of 
the polycistronic transcripts generated from the heavy and light strands into individual 
mRNA, tRNA or rRNA molecules. This led to the proposition of the ‘punctuation 
model’ of processing, where tRNA genes mark cleavage sites which separate the 
individual transcripts (Ojala et al., 1981). 5’ tRNA processing is achieved by the 
RNase P complex, consisting of RNase P protein 1-3 (MRPP1-3) (Holzmann et al., 
2008, Rossmanith and Holzmann, 2009). 3’ tRNA processing is achieved by RNase Z 
complex, consisting of elaC homologue 2 (ELAC2) and pentatricopeptide repeat 
domain 1 (PTCD1) (Sanchez et al., 2011, Takaku et al., 2003).  
After cleavage, tRNAs are matured by the addition of CCA sequence to the 3’ by 
ATP(CTP):tRNA nucleotidyltransferase, allowing for the addition of the amino acid 
(Nagaike et al., 2001). tRNAs are further processed by nucleoside modification. There 
have been 16 species of nucleoside modification identified, three of which are specific 
to mitochondria, and are essential for correct tRNA folding or function (Suzuki et al., 
2011).  
mRNAs from the heavy strand are polyadenylated at their 3’ end, by mitochondrial 
poly(A) polymerase (MTPAP) forming the functional stop codon in seven of the heavy 
strand genes (Nagaike et al., 2005, Tomecki et al., 2004). There is no unanimous 
function for the polyA tail on mRNA transcripts. Removal of the polyA tail has been 
achieved by either MTPAP silencing (Piechota et al., 2006), mitochondrial targeting of 
cytosolic poly(A)-specific exoribonuclease (PARN) (Wydro et al., 2010) or 
overexpression of mitochondrial poly(A)-specific exoribonuclease, phosphodiesterase 
12 (PDE12) (Poulsen et al., 2011, Rorbach et al., 2011). These studies demonstrate 
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poly(A) tail removal causes increase in ND1, ND2 and ND5 transcripts whilst 
decreasing the stability of ATP8/6, CO1 and CO2 (Poulsen et al., 2011, Rorbach et al., 
2011).  
rRNA is also subject to post-transcriptional modification. Two adenines in the 3’ stem-
loop of 12S rRNA are N6-dimethylated by TFB1M (Seidel-Rogol et al., 2003). 
Methylation at these positions is critical for assembly of the mitoribosomes and 
essential for efficient translation of mitochondrially-encoded proteins (Metodiev et al., 
2009). Further methylation sites have not been confirmed in humans, but appear in 
hamster mtDNA in both 12S and 16S, functioning mainly in ribosomal assembly or 
function (Rorbach and Minczuk, 2012).  
1.4.3 Replication 
Replication of mtDNA is essential to maintain a stable and sufficient copy number 
throughout cell division and as part of mtDNA turnover (degradation and replacement 
of mtDNA molecules). mtDNA replication occurs continuously within tissues, even in 
post-mitotic cells, and is not limited to a particular phase of the cell cycle (Bogenhagen 
and Clayton, 1977).  
Proteins of the mitochondrial replisome 
Polymerase Gamma (Pol γ) is the only mitochondrial polymerase, and consists of one 
catalytic subunit (encoded by POLG) and a dimer of accessory subunits (encoded by 
POLG2) (Gray and Wong, 1992, Lim et al., 1999). The catalytic subunit has DNA 
polymerase, 3’→5’ exonuclease and 5’-deoxyribose phosphate (dRP) lyase activity, 
whilst the accessory subunits promote processivity by enhancing DNA binding 
(Johnson et al., 2000). The exonuclease activity conveys proof-reading activity, and is 
required for degradation of newly incorporated nucleotides. The dRP lyase activity is 
important for base excision repair (BER) of mtDNA (Longley et al., 1998). Pol γ can 
utilise many different substrates as templates, including RNA, suggesting the enzyme 
has reverse transcriptase activity (Murakami et al., 2003). Although Pol γ preferentially 
incorporates deoxyribonucleotides over ribonucleotides during DNA replication, it has 
been shown that it can incorporate stretches of RNA into DNA, and can differentiate 
between the different ribonucleotide triphosphates (Kasiviswanathan and Copeland, 
2011, Murakami et al., 2003).  
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Pol γ cannot use dsDNA as a template, and therefore requires DNA to be unwound 
before replication can occur. Twinkle helicase (encoded by C10orf2) has sequence 
homology to T7 phage helicase, but lacks primase activity, and can exist as a hexamer 
or heptamer (Spelbrink et al., 2001, Ziebarth et al., 2010). Twinkle may be involved 
with initiation of replication or primer extension, as it can bind circular dsDNA without 
aid of an additional loading protein (Jemt et al., 2011). Twinkle helicase requires single-
stranded binding protein (SSBP1) to unwind more than short stretches of DNA 
(Korhonen et al., 2004).  
SSBP1 forms nucleoprotein fibrils within single-stranded regions of mtDNA (Van 
Tuyle and Pavco, 1985). SSBP1 forms tetramers, which wrap DNA around them 
through electropositive sites (Li and Williams, 1997, Yang et al., 1997). SSBP1 
stimulates the activity of Pol γ, and is essential for the replication of long stretches of 
DNA, increasing the replication processivity of Pol γ and Twinkle from 2 kb to 16 kb 
lengths of DNA (Genuario and Wong, 1993, Korhonen et al., 2004). Mutational 
analysis of SSBP1 reveals that separate domains of the protein are responsible for the 
stimulatory effect of Pol γ and Twinkle, and mutations affecting interaction with one 
does not necessarily affect the other (Oliveira and Kaguni, 2011).  
Additional proteins have been implicated in mtDNA replication, though do not form 
essential components of the ‘minimal replisome’. Topoisomerases relieve stress from 
supercoiled DNA, generated as DNA is unwound. There are two topoisomerases known 
to function within the mitochondria, mitochondrial topoisomerase 1 (TOP1MT) (Zhang 
et al., 2001) and topoisomerase IIIα (TOP3A). TOP1MT cleavage sites are mapped to 
the NCR, and primarily affect transcription, with only a knock-on effect with replication 
(Dalla Rosa et al., 2009, Zhang and Pommier, 2008). TOP3A functions in both the 
nucleus and the mitochondria, with alternative start codon usage providing a 
mitochondrial targeting sequence for some isoforms of the protein (Wang, 2002). Little 
is known about TOP3A in humans; however, research in trypanosomes and bacteria 
suggest the protein is needed to resolve junction intermediates at the end stage of 
replication (Scocca and Shapiro, 2008, Suski and Marians, 2008).  
RNASEH1 removes long stretches of RNA/DNA hybrids and has been proven 
important for maintenance of mtDNA levels (Cerritelli et al., 2003). Human telomerase 
(TERT) has been shown to localise to mitochondria, and copurifies with mtDNA and 
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known nucleoid proteins (Sharma et al., 2012). Knockdown of TERT in mice leads to 
mtDNA depletion, and overexpression can increase mtDNA copy number after 
depletion by ethidium bromide, suggesting a role for TERT in mtDNA maintenance 
(Sahin et al., 2011). TERT accumulates in the mitochondria during oxidative stress 
(Ahmed et al., 2008), which may support a role for TERT in mtDNA replication, but 
there is also a possibility the protein functions in double-strand break (DSB) repair, 
which can use RNA subsequently converted to DNA to repair damage (Storici et al., 
2007).  
Replication models 
There are three models of mtDNA replication: the strand asynchronous displacement 
model, the strand-coupled bidirectional model and the ribonucleotide incorporated 
throughout the lagging strand (RITOLS) model.  
Strand asynchronous replication is initiated at the H-strand origin (OH) in the non-
coding region (NCR), primed by transcription products from the light-strand (Chang 
and Clayton, 1985, Robberson et al., 1972). After replication of two-thirds of the H-
strand, the L-strand origin (OL) is exposed in the ‘WANCY’ tRNA region (Figure 
1.10A-B). Further analysis of the NCR revealed a second H-Strand replication origin, 
known as Ori-b, which, though a strong promoter site, is poorly understood (Yasukawa 
et al., 2006, Yasukawa et al., 2005). 
L-strand replication is initiated by synthesis of an RNA primer by POLRMT (Fuste et 
al., 2010, Wanrooij et al., 2008, Wong and Clayton, 1985). These studies demonstrated 
that when OL becomes single-stranded, it forms a hair-pin loop, allowing short primer 
synthesis by POLRMT, which is then utilised by Pol γ for lagging-strand DNA 
synthesis. SSBP1 overexpression causes a reduction in primer synthesis but an increase 
in DNA replication, suggesting the hair-pin loop functions to prevent binding of SSBP1 
to OL. This allows primer synthesis by POLRMT, but prevents non-OL binding 
elsewhere, which could inhibit replication progression (Wanrooij et al., 2008). 
POLRMT only requires the polyT stretch within the hair-pin loop and does not require 
additional factors, such as TFB2M, presumably because the template is already single-
stranded (Fuste et al., 2010). (Figure 1.10C-D).  
.  
Chapter 1  
34 
 
 
Figure 1.10 The strand asynchronous model. (A) Schematic for replication via the 
strand asynchronous mechanism. (B) Initiation of heavy-strand replication at OH, 
primers from transcription bind the replication origin, Pol γ extends the primer with 
DNA synthesis. Twinkle helicase and topoisomerases unwind DNA which is bound by 
SSBP1. RNASEH1 degrades the RNA primer. (C) OL forms a hair-pin loop which 
prevents SSBP1 binding, allowing primer synthesis by POLRMT. (D) Pol γ extends the 
RNA primer by DNA synthesis.  
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This model has been adapted to the RITOLS model, whereby replication occurs in the 
same manner, except the displaced parental H-strand is not single-stranded, but instead 
coated with RNA fragments (Yasukawa et al., 2006) (Figure 1.11A). Since the RNA 
stretches on the displaced strand are prone to degradation, this was proposed to account 
for the observation of the single-stranded replication intermediates which led to the 
strand-asynchronous model of replication (Yang et al., 2002). There are two proposed 
theories to how the RNA intermediates arise. Firstly, that the RNA fragments are 
generated by POLRMT directly on the displaced strand, since this can prime lagging-
strand synthesis, creating Okazaki fragments (Wanrooij et al., 2008) (Figure 1.11B). 
Secondly, pre-existing fragments of RNA, perhaps generated during transcription, are 
annealed to the displaced strand, and then processed into small fragments (the bootlace 
model) (Yasukawa et al., 2006) (Figure 1.11C). In the RITOLS model, after exposure of 
OL, the lagging-strand RNA is matured into DNA. This is likely to be dependent on 
Pol γ, as inhibition or mutation of the catalytic subunit prevents maturation of RNA 
intermediates (Wanrooij et al., 2007) (Figure 1.11D). This is supported by the reverse 
transcriptase function of Pol γ (Murakami et al., 2003). 
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Figure 1.11 The RITOLS model of mtDNA replication. (A) Schematic for replication 
via the RITOLS mechanism. (B) Initiation of heavy-strand occurs in the same manner 
as the strand asynchronous mechanism, with the addition that the displaced strand has 
short RNA fragments synthesised along its length or (C) is bound by long premade 
RNA fragments. (D) Light strand replication initiation is primed between tRNA
Asn
 and 
tRNA
Cys
, where a hairpin loop structure forms.  
Analysis of replication intermediates revealed that although some are single-stranded or 
coupled to RNA, presumably resulting from asynchronous replication, others were fully 
double-stranded, suggesting simultaneous replication of both strands (Holt et al., 2000). 
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This mechanism of replication resembles nuclear DNA replication, and thus has been 
called ‘conventional, strand-coupled Okazaki fragment associated (COSCOFA)’ 
replication (Figure 1.12A). Initiation occurs bidirectionally, downstream of OH in the 
‘initiation zone’, but is halted in one direction upon reaching OH (Bowmaker et al., 
2003, Yasukawa et al., 2005). As Pol γ can only replicate DNA in a 5’ → 3’ direction, 
leading strand synthesis is continuous, but the lagging strand must be synthesised in 
short fragments, primed by RNA (Okazaki fragments) (Figure 1.12B). Processing of 
Okazaki fragments occurs by the same means as in nuclear replication, with specialised 
helicases and flap-endonucleases (Holt, 2009). PIF1 is a helicase which unwinds short 
flaps, containing the 5’ RNA primers for each Okazaki fragment (Futami et al., 2007). 
SSBP1 can bind to the DNA in the flap to moderate the association of the flap 
endonclueases DNA2 and FEN1, which cleave the 5’ of the flap, and process the 
remaining nucleotides respectively (Liu et al., 2008, Zheng et al., 2008) (Figure 1.12C-
D). A DNA ligase, potentially ligase III, must then join each fragment to form a 
continuous strand.  
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Figure 1.12 The COSCOFA model of mtDNA replication. (A) Schematic for 
replication via the conventional, strand-coupled Okazaki fragment associated 
(COSCOFA) mechanism. (B) Initiation of replication occurs bidirectionally at the 
‘initiation zone’, with lagging-strand synthesis occurring alternately in each direction. 
(C) RNA primers for formation of Okazaki fragments are cleaved off, and (D) the 
remaining flaps removed by flap endonucleases.  
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The relative abundance of intermediates from different replication modes vary between 
tissue types, with RITOLS intermediates predominating in cultured cells, liver and 
kidney tissue, and COSCOFA intermediates being highest in skeletal muscle, heart and 
cultured cells recovering from depletion (Pohjoismaki and Goffart, 2011). 
Pausing and Termination 
The replication machinery has been shown to pause at particular positions on the 
mtDNA, which is enhanced in regions of MTERF binding (Hyvarinen et al., 2007). 
Replication pausing may serve to facilitate the passage of transcription and replication 
machinery, particularly at the tRNA
Leu
 position regulating the highly transcribed region 
of rRNA genes.  
As previously stated, one direction of COSCOFA replication terminates prematurely at 
OH, whilst the other direction continues around the entire genome, until meeting again 
at the NCR. Although not much is known of replication termination, it has been shown 
that 4-way junctions are formed in this region (Bowmaker et al., 2003). Twinkle and 
members of the MTERF family seem to be necessary for resolution of these molecules 
(Hyvarinen et al., 2011).  
Repair  
Originally it was thought that mitochondria had no DNA repair mechanisms; however, 
there are now several repair pathways identified which act in mitochondria (Stuart and 
Brown, 2006). This repertoire has been expanded to include base excision repair (BER), 
mismatch repair, and homologous/nonhomologous end-joining (Liu and Demple, 2010). 
Importantly, replication enzymes such as Pol γ and flap processing enzymes DNA2 and 
FEN1 are involved in BER. SSBP1 has been shown to prevent processing of damaged 
bases, such as excision of uracil, whilst DNA remains single stranded (Wollen Steen et 
al., 2012). Ensuring DNA is double-stranded ensures no nicks being formed in DNA. 
1.4.4 Nucleoids 
As previously stated, mtDNA is not as unprotected as once thought, but is contained 
within protein aggregates known as nucleoids. Limitations in labelling and microscopy 
have made estimating numbers of nucleoids and the mtDNA content of each nucleoid 
difficult (Bogenhagen, 2012). Recent advances in imaging have led to a conservative 
estimate of 1-3 mtDNA molecules per nucleoid, tightly packed into an average volume 
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of 830,000 nm
3
 (Brown et al., 2011, Kukat et al., 2011). TFAM facilitates this 
compaction by nonspecific binding and bending of the mtDNA within nucleoids 
(Kaufman et al., 2007). TFAM occupies a 22bp region of DNA when bound the HSP; 
however, the ratio of TFAM molecules to mtDNA is still under debate, and may vary 
widely between species, tissue types and gene expression conditions (Cotney et al., 
2007, Ngo et al., 2011, Rubio-Cosials et al., 2011). Aldehyde cross-linking and 
immunoaffinity purification established that the core components of the transcription 
and replication machinery, such as Pol γ and TFB2M, as well as a diverse range of 
proteins involved in mtDNA maintenance, are contained within nucleoids (Bogenhagen 
et al., 2008, Wang and Bogenhagen, 2006). This includes several mitochondrial 
ribosomal proteins, suggesting association of nucleoids with translational machinery. 
Immunoprecipitation using ribosomal recycling factor (a translational protein) identified 
well-known nucleoid proteins, further supporting the notion of linked transcription and 
translation (Rorbach et al., 2008).  
1.4.5 Translation 
The 13 protein coding genes of the mtDNA require translation by an independent 
system located in the mitochondria. An overview of this process can be seen in Figure 
1.13. 
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Figure 1.13 An overview of mitochondrial translation. Mitochondrial translation 
begins with initiation. (A) mtIF3 dissociates the LSU and mRNA transcripts bind the 
LSU. (B) mtIF2 recruits fMet-tRNA
Met
 to the p site. (C) mtIF2 is removed from the 
mitoribosome. (D) mtEFTu recruits the next aminoacylated tRNA. (E) mtEFTu is 
removed, mtEFTs exchanges GDP for GTP to recycle mtEFTu and mtEFG1 binds. (F) 
A peptide bond forms between the amino acids, a conformational change shifts the 
tRNA/mRNA along and the deacylated tRNA exits. (G) When a stop codon is 
encountered, mtRF1a binds. (H) The ester bond between the nascent peptide and tRNA 
is hydrolysed. (I) mtRRF and mtEFG2 are recruited to remove the mRNA and 
deacylated tRNA. (J) mtRRF and mtEFG2 leave the mitoribosome. 
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The mitochondrial translation system uses a different genetic code to cytoplasmic 
translation, with even a universal stop codon (UGA) being used instead as a tryptophan 
codon (Osawa et al., 1992). The codon recognition system is simplified to allow 
recognition of all codons by only the 22 tRNAs encoded by the mtDNA (Barrell et al., 
1980). The mRNA transcripts generated from transcription of mtDNA also differ, with 
little to no 5’ UTR sequence (Montoya et al., 1981) or 5’ 7-methylguanylate (m7G) cap 
(Grohmann et al., 1978) and with the polyA tail directly following, and sometimes 
forming, the stop codon (Ojala et al., 1981).  
Mitochondrial tRNAs 
Mitochondrial tRNAs form clover-leaf secondary and L-shaped tertiary structures, 
similar to cytosolic tRNAs, though there are small structural variations (Helm et al., 
2000). They are more heavily reliant on post-transcriptional modification for structural 
stability and function (Helm, 2006). For example, initiation of translation requires 
formylated methionyl-tRNA (fMet-tRNA
Met
). In cytosolic and bacterial translation, 
there are two independent methionyl-tRNAs, but in mitochondria there is just one, 
where a proportion is formylated by mitochondrial methionyl-tRNA transformylase 
(MTFMT) (Mikelsaar, 1983, Takeuchi et al., 1997). 
Mitoribosomes 
The mitoribosomes (55S) contain the two rRNAs (12S and 16S), encoded by the 
mtDNA, and approximately 81 mitochondrial ribosomal proteins (MRPs), encoded by 
the nuclear DNA (Smits et al., 2007). They lack some rRNA components compared to 
bacterial ribosomes, but have additional protein subunits. These, however, do not 
compensate for the lacking rRNA but form their own mitochondrial specific functions 
(Sharma et al., 2003).  
Translation initiation 
Initiation is the first stage of translation. There are two mitochondrial translation 
initiation factors (IFs), mtIF2 and mtIF3 (Koc and Spremulli, 2002, Ma and Spremulli, 
1995). They are orthologous to prokaryotic IFs, except that mtIF2 has a 37-amino acid 
insertion that allows it to function as IF1 does in bacteria, aiding the formation of the 
initiation complex (Gaur et al., 2008). mtIF3 begins initiation by dissociating the 
mitoribosome complex (55S) into the small (SSU; 28S) and large (LSU; 39S) ribosomal 
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subunits, thereby allowing the initiation complex to assemble (Figure 1.13A) (Christian 
and Spremulli, 2009). Despite lacking the 5’ m7G-cap or 5’UTR guidance sequences, 
the mRNA is bound to the SSU in a sequence-independent manner (Laursen et al., 
2005). This aligns the start codon (AUG) to the peptidyl (P) site of the mitoribosome. 
mtIF2, enhanced with GTP, is required for binding of fmet-tRNA
Met 
to the SSU (Figure 
1.13B) (Liao and Spremulli, 1990, Ma and Spremulli, 1996). Recombination of the LSU 
to the SSU complex triggers release of initiation factors (Figure 1.13C) (Haque et al., 
2008).  
Translation elongation 
There are three elongation factors: mtEFTu; mtEFTs and mtEFG1 (Hammarsund et al., 
2001, Ling et al., 1997, Xin et al., 1995). There is a homologue of mtEFG1, mtEFG2, 
which appears to have a role in ribosomal recycling rather than translocation (Tsuboi et 
al., 2009). Elongation begins with mtEFu binding GTP and an aminoacylated tRNA and 
determines whether the tRNA has been aminoacylated correctly (Figure 1.13D) (Nagao 
et al., 2007). This complex then moves to the A site, where the mitoribosome 
hydrolyses the GTP to release mtEFTu-GDP. This is then recycled by mtEFTs, which 
converts the bound GDP back to GTP (Figure 1.13E). A peptide bond forms between 
the amino acid in the P site and the newly added amino acid at the A site. Hydrolysis of 
GTP bound to mtEFG1 causes a conformation change in both mtEFG1 and the 
mitoribosome, translocating the mRNA and bound tRNA across, so the last amino acid 
is in the P site. The previous tRNA then exits the mitoribosome complex and the 
elongation cycle repeats (Figure 1.13F) (Smits et al., 2010b). 
Translation termination 
There are three factors responsible for termination of mitochondrial translation. 
Originally, mtRF1 was deemed a release factor, but it has been shown to lack release 
factor activity, with mtRF1a being the only release factor required for termination at the 
UAA and UAG stop codons (Nozaki et al., 2008, Soleimanpour-Lichaei et al., 2007, 
Zhang and Spremulli, 1998). Although AGA and AGG were considered stop codons in 
MT-CO1 and MT-ND6 transcripts, it was shown that these codons actually cause 
ribosome stalling and frameshifting to produce a UAG stop codon, terminated by 
mtRF1a (Temperley et al., 2010). Class II release factors in bacteria are responsible for 
dissociation of the release factors from the ribosome, but it remains unclear whether a 
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mitochondrial equivalent exists (Bertram et al., 2001). Stop codons are recognised by 
mtRF1a bound to GTP, and triggers hydrolysis of the ester bond joining the tRNA and 
nascent peptide at the P site (Figure 1.13G-H). After termination, the mRNA and 
deacylated tRNA must be removed from the ribosomal complex; this is achieved by the 
ribosomal recycling factors (mtRRF and mtEFG2/RRF2) (Figure 1.13I). GTP 
hydrolysis then enables release of the recycling factors from the ribosomes (Figure 
1.13J) (Rorbach et al., 2008, Tsuboi et al., 2009).  
Regulation of translation 
There is much unknown about regulation of mitochondrial translation. One possible 
mechanism involves the negative feedback system generated by the ATP-dependent m-
AAA protease, essential for quality control of inner membrane proteins (Nolden et al., 
2005). When the m-AAA protease processes MRPL32, it forms a tight association with 
the inner membrane. If excess respiratory subunits accumulate, they could block the m-
AAA protease, preventing processing of MRPL21 and decreasing the translation rate of 
new proteins.  
Several potential COXI specific regulators of translation have been identified. 
Mutations in TACO1 have shown lower levels of COXI being produced despite normal 
levels of COXI transcript (Weraarpachai et al., 2009). Leucine-rich PPR-motif 
(LRPPRC) may also function in COXI translation regulation by stabilising COXI and 
COXIII transcripts (Xu et al., 2004); however, it has also been thought to function in 
concert with heterogeneous nuclear ribonucleoprotein K (HnRNP K) and POLRMT in 
coupling transcription and translation (Shadel, 2004).  
Post-translational processing 
After translation, mitochondrial proteins are bound by chaperones such as HSP60 and 
HSP70, to prevent aggregation and ensure correct folding. HSP100/Clp chaperones 
disturb protein aggregates and process misfolded proteins by targeting them for 
refolding or degradation where appropriate (Voos and Rottgers, 2002). Proteases are 
responsible for quality control and degradation of aberrant proteins. Lon and Clp-like 
proteases are located in the matrix of the mitochondria, whereas AAA-proteases are 
positioned either side of the inner membrane (i-AAA (intermembrane space) and m-
AAA (matrix) (Koppen and Langer, 2007). 
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Mitoribosomes are directly associated with the inner membrane (Liu and Spremulli, 
2000), which allows for co-translational insertion of nascent peptides directly into the 
inner membrane. Several proteins are implicated in this process, including: Oxa1 
(Bonnefoy et al., 2009, Stuart, 2002); Mba1, Mrp20 and Mrpl40 homologues MRPL45, 
MRPL23 and MRPL24 respectively (Jia et al., 2003, Jia et al., 2009, Ott et al., 2006). 
LETM1, a homologue to yeast Mdm38, has also been implicated in this process through 
its interaction with MRPL36 (Piao et al., 2009). This would allow for efficient 
transition of peptides between translation machinery and addition to assembling 
complexes.  
The majority of identified assembly factors have been associated with Complex I or IV 
(Fernandez-Vizarra et al., 2009); however, assembly factors have been identified for all 
complexes, such as: NDUFA1 for Complex I (Vogel et al., 2005); SDHAF1 for 
Complex II (Ghezzi et al., 2009); BSC1L for Complex III (Pecina et al., 2004); SURF1 
for Complex IV and ATP11 for Complex V (Wang et al., 2001). Correct assembly into 
supercomplexes is also essential for efficient mitochondrial function, and explains how 
assembly defects for one complex can cause combined respiratory deficiency by 
secondary instability of other complexes (Schagger et al., 2004). There are also proteins 
essential for stability of particular supercomplexes. Tafazzin (encoded by TAZ) 
participates in cardiolipin metabolism, an inner membrane phospholipid, and mutations 
in this gene cause cardiolipin deficiency and instability of the I/III2/IV supercomplex 
(McKenzie et al., 2006). 
1.4.6 Regulation of biogenesis 
Regulation of the demand for energy is not dependent on a singular rate-limiting step, 
and is reliant on many factors such as enzyme content, concentration of intermediate 
substrates and the steady-state energy levels in each tissue (Fell, 1992). These 
parameters can contribute to the understanding of how different specialised organs 
regulate mitochondrial bioenergetics in a different manner (Pfeiffer et al., 2001). 
Mitochondrial biogenesis is an orchestrated process requiring the synthesis and import 
of proteins and lipids co-ordinated with the replication of mtDNA (Figure 1.14). 
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Figure 1.14 An overview of regulation of mitochondrial biogenesis. Temperature, 
exercise and calorie restriction can stimulate transcription factors responsible for 
upregulation of PGC1α expression and the post-translational modifications that regulate 
its activity. PGC1α induces downstream transcriptional responses to upregulate 
mitochondrial biogenesis (Adapted from Hock and Kralli, 2009).  
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Transcriptional co-regulators: The PGC1 family 
Mitochondrial biogenesis can be stimulated by numerous methods, both through 
environmental or physiological stimuli or molecular metabolic processes. Co-ordination 
of this vast number of interconnecting pathways is achieved mainly through the PPARγ 
coactivator 1 (PGC1) family of proteins. These proteins have integral transcription 
activation domains, the ability to interact with numerous different transcription factors, 
and sites of post-translational modification, all of which allow a deeper level of 
complexity to its interaction with regulatory proteins (Hock and Kralli, 2009).  
The predominant member of the family is peroxisome proliferator-activated receptor-γ 
coactivator 1 α (PGC1α; encoded by PPARGC1A), first identified through its interaction 
with PPARγ (Puigserver et al., 1998). This led to the subsequent identification of 
PGC1β and PRC through their sequence homology to PGC1α (Andersson and 
Scarpulla, 2001, Lin et al., 2002) 
Upregulation of PGC1α and PGC1β in skeletal muscle causes increased mtDNA 
content, mitochondrial gene expression and improved exercise ability (Calvo et al., 
2008). Inactivation of either gene causes decreased mitochondrial expression and 
mitochondrial activity, with mild phenotypic impairment such as poor response to cold 
temperatures and weakened exercise capacity (Lelliott et al., 2006, Leone et al., 2005). 
PGC1α and PGC1β induce similar, but not identical, transcriptional responses and thus 
can compensate for mutational loss or downregulation of each other. However, in mice, 
if both genes are knocked out simultaneously there is a synergistic impact on 
mitochondrial function, with severe respiratory defects and death shortly after birth (Lai 
et al., 2008). 
Regulation of the PGC1 family is first achieved through tissue-specific transcriptional 
control of these gene products. Expression is inducible through environmental and 
physiological stimuli such as response to cold and exercise (Handschin and Spiegelman, 
2006). Beyond transcriptional control, there is complicated regulation of PGC1α 
activity through post-translational regulation such as phosphorylation, acetylation, 
arginine methylation and ubiquitination (Jager et al., 2007, Lerin et al., 2006, Olson et 
al., 2008, Teyssier et al., 2005).  
Receptor-interacting protein 140 (RIP140) is the major repressor for mitochondrial 
biogenesis, and acts in opposition to the PGC1 family members. It interacts with similar 
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targets to PGC1α/β, and recruits additional corepressors such as CtBP and histone 
deacetylases (HDACS) (Christian et al., 2006, White et al., 2008). Gene silencing or 
knock-out of RIP140 in mice leads to increased mitochondrial gene expression and 
biogenesis, and acts, at least in part, through interaction with ERRα (Leonardsson et al., 
2004, Powelka et al., 2006). Like PGC1α, RIP140 is also regulated through post-
translational modifications, such as sumoylation, acetylation and arginine methylation 
(Ho et al., 2008, Mostaqul Huq et al., 2006, Rytinki and Palvimo, 2008). 
Physiological stimuli 
Endurance training and exercise is known to stimulate mitochondrial biogenesis as a 
response to rising cellular energy demand. Signals induced by physical activity include 
increased muscle contraction-induced Ca
2+
 levels, and cellular response to energy 
deficit through AMP-activated protein kinases (AMPKs). Exercise can also stimulate 
the sympathetic nervous system causing adrenergic and cAMP signalling (Rockl et al., 
2008).  
Adaptive thermogenesis in response to cold also activates the sympathetic nervous 
system inducing adrenergic stimulation with an increase of cAMP signalling 
(Klingenspor, 2003). This ultimately induces uncoupling proteins which cause the 
proton gradient produced through the ETC to generate heat rather than ATP (Cao et al., 
2004).  
In situations of long-term calorie restriction, energy substrates for respiration are limited 
and therefore mitochondria must become more efficient to maintain cellular energy 
levels. Calorie restriction was thought to increase mitochondrial biogenesis through 
pathways required to increase energy production efficiency, such as AMPK, Sirtuin 1 
(SIRT1) and endothelial nitric oxide synthase (eNOS) signalling (Lopez-Lluch et al., 
2006, Nisoli et al., 2005). However; recent evidence suggests that mitochondrial 
efficiency is increased without upregulation of mitochondrial mass (Lanza et al., 2012) 
and that calorie restriction merely preserves mitochondrial biogenesis during aging to 
extend lifespan (Picca et al., 2013).  
Molecular signalling pathways 
Partial control of mitochondrial biogenesis relies on the balance between ATP 
production and ATP consumption, mirrored by the respective levels of AMP (adenine 
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monophosphate) compared to ATP. When the AMP/ATP ratio is high, AMPKs are 
triggered, which send downstream signals to block energy-demanding processes whilst 
enhancing metabolic processes to generate ATP (Hardie, 2007). A downstream target of 
AMPKs is SIRT1, which deacetylates downstream targets such as PGC1α, forkhead box 
O1 and O3 (FOXO1/FOXO3a) (Greer et al., 2007). These proteins and their 
downstream targets represent the major pathways connecting external physiological 
stimuli to regulation of mitochondrial biogenesis. 
Ca
2+
 signalling induces mitochondrial biogenesis through calcineurin (a Ca
2+
-dependent 
phosphatase), Ca
2+
/calmodulin dependent kinases (CAMKs) and p38 MAPK (Rockl et 
al., 2008). These signalling molecules act upon the PGC1α promoter, in conjunction 
with transcription factors of the MEF2 and CREB/ATF2 families, to induce expression 
of PGC1α (Akimoto et al., 2008, Akimoto et al., 2005, Handschin et al., 2003, McGee 
and Hargreaves, 2004). p38 MAPK also stimulates PGC1α activity through 
phosphorylation (Puigserver et al., 2001). 
Adrenergic stimulation and cAMP signalling has been implicated in the regulation of 
mitochondrial biogenesis (Miura et al., 2007). The cAMP response-element binding 
protein (CREB) can induce gene expression in some genes directly through promoter 
binding, or indirectly through upregulation of PGC1α. It has also been shown to 
translocate to the mitochondria and cause the upregulation of mitochondrially-encoded 
genes (De Rasmo et al., 2009).  
Another mechanism of stimulation, is inducing the expression of eNOS, increasing 
intracellular nitric oxide (NO) levels, and further stimulating mitochondrial biogenesis 
through increased expression of PGC1α (Nisoli et al., 2005, Niwano et al., 2006). 
PPARγ and PGC1α expression has also been enhanced by induction of neuregulins, 
which can activate ErbB tyrosine kinases and increase mitochondrial expression and 
oxidative capacity (Canto et al., 2006, Lebrasseur et al., 2003). 
c-Myc binds to the promoter regions of 107 nuclear-encoded mitochondrial genes and 
can activate expression of PGC1β (Kim et al., 2008, Zhang et al., 2007). Although 
further study is required, the other functions of c-Myc would suggest a possible link 
between cellular proliferation and mitochondrial biogenesis. Similarly, YY1 
transcription factor (YY1) has been shown to complex with PGC1α in muscle, 
dependent on mammalian target of rapamycin (mTOR) (Cunningham et al., 2007). 
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Since mTOR promotes cellular growth in the presence of sufficient nutrients, it is 
conceivable that YY1 regulates mitochondrial biogenesis in response to nutrient levels 
and with subsequent cellular growth patterns. 
Downstream transcription factor responses 
Nuclear respiratory factor 1 (NRF1) was first identified through its binding with 
cytochrome c promoter; however, binding sites for NRF1 have been identified in the 
promoter regions of many mitochondrial genes (including TFAM, TFB1M and TFB2M) 
(Scarpulla, 2008, Virbasius et al., 1993a). NRF1 expression can be regulated through 
phosphorylation or interaction with PGC1 family proteins (Wu et al., 1999). Its activity 
is repressed by cyclin D1, linking mitochondrial biogenesis to cell cycle progression 
(Wang et al., 2006). NRF1 expression does not regulate mitochondrial biogenesis alone, 
as upregulation of NRF1 transcripts does increase the expression of some of its targets, 
but does not increase the capacity for respiration (Baar et al., 2003). Overexpression of 
NRF1 in adipocytes increases mtDNA copy number but decreases lipid content and 
does not stimulate an increase in ATP production in cells. Furthermore, in addition to 
mitochondrial metabolic changes, continuous NRF1 overexpression alters cellular 
proliferation, apotosis and inflammatory response and eventually leads to insulin 
resistence in adiopocytes (van Tienen et al., 2010).    
NRF2, more correctly known as GA repeat -binding protein (GABP) is a heterotetramer 
comprised of two subunits, GABPα (encoded by GABPA) and GABPβ1 or β2 (encoded 
by GABPB1 and GABPB2 respectively) (Virbasius et al., 1993b). It also has promoter 
binding sites in many nuclear mitochondrial genes, including a subset downregulated in 
diabetes (Mootha et al., 2004). With the addition of host-cell factor 1 (HCF1), 
phosphorylated GABP can recruit PGC1α and PGC-1-related coactivator (PRC) to 
further increase its transcriptional activity (Vercauteren et al., 2008).  
Peroxisome proliferator-activated receptors (PPARα, PPARγ, and PPARδ) are 
predominantly involved in lipid homeostasis and each is highly abundant in different 
tissues (Evans et al., 2004). They also regulate the expression of uncoupling proteins 
(UCPs) which allows adaptive responses to external stimuli such as exercise and cold 
temperatures in a tissue-specific manner (Puigserver et al., 1998). A PPAR response 
element (PPRE) has been identified in the promoter PGC1α, allowing PPARs to 
enhance the activity of the transcriptional co-activtors (Tanaka et al., 2003).  
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Estrogen-related receptors (ERRα, ERRβ, and ERRγ) are not regulated by estrogen, but 
instead are regulated by interaction with coactivators such as SRC or the PGC1 family, 
which can activate transcription of mitochondrial genes (Giguere, 2008, Schreiber et al., 
2003). ERRs bind to ERR response elements (ERREs) in the promoters of genes 
involved in fatty acid oxidation, components of OXPHOS, the TCA cycle, 
mitochondrial dynamics and stress response. In concert with receptor-interacting protein 
140 (RIP40), ERRs can become negative repressors of transcription, causing 
downregulation of genes typically upregulated by PGC1 coactivators (White et al., 
2008). They also have indirect stimulatory effect on biogenesis through upregulation of 
GAPBα and PPARα (Huss et al., 2004, Mootha et al., 2004). 
Mitochondrial dynamics and degradation 
The mitochondrial network is continuously fluctuating, resulting from multiple fission 
and fusion events. Key proteins responsible for mitochondrial dynamics are OPA1, 
MFN1, MFN2, FIS1 and DRP1. Mutations in these genes result in defects in 
mitochondrial dynamics leading to compromised energy production (Chen et al., 2005). 
Recent evidence also suggests that mitochondrial dynamics can contribute to the 
regulation of ATP production in normal physiological situations. In times of stress, cells 
can undergo stress-induced mitochondrial hyperfusion (SIMH) which is accompanied 
by an increase in cellular ATP content (Tondera et al., 2009). Since mitochondria are 
heterogeneous in terms of shape, structure, position and the distribution of internal 
respiratory components (Wikstrom et al., 2009), fusion events could promote functional 
complementation across the mitochondrial network to prevent loss of ATP production 
in particular regions of the network (Nakada et al., 2001). This is corroborated by the 
evidence that MFN2 is upregulated in situations of high energetic demand, and 
overexpression of MFN2 stimulates mitochondrial biogenesis and glycolysis (Bach et 
al., 2005, Bach et al., 2003). 
Mitochondrial dynamics are also responsible for maintenance of mitochondrial function 
through selective separation of dysfunctional segments of the mitochondrial network, 
which are then targeted for degradation through mitophagy (Twig et al., 2008).  
1.5 Genetic Variation and Disease 
In 1962, investigation of a female patient with severe hypermetabolism identified 
morphologically abnormal mitochondria in her muscle biopsy and an uncoupling of 
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mitochondrial oxidation and phosphorylation (Luft et al., 1962). In the 1970s there were 
several more cases with mitochondrial dysfunction reported, leading eventually to the 
first classification of mitochondrial diseases based on which area of metabolism they 
affected (DiMauro et al., 1985). Mitochondrial disorders can usually be classified more 
specifically into well-defined syndromes, but often show high levels of phenotypic 
overlap.  
1.5.1 Overview of mitochondrial disease phenotypes 
Mitochondrial disorders are often multisystemic, typically having dysfunction in organs 
with high energy demands. The diverse range of clinical phenotypes associated with 
mitochondrial diseases is highlighted in Table 1.2. 
Table 1.2 Clinical features in mitochondrial disorders. The clinical phenotypes 
common to mitochondrial disorders in adults and children listed by the affected system 
of the body (Adapted from Taylor and Turnbull, 2005). 
 System Adult Paediatric 
Neurological 
Migraine, strokes, epilepsy, dementia, 
myopathy, peripheral neuropathy, diplopia, 
ataxia, speech disturbances, sensorineural 
deafness 
Epilepsy, myopathy, psychomotor 
retardation, ataxia, spasticity, dystonia, 
sensorineural deafness 
Gastrointestinal  Constipation, irritable bowel, dysphagia Vomiting, failure to thrive, dysphagia 
Cardiac Heart failure, heart block, cardiomyopathy 
Biventricular hypertrophic 
cardiomyopathy, rhythm abnormalities 
Respiratory 
Respiratory failure, nocturnal 
hypoventilation, recurrent aspiration, 
pneumonia 
Central hypoventilation, apnoea 
Endocrinal  
Diabetes, thyroid disease, parathyroid 
disease, ovarian failure 
Diabetes, adrenal failure 
Ophthalmological  
Optic Atrophy, cataract, ophthalmoplegia, 
ptosis 
Optic atrophy 
Haematological - Anaemia, pancytopaenia 
Renal - Renal tubular defects 
Liver - Hepatic failure 
 
A core set of symptoms are used to classify each disease, but additional clinical 
presentations are common and variable. For example, myoclonic epilepsy with ragged-
red fibres (MERRF) is diagnosed based on myoclonus, ataxia and seizures but is 
frequently observed with a combination of psychomotor regression, peripheral 
neuropathy, short stature and sensorineural hearing loss (DiMauro and Schon, 2001). 
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1.5.2  Primary mtDNA mutations 
The first mtDNA point mutation discovered was m.11778G>A, in the protein coding 
gene MT-ND4, associated with Leber’s Hereditary Optic Neuropathy (LHON) (Wallace 
et al., 1988). This was shortly followed by the discovery of mtDNA macrodeletions of 
up to 7kb in patients with general mitochondrial myopathy (Holt et al., 1988). The first 
tRNA mutations, m.8344A>G and m.3243A>G, were identified in 1990 as the cause of 
myoclonic epilepsy with ragged-red fibres (MERRF) and mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) respectively 
(Goto et al., 1990, Shoffner et al., 1990).  
Scoring systems have been developed to determine the probability of newly discovered 
mutations in either RNA or protein-coding genes being pathogenic (McFarland et al., 
2004, Mitchell et al., 2006). The pathogenicity of all reported mtDNA mutations was 
assessed by Hellebrekers and colleagues (2012), and used to determine the possibility of 
pathogenic heteroplasmic mutation carriers having healthy children through 
preimplantation genetic diagnosis (PGD) (Hellebrekers et al., 2012).   
Mutations affecting protein synthesis 
Mutations disrupting mitochondrial protein synthesis can be either single deletions or 
point mutations in tRNA or rRNA genes. Mitomap (http://mitomap.org) lists 30 
confirmed (248 reported) pathogenic point mutations in tRNA/rRNA genes (correct as 
of 12/05/2014).  
Since any defects in protein synthesis will affect expression of all mitochondrial 
encoded proteins, disorders can be multisystemic. Additionally, defects in protein 
synthesis will generally cause lactic acidosis and mitochondrial proliferation, evidenced 
by the appearance of ragged-red fibres (RRFs) on muscle biopsy (DiMauro and Schon, 
2001).  
More than 50% of the identified pathogenic mutations are in tRNA genes, despite them 
only covering ~10% of the mitochondrial genome (Levinger et al., 2004). Mutations in 
tRNA genes can cause misfolding, prevent correct base modification, cause instability 
or affect aminoacylation (Scaglia and Wong, 2008). The majority of pathogenic 
mutations occur on the stem structures of tRNAs, particularly in the anticodon and 
aminoacyl acceptor stems (McFarland et al., 2004). 
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Of the two rRNA genes, pathogenic mutations have only ever been identified in the 
gene encoding 12S rRNA (RNR1). These mutations are typically associated with 
sensorineural deafness, the most common mutation being m.1555A>G (Rotig, 2011). In 
many cases, the mutation induces sensitivity to aminoglycosides, with variable clinical 
phenotypes when not exposed to the drug (Prezant et al., 1993). Penetrance can be 
variable, and there is evidence that genes involved in post-transcriptional modification 
of 12S rRNA can act as nuclear modifiers of the m.1555A>G mutation (discussed 
further in Section 1.5.3) (Bykhovskaya et al., 2004b, Guan et al., 2006). 
Mutations in protein-coding genes  
The mitochondrial genome encodes subunits for Complex I, III, IV and V. Mitomap 
lists 29 confirmed (226 reported) pathogenic point mutations in these genes (correct as 
of 12/05/14). The majority of these mutations are heteroplasmic, with the homoplasmic 
mutations seemingly modified by tissue-specific nuclear genes (Wong, 2007).  
Mutations have been found in all seven Complex I genes (MT-ND1-6, MT-ND4L), 
usually, but not exclusively, causing LHON, MELAS or Leigh syndrome (Brown et al., 
1995, Kirby et al., 2004, Lebon et al., 2003). Mutations in the only Complex III subunit, 
MT-CYTB, cause a more diverse set of clinical symptoms, but most commonly include 
exercise intolerance, myoglobinuria, hypertrophic cardiomyopathy and mitochondrial 
encephalopathy (Andreu et al., 1999). Mutations in any of the three Complex IV genes 
(MT-CO1-3) cause a wide range of clinical phenotypes, most commonly including 
myopathy, exercise intolerance, rhabdomyolysis, and severe early-onset Leigh 
syndrome (Horvath et al., 2005, Shoubridge, 2001). The majority of mutations in the 
two Complex V genes (MT-ATP6, MT-ATP8) cause Leigh syndrome, though cases with 
bilateral striatal necrosis (BSN) and neuropathy, ataxia, retinitis pigmentosa (NARP) 
have been identified (De Meirleir et al., 1995, Enns et al., 2006).  
mtDNA rearrangements 
Mitomap lists 133 deletions ranging in size from 4 to 10987 bases, and six small 
insertions ranging from 4 to 266 bp (correct as of 12/05/14). There has even been a case 
of a small, 7 bp inversion in the ND1 gene causing mitochondrial myopathy (Musumeci 
et al., 2000). 
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Whereas multiple deletions arise from nuclear mutations in genes involved in mtDNA 
maintenance, single mtDNA mutations arise from clonally expanded, sporadic events 
(Suomalainen and Kaukonen, 2001). Single mtDNA deletions are estimated to account 
for a quarter of adult mitochondrial diseases, and also to cause some cases of paediatric 
disease (Chinnery et al., 2000a). One mechanism suggests that homologous base pairs 
on alternative strands align and loop out regions of the mtDNA molecule during 
asynchronous replication (Shoffner et al., 1989), another suggests that the deletions 
occur during double-strand break repair (Krishnan et al., 2008). 
The common mtDNA deletion removes 4977 bp of DNA, containing several protein-
coding genes and many tRNA genes, whilst retaining the ability to replicate (Barritt et 
al., 1999, Chan et al., 2005, Chen et al., 1995). Although a diverse range of phenotypes 
occur due to single deletions, the most commonly associated syndromes are Pearson 
marrow-pancreas syndrome (PMPS), Kearns–Sayre syndrome (KSS) and Progressive 
external ophthalmoplegia (PEO) (Pitceathly et al., 2012).  
1.5.3 nDNA mutations 
The first nuclear mutation affecting mitochondrial function was described in a subunit 
of Complex II, causing Leigh Syndrome (Bourgeron et al., 1995). 
Structural subunit genes 
The most common mutations discovered in nuclear encoded OXPHOS subunits are in 
Complex I genes. Usually, mutations in nuclear Complex I subunits result in Leigh 
Syndrome (Loeffen et al., 1998), but others have been identified in patients with 
hypertrophic cardiomyopathy and encephalomyopathy (Benit et al., 2003). Complex II 
subunit mutations have also resulted in Leigh Syndrome (Bourgeron et al., 1995) but 
most often result in paragangliomas (Baysal et al., 2000). Complex III and IV mutations 
are more rare, with variable associated phenotypes such as hypoglycaemia and lactic 
acidosis (Haut et al., 2003) and infantile encephalomyopathy respectively (Massa et al., 
2008). To date, there has been no complex V nuclear subunit mutations identified.  
mtDNA maintenance and mitochondrial depletion syndromes (MDS) 
Maintenance of mtDNA levels requires a diverse set of proteins surrounding replication 
of the mitochondrial genome. This includes Pol γ, both the catalytic and accessory 
subunits (encoded by POLG and POLG2 respectively), along with additional proteins 
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involved with replication such as the helicase Twinkle (encoded by C10orf2). It also 
involves maintenance of a stable dNTP pool to supply Pol γ during replication. 
Mutations in genes responsible for dNTP pool maintenance often lead to induced point 
mutations, deletions and mtDNA depletion (Copeland, 2008, Saada, 2004).  
The first mutation identified in POLG was associated with progressive external 
opthalmoplegia (PEO) with classical appearance of mtDNA deletions (Van Goethem et 
al., 2001). Since then, further mutations have been found commonly associated with 
Alpers’ syndrome (Naviaux and Nguyen, 2004) and several types of ataxia-neuropathy 
such as sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO) (Van 
Goethem et al., 2001). 
Later, a mutation was identified in POLG2, causing a phenotype similar to that caused 
by POLG mutations in PEO, presumably through failure to enhance processivity of Pol 
γ (Longley et al., 2006). Mutations in C10orf2 (Twinkle) have also been found 
associated with PEO (Spelbrink et al., 2001) and SANDO (Spelbrink et al., 2001). 
Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), 
member 4 (SLC25A4; formerly adenine nucleotide transporter 1, ANT1), has also been 
found to cause PEO when mutated (Kaukonen et al., 2000).  
There are several genes regulating dNTP pools implicated in mitochondrial diseases. 
Mutations in thymidine phosphorylase (encoded by ECGF1) are commonly associated 
with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) (Nishino et al., 
1999). Mutations in mitochondrial thymidine kinase (TK2) cause dysfunction mainly in 
skeletal muscle, where TK2 expression is the highest (Saada et al., 2003), causing fatal 
myopathy and mitochondrial depletion in infants (Saada et al., 2001). Deoxyguanosine 
kinase (DGUOK) mutations cause severe hepatocerebral forms of mitochondrial 
depletion syndrome (MDS) (Mandel et al., 2001). Further genes affected by mutations 
causing MDS in various forms include: deoxynucleotide carrier (SLC25A19) 
(Rosenberg et al., 2002); succinyl-coA subunits (SUCLG1/SUCLA2) (Elpeleg et al., 
2005, Ostergaard et al., 2007); MPV17 (Spinazzola et al., 2006) and p53-inducible 
ribonucleotide reductase (RRM2B) (Bourdon et al., 2007). 
Several mutations were identified in OPA1, a mitochondrial fusion gene, as causing 
dominant optic atrophy plus (DOA+) (Amati-Bonneau et al., 2008, Hudson et al., 
2008). Though the condition mainly affects the ocular system, it was later established 
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that mutations in OPA1 usually cause multi-system neurological dysfunction (Yu-Wai-
Man et al., 2010). Later, in patients suffering with optic atrophy, axonal sensorimotor 
neuropathy and cerebellar ataxia, mutations in another mitochondrial fusion gene, 
MFN2, were identified (Rouzier et al., 2012). Mutations in both OPA1 and MFN2 cause 
accumulation of somatic mtDNA deletions, and the disease mechanism is suspected to 
be either increased rate of de novo mutation formation or accelerated clonal expansion 
of pre-existing mutations (Yu-Wai-Man and Chinnery, 2012). 
Translation factors 
Since mitochondrially-encoded proteins require their own translation machinery, it is 
inevitable that mutations in genes encoding these proteins will affect mitochondrial 
function. Mutations have been identified in proteins covering a broad range of 
translational functions. Mutations in mitoribosomal protein genes, such as MRPS16, 
cause fatal neonatal lactic acidosis (Miller et al., 2004). Mutations in genes encoding 
elongation factors, such EFTu or EFG1, can cause severe lactic acidosis and 
progressive, fatal encephalopathy (Valente et al., 2007). There is also a wide range of 
tRNA processing proteins essential for mitochondrial translation. The first group are 
tRNA synthetases, responsible for aminoacylation of the tRNAs. Mutations in DARS2 
were found in 30 families with Leukoencephalopathy with brain stem and spinal cord 
involvement and lactate elevation (LBSL) (Scheper et al., 2007). TRMU is responsible 
for 2-thiolation of the wobble bases in tRNA-Lys, tRNA-Gln, and tRNA-Glu, and 
mutations can cause acute liver failure in infancy (Zeharia et al., 2009). PUS1 converts 
uridine to pseudouridine in tRNAs, thought to stabilise the tertiary structure and aid the 
peptidyl transferase, and mutations in PUS1 cause mitochondrial myopathy, lactic 
acidosis and sideroblastic anaemia (MLASA) (Bykhovskaya et al., 2004a). Paraplegin 
is a protein of the m-AAA protease, involved in quality control and ribosomal 
processing. A mutation has been found in this gene causing hereditary spastic 
paraplegia (Casari et al., 1998). 
Import proteins 
Defects in mitochondrial import can have widespread phenotypic consequences due to 
the diverse nature of proteins requiring import into mitochondria. Mutations in 
TIMM8A, a component of the inner membrane translocase complex, have been 
identified as causing deafness-dystonia syndrome (DDS; also known as Mohr-
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Tranebjaerg syndrome, MTS) and Jensen Syndrome (Jin et al., 1996, Tranebjaerg et al., 
2000). Mutations in TIM23 complex protein DNAJC19 cause dilated cardiomyopathy 
with ataxia (DCMA) syndrome (Davey et al., 2006). 
Complex assembly factors 
Many mutations have been found in assembly factors for Complex I, III, IV and V. 
Mutations in Complex I assembly factor gene, NDUFAF, cause decreased Complex I 
activity leading to progressive encephalopathy (Ogilvie et al., 2005). Mutations in 
Complex III assembly factor BCS1L have been associated with hepatic failure, 
tubulopathy and encephalopathy (de Lonlay et al., 2001). Complex IV assembly factor 
mutations are the most abundant, such as SURF1 mutations causing Leigh Syndrome 
(Tiranti et al., 1998), and SCO1/SCO2 mutations causing neonatal hepatic failure, 
encephalopathy and neonatal cardioencephalomyopathy (Papadopoulou et al., 1999, 
Valnot et al., 2000). Despite no mutations in Complex V nuclear subunit genes, 
mutations in ATP12, a complex V assembly gene, have been described as causing early-
onset encephalopathy and lactic acidosis (De Meirleir et al., 2004). 
Nuclear modifiers of mtDNA mutations 
Some mtDNA mutations require nDNA mutations acting in concert to produce distinct 
phenotypes. In 90% of cases with LHON, 1 of 3 mtDNA mutations are present, 
m.3460G>A, m.11778G>A or m.14484T>C. However, the presence of any of the 
mutations alone is not sufficient to cause LHON, with only 50% of males and 10% of 
females with a homoplasmic mutation developing a clinical phenotype (Man et al., 
2003). This suggests a nuclear modifying mutation is required for expression of the 
disease phenotype, which is yet to be identified (Hudson et al., 2010, Hudson et al., 
2011).  
The mtDNA mutation m.1555A>G in 12S rRNA is associated with maternally inherited 
deafness, and several nuclear gene mutations have been found which modify the 
phenotypic expression of this mutation. This includes some of the proteins responsible 
for methylation of 12S rRNA, TRMU and TFB1M (Bykhovskaya et al., 2004b, Guan et 
al., 2006). 
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1.5.4 Accumulation of mtDNA mutations with age 
Approximately 90% of available tissue oxygen is consumed by mitochondria, 1-5% of 
which is leaked as oxygen radicals (O2·
-
), by Complex I and III (Richter et al., 1995). 
These reactive oxygen species (ROS) are typically converted to hydrogen peroxide 
(H2O2) by manganese-superoxide dismutase (MnSOD), then subsequently detoxified by 
catalase (CAT) or glutathione peroxidase (GPx) (Fridovich, 1997). However, some 
ROS evade detoxification and can cause damage to nearby proteins and mtDNA 
molecules.  
Many mitochondrial proteins are susceptible to oxidative damage, including proteins 
directly involved in energy metabolism, such as glutamate dehydrogenase (GDH) and 
support proteins such as prohibitin (PHB), which prevents protein misfolding (Conrad 
et al., 2001, Schleicher et al., 2008).  
Pathogenic mutations affecting OXPHOS capacity have been shown to exacerbate the 
leak of oxygen radicals from mitochondrial complexes (Piccolo et al., 1991, Smits et 
al., 2010a). Although somatic mutations can be introduced onto individual mtDNA 
molecules, the accumulation of high enough heteroplasmy levels to cause loss of 
mitochondrial activity is more likely occur from clonal expansion of mtDNA mutations 
present at birth (Elson et al., 2001), as studies show affected cells to have a single 
mutation type. There is evidence of tissue-specific ‘hot spots’ where mutations are 
frequently discovered, particularly in the 407-411 region of mtDNA (Corral-Debrinski 
et al., 1992, Nekhaeva et al., 2002), though age-related mutations can accumulate across 
the whole genome (Kraytsberg et al., 2006, Michikawa et al., 1999). Accumulation of 
mtDNA macrodeletions has also been observed in aged tissues (Cortopassi et al., 1992). 
The consequence of mtDNA mutations in aged tissues is evidenced by the mosaic loss 
of COX-activity in some tissues (such as muscle), strikingly similar to that of 
mitochondrial disease (Brierley et al., 1998, Muller-Hocker et al., 1992). 
1.5.5 Mitochondrial involvement in common complex disease 
mtDNA variants are also causative or associated with common complex diseases. 
Diabetes is the most common metabolic disease, and several mtDNA variants have been 
found to be the cause in a small number of cases (Lowell and Shulman, 2005). There is 
also accumulating evidence for mtDNA variants in the predisposition of common 
diseases such as diabetes, Alzheimer’s disease and Parkinson’s disease (Lin and Beal, 
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2006). Several studies have identified associations between particular haplogroups and 
the occurrence of common diseases; however, results often contradict one another, 
leaving the relevance of any identified association unclear (Chagnon et al., 1999, Ross 
et al., 2003, van der Walt et al., 2004, van der Walt et al., 2003).  
Some mutations in nuclear-encoded mitochondrial genes are thought to cause tumours, 
such as fumarate hydratase mutations in uterine leiomyomas and renal cell carcinomas 
(Lehtonen et al., 2004), and Complex II subunit mutations in paraganglioma formation 
(Astuti et al., 2001, Baysal et al., 2000). Increased ROS production is implicated in the 
pathogenesis of tumour formation, as MnSOD knockout in mice increased cancer 
incident by 100% (Van Remmen et al., 2003), and many tumours have reduced MnSOD 
activity (Xu et al., 1999). Accumulation of somatically acquired mtDNA mutations in 
cancers have also been observed, suggesting a possible link between risk of cancer and 
aging (Petros et al., 2005). 
1.5.6 Treatment of mitochondrial disease through manipulation of biogenesis 
In most cases, mitochondrial disease cannot be prevented and treatment options are 
limited; however, several therapeutic strategies are being developed to combat a diverse 
range of mitochondrial disorders. These include replacement of defective gene products, 
scavenging toxic intermediates, optimising ATP synthesis and bypassing defective 
OXPHOS components (Wenz et al., 2010).  
Manipulation of Ca2+ concentration has potential therapeutic uses, as increases in 
mitochondrial Ca2+ concentration can stimulate dehydrogenases partaking in the TCA 
cycle with increased downstream ATP synthesis (Visch et al., 2004).  
Another method of increasing ATP synthesis to alleviate mitochondrial dysfunction is 
to stimulate biogenesis, so increasing the overall number of OXPHOS subunits. This 
principle was demonstrated to be successful by transgenic overexpression of PGC1α, 
which increased mitochondrial mass, improved energy production and rescued the 
myopathy phenotype caused by COX deficiency (Wenz et al., 2008). Upregulation of 
PGC1α/β in human cultured cells with either Complex III/IV deficiency or the 
m.3243A>G mutation improves OXPHOS function and respiratory capacity (Srivastava 
et al., 2009). This can be adapted from mice to benefit humans by exercise-induced 
stimulation of biogenesis through AMPK and Ca2+ signalling (Benton et al., 2008, 
Wenz et al., 2009).  
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Pharmacological agents have been developed to stimulate biogenesis without the need 
for exercise, which can be challenging for some patients with mitochondrial disease. 
Bezafibrate treatment has been shown to ameliorate mitochondrial myopathy in mouse 
models with COX deficiency (Wenz et al., 2008), and restore OXPHOS capacity in 
human cell lines with various complex deficiencies or tRNA mutations (Bastin et al., 
2008, Wenz et al., 2011).  
Modulation of mitochondrial biogenesis as a therapeutic strategy has a wider scope of 
use than solely in mitochondrial disease. Glycogen synthase kinase-3 (GSK) inhibitors 
can restore mitochondrial biogenesis to neurones suffering oxygen-glucose deprivation 
(OGD) as a result of ischemic stroke (Valerio et al., 2011). Natural polyphenolic 
compounds, commonly found in food, have been shown to be potent stimulators of 
mitochondrial biogenesis. The benefits of a Mediterranean diet in reduction of 
cardiovascular disease are attributed in part to hydroxytryrosol (HT), found in olive oil, 
which has been shown to stimulate expression of PGC1α and increase mitochondrial 
biogenesis (Hao et al., 2010). Resveratrol (RSV) is found in grape skins, and the 
treatment of mice with RSV significantly increased their aerobic capacity and prevented 
diet-induced obesity and insulin resistance (Lagouge et al., 2006).  
  
Chapter 1  
62 
 
1.6 The aims of this study 
This PhD endeavours to understand the regulation of mitochondrial biogenesis and the 
relevance of these processes during embryonic development, to inheritance and in 
mitochondrial disease.  
1.6.1 Chapter 3: Investigating the inheritance of pathogenic mtDNA mutations 
Due to the mtDNA bottleneck, heteroplasmy levels can rapidly shift between 
generations. The central aim of this project is to improve our understanding of the 
variance in heteroplasmy inheritance in the population. I will assay the heteroplasmy 
levels in a large cohort of mother-child pairs for three common pathogenic mtDNA 
mutations, m.3243A>G, m.8344A>G and m.8993T>G. I will use these to calculate the 
change in heteroplasmy beween each mother and her children and establish whether any 
mutations show selection bias as they pass through the mtDNA bottleneck.  
I will compare these results to a meta-analysis of previously published studies for these, 
and two additional mutations, m.11778G>A and m.3460G>A.  
Summary 
1. Assess the most reliable method for measuring mtDNA heteroplasmy values, 
testing restriction fragment length polymorphism (RFLP) analysis and 
pyrosequencing.  
2. Measure the heteroplasmy of mother-child pairs for three mutations: 
m.3243A>G,  m.8344A>G and m.8993T>G. 
3. Use mother-child pairs to generate data for variance caused by the mtDNA 
bottleneck, establishing whether any mutation has skewed selection. 
4. Collate heteroplasmy data from available published resources for five mtDNA 
mutations: m.3243A>G; m.3460G>A; m.8344A>G; m.8993T>G; m.11778G>A. 
1.6.2 Chapter 4: Gene expression during murine embryogenesis 
The mechanism for how the mtDNA bottleneck skews heteroplasmy values between 
generations has not yet been fully elucidated. Crucial to formation of the bottleneck is 
the dramatic increase in mtDNA replication rate that allows primordial germ cells 
(PGCs) to repopulate their mitochondrial genomes. Analysis of mtDNA copy number 
during embryogenesis has been undertaken in many laboratories, including our own. I 
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aim to monitor the expression of genes related to mitochondrial biogenesis and 
replication at critical stages of embryonic development, allowing identification of the 
stage at which mtDNA replication rate increases. As this area is novel in our group, this 
project will also involve setting up and optimising gene expression analysis on tissue 
which is very limited.  
Summary 
1. Selection of a gene panel suitable for studying mitochondrial related-gene 
expression during murine embryogenesis. 
2. Gene expression analysis during pre-implantation embryogenesis. 
3. Optimising gene expression analysis from PGCs during post-implantation 
embryogenesis.  
1.6.3 Chapter 5: Identification of mtDNA copy number regulatory factors 
To complement the investigation of mitochondrial gene expression during murine 
embryogenesis, I will establish a human cell culture model to mimic the regulation of 
mtDNA copy number observed during the bottleneck. This will allow identification of 
regulated genes, crucial to the process of recovering mtDNA copy number in dividing 
cells. There are many therapeutic agents which target components of the mitochondrial 
biogenesis pathways. These offer the potential to investigate how modulation of 
mtDNA replication and biogenesis may affect mtDNA copy number repopulation 
during embryogenesis, and the subsequent impact on heteroplasmy variance observed 
between generations. 
Summary 
1. Selection of the most suitable drugs and concentrations to test for depletion of 
mtDNA and optimisation of the repopulation assay. 
2. Assay the gene expression patterns of several known mitochondrial biogenesis 
replication factors (TFAM; NRF1; POLG; POLG2) during repopulation of 
cellular mtDNA copy. 
3.  Identify the most suitable experimental technique for further in-depth analysis 
of mitochondrial gene expression.  
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4. Assess techniques to alter gene expression of key genes identified during 
depletion/repopulation as a potential method for modulating the mtDNA 
bottleneck in vivo. 
1.6.4 Chapter 6: Gene expression analysis in MERRF muscle fibres 
Ragged-red fibres (RRFs) are a common hallmark of many mitochondrial diseases, 
caused by proliferation of mitochondria in the subsarcolemmal region of muscle tissue. 
This provides a unique model to study mitochondrial biogenesis relevant to human 
disease. Previously, gene and protein expression in RRFs have only been visualised by 
immunohistochemistry or in situ hybridisation. In this chapter, I will first develop 
methods to visualise RRF in tissues, and allow extraction of intact RNA for broad 
analysis of mitochondrial-related gene expression in isolated populations of fibres. 
Summary 
1. Investigation of techniques to identify ragged-red fibres in muscle sections. 
2. Optimise a protocol to ensure RNA quality remains high during tissue 
preparation and identification of RRF. 
3. Optimise a protocol for RNA extraction from laser-microdissected muscle 
fibres. 
4. Gene expression analysis from isolated populations of muscle fibres. 
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2.1 Primer Design 
Gene reference sequences were identified using RefSeq (Maglott et al., 2000, Pruitt et 
al., 2009). Primer oligonucleotides for polymerase chain reaction (PCR) were designed 
using Primer3 (Rozen and Skaletsky, 2000) and tested using UCSC In Silico PCR 
(Fujita et al., 2011) to ensure the product was specific to the region of interest. When 
designing primers for cDNA gene expression analysis, special care was taken to design 
primer pairs around exon boundaries, to exclude the possibility of genomic DNA 
amplification. In genes where alternative splicing is present, primer sets were designed 
to amplify products for all known transcript variants. Primer pairs were typically 
designed at the 3’ end of the transcript, to limit the effect of any undetected RNA 
degradation on the qPCR signal. 
2.2 Primary PCR and agarose gel electrophoresis 
PCRs were performed using a Veriti
®
 96-well Thermal Cycler (Applied Biosystems, 
Life Technologies, Paisley, UK). 
2.2.1  GoTaq® reaction  
GoTaq
®
 DNA Polymerase reaction (All reagents from Promega, Southampton, UK): 
1 U GoTaq® polymerase, 1x GoTaq® Buffer (1.5mM MgCl2), 2mM dNTPs (dATP, 
dTTP, dCTP and dGTP), 0.25 µM forward and reverse primers, with ~30 ng DNA 
template and deionised water (d.H2O) to 30 µL. PCR program: 94 °C 4 min; 94 °C 
1 minute, 60 °C 1 min, 72 °C 1 min for 30 cycles followed by a 72 °C for 10 min 
extension. Unless specified, all PCR reactions were cycled with an annealing 
temperature of 60 °C. 
2.2.2  ImmolaseTM reaction 
Immolase
TM
 DNA Polymerase reaction (All reagents from Bioline, London, UK): 1 U 
Immolase
TM
 polymerase, 1X ImmoBuffer, 2 mM dNTPs (dATP, dTTP, dCTP and 
dGTP), 0.25 µM forward and reverse primers, with ~30 ng DNA template and d.H2O to 
25 µL. PCR program: 95 °C 10 min; 95 °C 45 s, 60 °C 45 s, 72 °C 1 min for 30 cycles 
followed by a 72 °C for 10 min extension. Unless specified, all PCR reactions were 
cycled with an annealing temperature of 60 °C. 
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2.2.3  Agarose gel electrophoresis 
The PCR product was analysed on an agarose gel. The PCR product (typically 5 µL) 
was mixed with one volume Orange G loading buffer (50% Glycerol, 50% H2O, Orange 
G (Sigma-Aldrich). Unless specified otherwise, agarose gels were made with 1.5% 
(w/v) Seakem
®
 LE agarose (Helena Bioscience, Gateshead, UK) and 0.4 µg Ethidium 
Bromide (Sigma-Aldrich, Dorset, UK) in 1X TAE buffer. The gels were 
electrophoresed in 1X TAE at 50-70 V for 45 min to 2 h depending on the expected 
fragment sizes. One volume DNA ladder (Hyperladder I-V, Bioline) was 
electrophoresed alongside PCR product to aid in sizing DNA fragments.  
Agarose gels were imaged under UV and analysed using the GelDoc-It
®
 Imager (UVP, 
Cambridge, UK). 
2.3 Bacterial Cloning 
2.3.1  Ligation and transfection 
Ligation templates were created by amplifying fragments of DNA from the region of 
interest using a standard GoTaq Polymerase reaction (Section 2.2.1). The PCR product 
was ligated into the plasmid vector overnight at 4 °C following the standard pGEM-T 
Easy Vectors protocol (Promega). 50 µL JM109 (Promega) competent cells were used 
for transformation with 2 µL ligation product. The cells were placed on ice for 20 min, 
followed by heat-shock at 55 °C for 45-55 s, and then returned to ice. 
2.3.2  Bacterial culture 
Lysogeny broth (LB) culture media was prepared with bacto tryptone (1%; w/v), yeast 
(0.5%; w/v) and NaCl (1%; w/v). LB agar was prepared by the addition of bacterial 
culture agarose (1.5%; w/v), X-gal (75 mg/ mL), IPTG (0.5 µL/ mL) and Ampicillin 
(50 mg/ mL) to LB culture media (All from Sigma-Aldrich). Under sterile conditions, 
LB media was poured whilst molten into culture dishes and allowed to cool. To increase 
bacterial population, 475 µL LB media was added to the transformation mixture and 
incubated for 1.5 h at 37 °C.  
With variable ligation efficiency, multiple dilutions of cells were spread onto agar plates 
under sterile conditions to obtain optimal yield for individual colonies. If the ligation 
efficiency was expected to be low, the cells were centrifuged for 5 min at 1000 x g and 
the pellet resuspended in 100 µL LB media. The total volume was spread onto an agar 
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plate under sterile conditions. All plates were incubated overnight at 37 °C, including a 
negative control to exclude the possibility of contamination.  
The following day, individual white colonies (transfected with plasmids containing the 
desired insert) were picked and streaked across new plates and left to culture for 8 h at 
37 °C to expand the population. Blue colonies indicate successful transfection, but 
plasmids without successful ligation of the PCR product. Samples from streaks were 
harvested and placed in 5 mL LB Agar (with the addition of 50 mg/ mL Ampicillin) and 
left to culture overnight at 37 °C with shaking.  
The following day, DNA was extracted using the QIAprep Spin Miniprep Kit 
(QIAGEN, Manchester, UK) standard protocol (Section 2.8.2). 
2.4 Restriction Fragment Length Polymorphism (RFLP) Analysis 
2.4.1 Last cycle fluorescent polymerase chain reaction (PCR) 
PCR was completed using the standard GoTaq Protocol (Section 2.2.1) with one 
modification. The program was paused before the last cycle and a mix (0.5 µL) with a 
fluorescently labelled primer was added: 0.5U GoTaq
®
 polymerase, 1x GoTaq
®
 Buffer 
(1.5mM MgCl2), 2mM dNTPs (dATP, dTTP, dCTP and dGTP), 2 µM forward and 
reverse primers (one standard, one fluorescent). The program was continued with one 
further cycle of 94°C 1 min, 58 °C 1 min, 72 °C 1 min followed by a 72 °C for 10 min 
extension.  
2.4.2 Restriction digest 
The digest reaction mix was 10 U restriction enzyme, compatible 1X restriction buffer, 
with ~10-20ng PCR product and d.H2O to 20 µL. The reaction was incubated overnight 
at 37 °C (All reagents from New England BioLabs, Hitchin, UK). 
2.4.3 Mapping and analysis 
For analysis of the digested fragments, 2 µL digest product was loaded onto a 96-well 
PCR plate with Hi-Di
®
 (8.5 µL) and Rox-500 size standard (0.5 µL). The plate was 
analysed on an ABI 3130xl Genetic Analyser, using a fragment analysis program to 
read the lengths of DNA fragments tagged with fluorescent primers. RFLP analysis was 
performed using GeneMapper
®
 Software v4.1 (all reagents and equipment supplied by 
Applied Biosystems, Life Technologies). 
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2.5 Pyrosequencing Analysis  
2.5.1 Assay and primer design 
Primers for both primary and sequencing reactions were designed using PyroMark
®
 
Assay Design SW 2.0 (QIAGEN). Selected primer sets were deemed to be ‘high 
quality’, indicating the software identified no problems or concerns and the primers 
were compatible. 
Assays for specific primer sets were created using the PyroMark
®
 Q24 Software 
(QIAGEN). 
2.5.2  Primary PCR with biotinylated primers 
The primary PCR was a 25 µL GoTaq® Hot Start Polymerase (Promega) reaction: 1 U 
GoTaq
®
 Hot Start polymerase, 1x Colourless GoTaq
®
 Flexi Buffer (1.5mM MgCl2), 
2mM dNTPs (dATP, dTTP, dCTP and dGTP), 0.25 µM forward and reverse primers, 
with ~30 ng DNA template and d.H2O to 30 µL. PCR program: 95 °C 10 min; 94 °C 
30 s, 60 °C 30 s, 72 °C 30 s for 30 cycles followed by a 72 °C for 10 min extension.  
2.5.3 Product clean-up and pyrosequencing 
After assessment of PCR product quality and quantity using agarose gel electrophoresis 
(Section 2.2.3), 5-20 µL PCR product was added to the binding solution (40 µL binding 
buffer, 2 µL streptavidin-coated Sepharose® beads) with 18-33 µL H2O to a total volume 
of 80 µL. The samples were agitated for 10 min to bind the DNA to the beads. Using the 
hand-held vacuum tool, the DNA was washed with Ethanol (70%), followed by 
Denaturation Solution and Wash Buffer. The product was eluted from probes in 25 µL 
annealing solution (annealing buffer containing 0.3 µM sequencing primer; all reagents 
from QIAGEN).  
The pyrosequencing was completed on a PyroMark
®
 Q24 (QIAGEN). 
2.5.4 Analysis of results 
Analysis was performed using PyroMark
®
 Q24 Software. Any reads flagged as low 
quality were repeated until satisfactory. Percentage heteroplasmy was automatically 
calculated by the software.  
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2.6 Sanger Sequencing 
Primary PCR products were generated using the Immolase PCR reaction described in 
Section 2.2.2. 
2.6.1 ExoSAP-IT treatment of primary PCR products 
ExoSAP-IT (GE Healthcare, Amersham, UK) contains the enzymes Exonuclease I and 
Shrimp Alkaline Phosphatase. It removes unincorporated dNTPS and primers and is an 
essential pre-sequencing treatment. Approximately 10-20 ng of primary PCR product 
(dependent on fragment length) was added to 2 µL ExoSAP-IT. It was incubated at 
37 °C for 30 min, followed by enzyme inactivation at 80 °C for 15 min. 
2.6.2 BigDye® terminator v3.1 cycle sequencing 
For the 20 µL sequencing reaction, BigDye® Cycle Sequencing RR-100 (1 µL), 1X 
BigDye
®
 Terminator v3.1 Sequencing Buffer and 0.5 µM forward or reverse primer 
(specific to each reaction) were combined with the ExoSAP-IT treated PCR product and 
d.H2O to 20 µL). Reactions were cycled under the following conditions: 96 °C 1 min, 
25 cycles of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 4 min. 
2.6.3 Ethanol precipitation 
To precipitate DNA fragments, 3 M Sodium Acetate (2 µL) (Sigma-Aldrich), 125 mM 
EDTA (2 µL) (Sigma-Aldrich) and 100% Ethanol (70 µL) were added to the cycle 
sequenced product, mixed gently, and incubated at room temperature in the dark for 
15 min to allow for DNA precipitation. Following precipitation, it was centrifuged at 
2000 x g for 30 min. After centrifugation, the solution was removed by inverting and 
centrifuging on the lowest setting for 15 s. To wash the pellet, 70% ethanol (100 µL) 
was added and the samples were centrifuged again at 1650 x g for 15 min. The ethanol 
was removed again, and the pellets were left to dry at room temperature in the dark for 
20 min.  
2.6.4 Sequence analysis 
The DNA pellets were resuspended in 10 µL Highly de-ionised (Hi-Di®) formamide, 
heated to 95°C for 2 min and then cooled on ice. Capillary sequencing was completed 
on the ABI 3130xl Genetic Analyser. The resulting raw data was then analysed using 
SeqScape
®
 v2.1.1 software (All supplied by Applied Biosystems, Life Technologies). 
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Mitochondrial DNA sequences were compared to the revised Cambridge Reference 
Sequence (rCRS) (NC_012920; http://www.ncbi.nlm.nih.gov/genbank/). Any potential 
changes identified were confirmed by sequencing in reverse. 
2.7 Tissue Culture 
To prevent contamination, primary cell culture was performed in a Heraeus HERAsafe 
HS-12 class II biohazard hood (Fisher Scientific, Loughbourough, UK). Reagents were 
prewarmed to 37°C before use with cultured cells. Cells were grown in either 
CELLSTAR
®
 Cell Culture Flasks (25/75/225 cm2) or 6-well Cell Culture Plates 
(Greiner Bio-one, Stonehouse, UK) at 37°C in a humidified Heracell 150i cell culture 
incubator (Fisher Scientific, UK) containing 5% CO2. 
2.7.1 Media change and subculture 
Primary myoblasts were cultured using Skeletal Muscle Cell Growth Medium with 
addition of the Supplement Mix (Promocell, Heidelberg, Germany), 10% or 15% Fetal 
Bovine Serum (FBS), 2 mM L-Glutamine, 50 µg/ mL uridine and 30 µg/ mL Gentamicin 
(All reagents Gibco, Life Technologies).  
Primary fibroblasts were cultured using Dulbecco's Modified Eagle Medium (DMEM; 
Gibco, Life Technologies) containing 25mM D-glucose, 1 mM sodium pyruvate, 2 mM 
L-glutamine with the addition of 10% FBS, 50 µg/ mL uridine, Penicillin (500 U/mL) 
and Streptomycin (500µg/ mL) (All from Gibco/ Life Technologies). 
Medium was changed at least every third day of culture. Before addition of new 
medium, the old medium was aspirated away and the cells washed with sterile 
phosphate buffered saline (PBS; Oxoid, Basingstoke, UK). 
To subculture cells, the old medium was first removed by aspiration, and the cells 
washed with PBS. To dissociate the cells from the flask, enough 1x Trypsin-EDTA 
solution (0.05% trypsin) (diluted in PBS) was added to create a thin layer over the cells. 
The flasks were then incubated at 37°C for 3-5 minutes, making sure all cells were 
detached before adding two volumes of medium to neutralise the trypsin. Cells were 
then pelleted by centrifugation at 1200 rpm for 5 min. The old media was aspirated off, 
and the cell pellet was then re-suspended in fresh media, and new flasks were re-seeded 
at the required cell density. 
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2.7.2  Freezing cells for storage 
For long-term storage, cell pellets were re-suspended in 1 mL ‘freezing medium’ 
consisting of 70% (v/v) DMEM, 20% FBS and 10% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich). The cryovial was placed in a Nalgene
®
 Mr. Frosty isopropanol bath 
(Sigma-Aldrich) and then in a -80 °C freezer, allowing a gradual cooling rate of 
1°C/min. After 48 hr at -80 °C, cryovials were moved to liquid nitrogen (L.N2) for long-
term storage.  
2.7.3 Cell counting 
Estimates of cell number were made using an Improved Neubauer Cell Counting 
Chamber (Hawksley, Lancing, UK). Cell pellets were resuspended in 1 mL PBS, then 
50 µL was transferred to a clean 200 µL Eppendorf tube and mixed in equal volumes 
with Trypan Blue (Sigma-Aldrich). 20 µL of this solution was loaded into each side of 
the cell counting chamber. The number of viable (unstained) cells in the four corner 
squares (1 mm2; volume 0.1 µL) of each side were counted and an average taken. This 
number was multiplied by 10
4
 to calculate the total number of viable cells in 1 mL of 
resuspension media. 
2.7.4 Pelleting cells for extraction 
Cells to be used for downstream applications, such as DNA/RNA/Protein extractions, 
were pelleted by centrifugation at 1200 rpm for 5 min, the old medium was removed by 
aspiration and the cells re-suspended in 1 mL PBS to wash away medium traces. The 
cells were centrifuged again under the same conditions, the PBS supernatant removed 
and the cell pellets frozen at -80°C. 
2.7.5 Mycoplasma detection 
Cell cultures were tested when initially removed from storage, monthly, or before being 
frozen down by the MycoAlert
®
 Mycoplasma Detection Kit (Lonza, Basel, 
Switzerland). All reagents were brought to room temperature before use. The old 
medium from cell culture was centrifuged at 1500 rpm for 5 min to pellet any cells or 
debris. 100 µL of supernatant was transferred into a 96-well white-walled plate well, 
and 100µL MycoAlert
®
 Reagent was added and incubated at room temperature for 5 
min. This control 1-second integrated reading was taken (Read A). The MycoAlert
®
 
substrate was then added and incubated at room temperature for 10 min. Another 
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reading was then taken (Read B), and the ratio between the first and second reading 
calculated (Read B/Read A). As the substrate is processed only by mycoplasma 
uninfected cells have a ratio <1, whereas infected cells have a ratio >1. 
2.7.6 Differentiation of myoblasts into myotubes 
To differentiate myoblasts, they were first grown to full confluency, then the medium 
was changed to DMEM containing 25mM D-glucose, 1 mM sodium pyruvate, 2 mM L-
glutamine with the addition of 2% horse serum, and 30 µg/ mL gentamicin (All from 
Life Technologies). Cells were not subcultured, only the medium was changed and cells 
were left to differentiate for at least five days. 
2.7.7 Gelatin-coating coverslips for immunocytochemistry 
Cells to be used for immunocytochemistry required growing on removable glass 
coverslips. However, some cell types have poor adherence to glass, so the coverslips 
were first coated in gelatin. A 0.1% gelatin (Sigma-Aldrich) in d.H2O solution was 
autoclaved, and used to cover sterile coverslips in 6-well plates. The plates were chilled 
overnight at 4 °C, then the gelatin was removed by aspiration and the wells washed with 
sterile PBS. Plates were stored at 4 °C with PBS for later use or used immediately. 
2.8 DNA Extraction 
2.8.1 DNA extraction from cultured cells 
DNA was extracted from frozen cell pellets using the DNeasy Blood & Tissue Kit 
(QIAGEN) which lyses cells and binds total DNA (nuclear and mitochondrial) to the 
column membrane, and with centrifugation and washing, removes contaminants and 
enzyme inhibitors. The DNA was then eluted into 30-100 µL low-salt Tris buffer 
supplied (Buffer EB). 
2.8.2 DNA extraction from bacterial cells 
Bacterial cultures were incubated overnight at 37 °C with shaking and then centrifuged 
to create a pellet. The DNA was extracted using the QIAprep Spin Miniprep Kit 
(QIAGEN), which uses alkaline lysis and high salt conditions to absorb only DNA onto 
a silica membrane. The membrane was washed to remove endonucleases and salts, then 
the DNA was eluted into 30-100 µL low-salt Tris buffer (Buffer EB).  
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2.9 RNA Extraction and Quality Control 
2.9.1 Solution preparation 
Laboratory water may contain ribonucleases (RNases), which will degrade the RNA in 
samples if not first inactivated. Autoclaving alone is not generally enough to 
permanently inactivate RNases, as the enzymes renature once cooled. All water used in 
RNA handling was pre-treated with 0.1% diethylpyrocarbonate (DEPC; Sigma-
Aldrich), incubated at room temperature overnight, and then autoclaved to inactivate the 
chemical. Any solutions requiring water, such as 70% ethanol, were made using DEPC-
treated water. 
2.9.2 RNA extraction from cultured cells 
RNA was extracted from cultured cells using the RNeasy
®
 Mini Kit (QIAGEN). Cells 
were first lysed, and then homogenised using a guanidine-thiocyanate based lysis buffer 
provided (Buffer RLT with β-mercaptoethanol) and QIAshredders, a biopolymer spin 
column designed to reduce viscosity caused by cellular debris. Addition of ethanol 
allowed binding of RNA to the RNeasy
®
 spin columns, which were then washed in 
high-salt buffers to remove contaminants. The RNA was typically eluted in 30-50 µL 
RNase-free H2O supplied.  
2.9.3 RNA extraction from muscle tissue 
RNA extraction from small samples, such as laser microdissected cells, was done using 
the Arcturus
®
 PicoPure
®
 RNA Isolation Kit (Life Technologies). It uses high-recovery 
MiraCol
TM
 purification columns to bind RNA, and stringent washes to remove 
impurities. RNA was typically eluted in 10-15 µL low ionic strength buffer provided 
(Buffer EB).  
2.9.4 Ethanol precipitation of RNA 
RNA is soluble in water due to the polarity of both water and the phosphate groups in 
RNA. Ethanol is non-polar and, in combination with positive salt ions, allows the 
precipitation of RNA out of solution, which can be pelleted and redissolved in a smaller 
amount of liquid for a high concentration sample. After RNA extraction, samples were 
combined and 0.1 volume 3 M sodium acetate (Sigma-Aldrich) and 2.2 volumes of 
100% ice cold ethanol were added. The samples were centrifuged at 4 °C, 10,000 x g for 
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10 min. The ethanol was then removed carefully, without disturbing the RNA pellet, and 
replaced with 500 µL ice cold 70% ethanol. The samples were centrifuged again at 4 °C, 
10,000 x g for 5 min. The ethanol was removed again and the RNA pellet allowed to air 
dry for 15 min. The RNA was dissolved in a lower volume of RNase-free H2O. 
Concentration was analysed on the NanoDrop 2000 UV-Vis Spectrophotometer 
(Thermo Scientific) and Agilent 2100 Bioanalyzer (Agilent Technologies, Cheadle, 
UK). 
2.9.5 RNA quality control 
The purity of RNA samples was measured using the NanoDrop 2000 UV-Vis 
Spectrophotometer with absorbance at 260 nm. The 260/230 and 260/280 ratios 
determine whether any contaminants such as phenol or protein are present in the 
sample. The 260/230 ratio should be between 2-2.2 and the 260/280 ratio should be 
between 1.8-2. 
The RNA integrity was analysed on the Agilent 2100 Bioanalyzer using the RNA 6000 
Pico Kit. A RIN score of 7-10 is acceptable, any RNA samples with a RIN score less 
than 7 was discarded and not used for gene expression analysis.  
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Figure 2.1 Examples of RNA samples with varying degradation. A.) RNA with low 
degradation with a 8.9 RIN. B.) RNA with partial degradation with a 6.4 RIN. C.) RNA 
with severe degradation with a 3.7 RIN.  
2.10 RNA amplification 
RNA amplification was achieved using the Arcturus
®
 RiboAmp
®
 HS PLUS RNA 
Amplification Kit. The kit is designed to produce microgram quantities of amplified 
antisense/amplified RNA (aRNA) from low (100 pg) quantities of total cellular RNA. 
The first reaction generated single-stranded cDNA (from mRNA transcripts) with an 
incorporated T7 promoter sequence. This was converted to double-strand cDNA which 
was purified using MiraCol™ Purification Columns. In vitro transcription was 
performed using a T7 RNA polymerase, which yields antisense RNA (aRNA), also 
purified using MiraCol™ Purification Columns. This aRNA can be used for a second 
round of amplification.  
Control RNA 
RIN 8.9 
 
 
Partially degraded 
RIN 6.4 
 
Badly degraded 
RIN 3.7 
 
Marker 
18S 28S 
A.) 
B.) 
C.) 
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2.11 cDNA Synthesis 
SuperScript III First-Strand Synthesis System (Invitrogen) 
SuperScript III synthesises first-strand cDNA from 1 pg to 5 µg of total RNA. First the 
primers are annealed to the template. Oligo dTs were used to amplify mRNAs only and 
random hexamers were used to amplify both rRNA and mRNA, depending on which the 
situation required. Oligo dTs are more efficient than random hexamers at generating 
templates for qPCR, therefore random hexamers were only used when rRNA genes 
were also being assessed or if targets were not polyadenylated.  
WT-Ovation
®
 RNA Amplification and One-Direct Systems (NuGEN) 
The WT-Ovation
®
 RNA Amplification System is designed for use with an input of 5 to 
50 ng total RNA. The WT-Ovation® One-Direct Amplification System is designed for 
use with either cell lysates, or 10 to 500 pg of total RNA.  
Both systems rely on Ribo-SPIA (Single Primer Isothermal Amplification) technology. 
First-strand cDNA was prepared with reverse transcription using primers targeted to 
either the polyA tail or randomly across the transcript, with a unique RNA tag at the 5’ 
end of the primer. The RNA in this cDNA/RNA heteroduplex was fragmented to 
generate priming sites for DNA polymerase, and the second-strand was synthesised, 
leaving a DNA/RNA tag at one end. The SPIA
®
 amplification utilised by these systems 
is a linear isothermal DNA amplification process. RNase H was used to degrade the 
RNA in the unique tag sequence, exposing the DNA segment of the tag, allowing for 
binding of a second RNA/DNA primer. This primer was then extended by DNA 
polymerase, displacing the existing strand. The cycle was repeated several times to 
amplify the cDNA up to 1,500-fold with the minimum RNA requirement.  
2.12 Quantitative Real-time PCR 
Quantitative real-time PCR (qPCR) utilises a double-strand DNA intercalating dye 
(SYBR) to measure fluorescent intensity relative to the amount of PCR product 
produced at each cycle. The PCR reactions were performed on a MyIQ
TM
 thermocycler 
(Bio-Rad, Hemel Hempstead, UK). The raw data was analysed on iQ5™ optical system 
software v.2.0 (Bio-Rad), to determine at which cycle the fluorescence units pass a set 
threshold level for each sample, known as the threshold cycle (Ct). This allowed 
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comparison of the relative amounts of different genes or mRNA transcripts. All the 
qPCR preparation steps were performed in a UV-sterilised Aura PCR workstation. 
2.12.1  qPCR reaction  
The qPCR reaction was 25 µL for each sample, made with 1X iQ™ SYBR® Green, 
0.5 µM forward and reverse primer with 1 µL template and d.H2O to 25 µL. All 
reactions were prepared in a UV-sterilised Aura PCR workstation (Bioair Instruments, 
Milan, Italty) to avoid any cross-contamination.  
The PCR program was: 95 °C, 3 min; 95 °C for 10 sec followed by 62.5 °C for 1 min for 
40 cycles; 95 °C 1 min; and a melt curve. The melt curve was performed by monitoring 
loss of fluorescence signal after each of the 10-second incubation steps, rising from 
65 °C to 95 °C in 0.5 °C increments. 
2.12.2 Quality control 
The efficiency of each reaction was measured using standard curves generated using 1 
in 10 serial dilutions of either control cDNA or purified DNA templates. As the amount 
of DNA should double with every PCR cycle, the Ct value of each 10-fold dilution 
should be 3.3 cycles apart. The ‘no template control’ should be no lower than 35 cycles 
(Figure 2.2A). The threshold must be set during the log phase, where each curve 
appears as a straight line stretch (in log view) (Figure 2.2B). When the standards are 
plotted, the efficiency of the reaction (represented as E) should be >95%, the R
2
 should 
be > 0.98 (indicating accurate dilutions and pipetting), and the slope between -3.2 to -
3.5. Melt curve analysis, which distinguishes between product sizes and G-C content, 
should show a single peak for each expected amplification product (Figure 2.2D-F). 
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Figure 2.2 Quality control of real-time qPCR. Standard curves generated using 10-
fold dilution of PCR template. (A) Amplification chart shows uniform spacing of each 
set of dilutions. (B) Logarithmic (log) view of amplification curve, with the threshold 
set during the log phase. (C) When the Ct values of the standards are plotted, the 
efficiency of the reaction is 96.4%, the R
2
 is 0.999, and the slope -3.411 (D) Melt curve 
analysis distinguishes between product sizes and G-C content. (E) Melt peak for a single 
product is sharp with only one peak. (F) Melt peaks for different amplification reactions 
shows two distinguishable peaks indicating two different products.  
Each standard was analysed in duplicate and each sample was analysed in triplicate. The 
standard deviation between each sample triplicates was <0.25, or was repeated. 
2.13 TaqMan® Low Density Array (TLDA) cards 
The TaqMan
®
 Custom Array is a 384-well micro fluidic card which allows 384 
simultaneous real-time PCR reactions for up to eight samples. The assays are pre-loaded 
in each of the wells with only the addition of cDNA and TaqMan
®
 Universal PCR 
Master Mix into each port on the card. 
2.13.1 Designing the TLDA cards 
Custom TLDA cards are designed using Applied Biosystem’s configuration tool. Each 
384-well microfluidic card can be designed to analyse between 1-8 samples and 12-384 
assays, depending on the format chosen. Each port (8 in total) requires 50 µL of cDNA. 
Depending on the format chosen, one sample may require two or more ports, which 
must be taken into consideration.  
A. B. C. 
D. E. F. 
NTC 
Standards Threshold 
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2.13.2 Loading the TLDA cards 
The TLDA cards were incubated for 15 minutes prior to loading the sample. For each 
port to be used, 50 µL of cDNA was mixed gently with 50 µL of TaqMan® Universal 
PCR Master Mix before loading.  
Once loaded, cards were fitted to custom TaqMan
®
 card holders and buckets for the 
Multifuge 1S-R Benchtop Refrigerated Centrifuge (Heraeus, Thermo Scientific, 
Waltham, USA). With a ramp up/down rate of 9, the cards are centrifuged at 1200 rpm 
(331 x g) for two separate sessions of one minute. The wells of the card were sealed 
using the TaqMan
®
 Array Micro Fluidic Card Sealer, which depresses the foil within 
the main fluid distribution channels of the card. The ports were then cut away.  
The cards were analysed on the 7900HT Fast Real-Time PCR System (Applied 
Biosystems). The TaqMan
®
 Array Micro Fluidic Card Thermal Cycling Block and 
correct plate adapter must be fitted to the PCR instrument tray for use with TLDA cards. 
The plate setup was loaded from the Array Information CD provided with the cards. 
The correct cycling conditions were: 45 °C 10 min, 94 °C for 10 min, and 45 cycles of 
94 °C for 30 s followed by 60 °C for 1 min. 
2.13.3 Analysis of results 
Results were generated from the 7900HT Fast Real-Time PCR System (Applied 
Biosystems) using the compatible SDS 2.4 software. Analysis of the results file was 
completed using RQ manager. The automatic baseline and a threshold of 0.2 were used 
for analysis of each plate. Any outliers or failed wells were omitted from the analysis. 
2.14 SDS-PAGE and Western Blotting 
2.14.1 Protein extraction from fibroblast pellets 
Cells were washed with PBS before centrifugation and the pellets were stored at -80 °C. 
Cell pellets were defrosted on ice for 5 min and then lysed in 50 µL lysis buffer. The 
lysis buffer mix is 50 µL 1 M Tris (pH 7.5) (Sigma-Aldrich), 26 µL 5 M NaCl (BDH), 
4 µL 0.5 M MgCl2 (BDH), 10 µL 100 mM PMSF (Sigma-Aldrich), 10 µL Triton X-100 
(Sigma-Aldrich). The lysis mix containing cells was vortexed for 30 s to homogenise 
the suspension. To remove cellular debris, the tubes were centrifuged at 2500 rpm for 
2 min at 4 °C and the supernatant removed to a clean tube. Protein concentration was 
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determined using the NanoDrop 2000 UV-Vis Spectrophotometer, measuring at 
280 nm. Protein was diluted to 2.5 µg/ µL using protease inhibitor (Pi) mix (Roche) with 
an addition of 5 µL 100 mM PMSF. The protein solution was mixed with an equal 
volume of loading dye. The loading dye mix is: 5 mL 0.5 M Tris-HCl (pH 6.8), 2 mL 
glycerol, 0.4 g SDS, and 0.01 g bromophenol blue (all reagents from Sigma-Aldrich). 
Protein aliquots were frozen for later use at -80 °C or used directly in SDS-PAGE. 
2.14.2 SDS-PAGE 
Before use, the protein samples required the addition of 15 U benzonase nuclease 
(Novagen
®
, Merck Millipore, Watford, UK) per 20 µL sample, and were incubated at 
37 °C for 30 min to prevent COXI aggregation.  
SDS-PAGE was performed using Mini-Protean Tetra Cell apparatus (Bio-Rad). 
Polyacrylamide separating gels were made to either 14% or 8%, depending on the size 
of the proteins to be separated. Gel mixes (14%/ 8%) include (4.66/ 2.68 mL) 29:1 30% 
bisacrylamide (Amresco, Solon, USA) and (4.11/ 6.11 mL) H2O, 1 mL 3.75 M Tris-HCl 
(pH 8.5) (Sigma-Aldrich), 100 µL 10% SDS solution (Sigma-Aldrich), 10 µL TEMED 
(Sigma-Aldrich) and 100 µL 10% APS solution (Sigma-Aldrich). After loading the gel 
solution into the casting cassette, a layer of isopropanol was added to ensure a smooth 
upper gel line and to prevent evaporation during the polymerisation process.  
Once the separating gel has polymerised, the isopropanol was removed and the 4% 
stacking gel can be added (approximately 3 cm layer). The 4% gel mix is 0.625 mL 29:1 
30% bisacrylamide (Amresco), 3.025 mL H2O, 1.25 mL 0.5 M Tris/HCl (pH 6.8) 
(Sigma-Aldrich), 50 µL 10% SDS solution (Sigma-Aldrich), 5 µL TEMED (Sigma-
Aldrich) and 50 µL 10% APS solution (Sigma-Aldrich). The comb is inserted before the 
stacking gel was allowed to polymerise.  
Once the stacking gel was set, the gels were placed in the tank with 1X running buffer: 
3.03 g Trizma® base, 14.4 g glycine and 1 g SDS in 1 L d.H2O (All reagents from 
Sigma-Aldrich). The comb was removed and the protein loaded at two different 
concentrations to control for saturation. Novex
®
 Sharp Pre-stained protein ladder 
(Invitrogen, Life Technologies) was added to the first lane to check the sizing of 
proteins. 
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The gel was electrophoresed at 10 mA through the stacking gel, and 25 mA through the 
separating gel for varying lengths of time, depending on the proteins to be separated.  
2.14.3 Western Blotting 
After electrophoresis, the gel was equilibrated in 1X transfer buffer for 10 min. The 
transfer buffer was made with 3.03 g Trizma® base, 14.4 g glycine and 0.2 g SDS and 
10% methanol in 1 L dH2O. The polyvinylidene difluoride (PVDF) membrane was 
activated in methanol for 20 s then washed in 1X transfer buffer for 1 min. The gel and 
membrane were both inserted between filter paper and sponges in the transfer cassette, 
and transferred in 1X transfer buffer at max mA for 1 h or 30 V/ 120mA overnight at 
4 °C.  
2.14.4  Probing the blot 
Non-specific binding sites were blocked by incubating the blot for 1 h at room 
temperature with either 5% milk (Marvel, Premier Foods, St. Albans, UK) or 5% BSA 
(Sigma-Aldrich) in Tris-buffered saline with Tween20
® 
(TTBS), to block non-specific 
binding sites. Primary antibodies were incubated for either 1 h at room temperature or 
overnight at 4 °C with shaking. After primary antibody probing, the blot was washed 
with TTBS for three periods of 10 min. TTBS was prepared with 20 mL 1 M Tris (pH 
7.0) (Sigma-Aldrich), 29.2 g NaCl (VWR, Lutterworth, UK) and 1 mL Tween20® 
(Sigma-Aldrich) up to 1 L with d.H2O. 
After the TTBS washes, the blot was probed for 1 h with HRP-conjugated secondary 
antibody using the appropriate species to match the primary antibody used. This was 
followed with three more 10 min TTBS washes.  
2.14.5 Visualisation of the blot 
To visualise the blot, 1 mL solution A was added to 25 µL of solution B from the ECL 
Plus Western Blotting Detection Reagents (GE Healthcare, Little Chalfont, UK). The 
solution was evenly distributed over the surface of the blot and incubated in the dark for 
4 min. The excess ECL-Plus mix was removed, and the blot protected in a plastic wallet.  
The blots were visualised on a BioSpectrum
®
 Imaging System (UVP). White-light 
images of the blot were used to align the ladder to the protein band images to ensure the 
protein bands observed were the expected size.  
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Quantification of bands was completed using Fiji imaging software 
(http://fiji.sc/wiki/index.php/Fiji), calculating the ratio between the intensity area of the 
protein of interest and a reference protein (such as β-Actin). 
2.15 Immunocytochemistry on cultured cells 
2.15.1 Cell fixation 
Cells were washed with PBS to remove traces of media and then incubated with 4% 
paraformaldehyde (PFA) at room temperature for 30 min. The PFA was then removed 
and the cells washed with PBS for 3 x 5 min. The cells can be stored at 4 °C in 0.1% 
sodium azide solution for up to two weeks or used directly for antibody staining.  
2.15.2 Antibody staining 
After fixing cells with 4% PFA in PBS, the cells were incubated with 0.1% TritonX 100 
(Sigma-Aldrich) for 15 min to permeabilise the membrane. The cells were blocked with 
5% BSA for one hour, then incubated with the primary antibody for 1 h. After removal 
of the antibody, the cells were washed with PBS for 3 x 5 min. The cells were incubated 
with the appropriate fluorochrome-conjugated secondary antibody for 1 h and washed 
again with PBS for 3x 5 min.  
2.15.3 Microscopy 
Fluorescent images were captured using an Axio Imager microscope with an attached 
ApoTome and AxioCam HRc digital camera. Images were analysed using the 
compatible AxioVision software (All from Carl Zeiss).  
2.16 Cryosectioning of muscle tissue 
Muscle blocks to be sectioned were snap frozen in L.N2-cooled-isopropanol and 
mounted on filter paper using OCT. Before sectioning, they were allowed to equilibrate 
to -20 °C in the cryostat. Sections were typically cut between 8-20 µM and mounted 
onto either glass or PEN-membrane slides. Slides were frozen at -80 °C for later use or 
allowed to air dry for 30 min before processing.  
2.17 Histochemistry on muscle sections  
2.17.1 Combined COX-SDH 
Each solution was made fresh and used immediately with a final volume of 1 mL. 
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The stain for COX activity was prepared with 4 mM 3,3’-diaminobenzidie 
tetrahydrochloride (DAB), 100 mM cytochrome c and a few crystals of catalase (All 
reagents from Sigma-Aldrich). The sections were incubated for 40-45 min at 37 °C, then 
washed three times with 0.1 M PBS. 
The stain for SDH activity was made with 1.5 mM nitroblue tetrazolium (NBT), 0.13 M 
Sodium Succinate, 0.2 mM phenazine methosulfate (PMS) (All reagents from Sigma-
Aldrich). The sections were incubated for 35-40 min at 37 °C then washed three times 
with 0.1 M PBS. 
The sections were dehydrated and mounted or taken for further processing (see Section 
2.17.3). 
2.17.2 Modified Gomori trichrome 
Modified Gomori trichrome was used to identify ragged-red fibres (RRF). Stained 
nuclei will appear red-purple, normal muscle myofibrils will appear green, and 
intermyofibrillar muscle membranes will appear red. Abnormal mitochondria 
accumulate in the subsarcolemma region of muscle and have a distinct ‘Ragged-Red’ 
appearance. The solution was made using 0.6% Chromotrope 2R 0.3% Fast Green FCF, 
0.6% Phosphotungstic acid (All Sigma-Aldrich) and 1% glacial acetic acid in distilled 
water. The pH was adjusted to 3.4 using 1 M NaOH. Sections cut no thicker than 12 µm 
were first stained with Harris Haematoxylin (Sigma-Aldrich) for 5 min then rinsed in 
distilled water. They were stained with modified Gomori trichrome stain for 10 min. 
The stain was differentiated from purple to green using three successive washes in 0.2% 
acetic acid solution. The sections were dehydrated and mounted or taken for further 
processing (see Section 2.17.3). 
2.17.3 Section dehydration and mounting 
Sections on glass slides are dehydrated in progressively more concentrated ethanol 
solutions (70%, 2 min; 90% 2 min; 100%, 2 min; 100%, 10 min), immersed in Histo-
Clear
®
 (Fisher Scientific) for 2 min (2 x 1 min sessions) and then mounted with 
distyrene plasticizer and xylene (DPX; VWR). Sections on membrane slides for laser 
microdissection required rapid processing in ice cold ethanol (70% 2 min; 100% 2 min), 
do not need Histo-Clear
®
 treatment and were not mounted.  
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2.18 Laser Microdissection 
Laser microdissection was performed using a Leica AS LMD laser microscope (Leica 
Microsystems, Germany). This system uses contact-free UV-laser microdissection and 
gravity capture into the caps of individual 0.5 mL tubes. Tissue sections were mounted 
facing downwards towards the cap lid. Tissue was dissected into both dry caps and caps 
with added lysis buffer. If fluorescent microscopy was required for visualisation of 
staining, the software was switched to fluorescent mode and the appropriate filter 
chosen for the fluorophore in use. 
2.19 Statistical analysis 
All statistical analyses were performed using GraphPad Prism
®
 v.6 statistical software 
(GraphPad Software Inc., La Jolla, USA). 
To determine the significance of differences in the means of two independent groups 
with equal variance an unpaired t-test at a confidence level of 95% was employed. 
Results were considered significant if the p-value < 0.05 (*), <0.01 (**), <0.001 (***). 
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3.1 Introduction 
Mutations on mtDNA are a major cause of human disease, affecting at least 1 in 5000 of 
the population (Chinnery et al., 2000a, Schaefer et al., 2008). In a study of mtDNA 
sequences in the cord blood from clinically unaffected live-births, common pathogenic 
mtDNA mutations were detected in 0.5% of individuals (Elliott et al., 2008).  
Homoplasmic mutations are typically associated with an organ-specific, mild 
biochemical phenotype, such as m.1555A>G in 12S rRNA causing isolated sensori-
neural deafness (Prezant et al., 1993). Many pathogenic mtDNA mutations are 
heteroplasmic, where mutant load tends to correlate with the severity of the disease and 
explains the clinical heterogeneity between siblings of the same family (Chinnery et al., 
1997, Chinnery et al., 1998, White et al., 1999a).  
mtDNA deletions are not frequently transmitted, with a risk of approximately 1 in 24 
chance of an affected mother having an affected child (Chinnery et al., 2004). However, 
the majority of point mutations are readily transmitted from mother to child and 
inheritance is dependent on the type of mutation (Elson et al., 2009). There are rapid 
shifts in m.8993T>G/C heteroplasmy levels between generations, leading to smaller 
pedigrees as the mutation is rapidly lost or fixed (White et al., 1999a). In contrast, large 
shifts in m.8344A>G heteroplasmy are rare, causing the mutation to persist through 
many generations (Larsson et al., 1992). 
Analysis of heteroplasmy in 82 single primary oocytes from a woman carrying 
m.3243A>G suggested a random genetic drift mechanism of inheritance (Brown et al., 
2001). However, selection of m.3243A>G may be dependent on the mother’s mutant 
load, as women with heteroplasmy >50 % tend to have children with the same or lower 
heteroplasmy (Uusimaa et al., 2007). 
Random genetic drift does not appear to be the mechanism by which the m.8993T>G 
mutation is inherited. Seven oocytes from a woman with approximately 50 % 
m.8993T>G heteroplasmy were assayed for the mutation; one was found to have 0 % 
and the others all had greater than 95 % (Blok et al., 1997).  
By creating homozygous knock-in mice that express a proof-reading-deficient version 
of the polymerase gamma catalytic subunit, a mouse model was developed with 
increased levels of mtDNA point mutations and deletions (Trifunovic et al., 2004). 
Backcrossing allowed removal of the mutant Polg gene, whilst maintaining a 
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heteroplasmic state of several mtDNA mutations (Stewart et al., 2008).The mice from 
six successive generations were assayed for mtDNA heteroplasmy levels of each 
mutation. It was discovered that non-synonmyous changes in protein coding genes were 
rapidly lost from mouse pedigrees, suggesting a strong purifying selection against 
deleterious mutations in the mouse germ line. Further evidence for purifying selection 
was achieved through the introduction of two mtDNA mutations into the female germ 
line of mice, a severe frameshift mutation in MT-ND6 and more mild, mis-sense 
mutation in MT-CO1 (Fan et al., 2008). The severe mutation was rapidly lost within 
four generations, but the mild mutation was retained over successive generations.  
It is possible that the mtDNA bottleneck and the process of purifying selection are 
linked, but they could also occur independently. The mechanism of selection could be at 
the organellar or cellular levels, explaining how even low levels of heteroplasmy could 
be selected against. There is evidence that defective mitochondria are separated and 
targetted for degradation through autophagy (Twig et al., 2008). 
3.1.1 Research aims 
Different techniques and laboratories have variable accuracy and sensitivity when 
measuring heteroplasmy levels in DNA samples. To eliminate the sources of technical 
variability, the heteroplasmy levels of three common mtDNA mutations (m.3243A>G, 
m.8344A>G and m.8993T>G) will be assessed in a large cohort of mother-child pairs. 
This will establish whether the inheritence of pathogenic mtDNA mutations is dictated 
purely by random genetic drift, or whether some or all mutations are positively or 
negatively selected.  
These results will then be compared to meta-analyis of previously published data for 
these and two further mutations (m.11778G>A and m.3460G>A) to establish whether 
these results have been corroborated. 
3.2 Materials and Methods 
3.2.1 DNA samples 
This study had the relevant institutional approval, and written informed consent was 
obtained from all of the subjects involved. DNA samples for mother-child pairs were 
collated from NCG Mitochondrial Diagnostic Service (Newcastle, England), Division 
of Molecular Neurogenetics, Istituto Nazionale Neurologico C. Besta (Milan, Italy), 
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Medizinisch Genetisches Zentrum (MGZ) (Munich, Germany), The Centre for 
Mitochondrial Medicine (Bergen, Norway) and Dipartimento di Scienze Neurologiche, 
Università di Bologna (Bologna, Italy) (Table 3.1).  
Table 3.1 DNA samples collated for heteroplasmy measurements. DNA samples 
(n=147) extracted from blood from individuals with either m.3243A>G, m.8344A>G or 
m.8993T>G were collated from Newcastle (n=89), Milan (n=24), Munich (n=11), 
Bergen n=10) and Bologna (n=13). All samples included are in unrelated mother-child 
pairs. 
Mutation Cohort Source Individuals Pedigrees Transmissions 
m.3243A>G 
Newcastle (England) 70 26 44 
Milan (Italy) 14 7 7 
Bergen (Norway) 10 4 6 
 Total 94 37 57 
  
 
  
m.8344A>G 
Newcastle (England) 19 8 11 
Milan (Italy) 10 5 5 
Munich (Germany) 4 1 3 
 Total 33 14 19 
  
 
  
m.8993T>G 
Munich (Germany) 7 3 4 
Bologna (Italy) 13 5 8 
 Total 20 8 12 
3.2.2 Generation of heteroplasmic controls  
The disease control DNA sample for each mutation was selected from a patient with 
known high heteroplasmy levels to make isolation of the mutation during cloning more 
efficient. Control DNA did not have any of the mutations studied here. Amplicons from 
these samples were generated using a standard GoTaq PCR reaction (Section 2.2.1), 
using the primer sets in Table 3.2. The amplicons were ligated and transformed into 
competent bacterial cells following the standard cloning protocol (Section 2.3). Plasmid 
DNA was extracted following the QIAprep Spin Miniprep Kit (QIAGEN). Extracted 
DNA was sequenced using Big-Dye Terminator Cycle Sequencing (Section 2.6), using 
the same primers in Table 3.2 to identify whether the clone was mutant or wild-type at 
each relevant position.  
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Table 3.2 Primers for ligation templates. Primer sequences to create templates for 
ligation into plasmid vectors for the MELAS fragment (m.3243A>G), MERRF 
fragment (m.8344A>G), and LS/NARP fragment (m.8993T>G). 
Mutation Primer Sequence Position  
Size 
(bp) 
m.3243A>G 
F-TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 3017- 
3374 
357 
R-CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG 
m.8344A>G 
F-TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC 8196- 
8740 
544 
R-CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC 
m.8993T>G 
F-TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC 8656- 
9201 
545 
R-CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG 
3.2.3 Creation of heteroplasmic templates 
To assess the reliability of heteroplasmy measurement techniques, standards were made 
with heteroplasmy levels varying between 0 and 100%. The concentration of plasmid 
DNA collected was determined using the Nanodrop Spectrophotometer ND-1000. 
Dilutions were made so that both wild-type and mutant DNA had the same 
concentration (~20 ng/ µL). Heteroplasmy templates were prepared by mixing different 
volumes of the wild-type and mutant DNA clones yielding mixes between 5% and 95%. 
3.2.4 Restriction Fragment Length Polymorphism (RFLP) 
The primary PCR for RFLP analysis was a 30 µL GoTaq reaction (Section 2.2.1). 
Primers used in the PCR reaction are shown in Table 3.3. RFLP was carried out 
following the standard protocol (Section 2.4). 
Table 3.3 Primers for amplification of fragment for RFLP analysis. The primer 
sequences used to amplify products for RFLP analysis of m.3243A>G mutation 
indicating the position on the mtDNA covered and which are 6-FAM fluorescently 
tagged (*).  
 Mutation 
(Position) 
Primer Sequence 
Position of 
Primer 
Size (bp) 
MELAS 
(m.3243A>G) 
*F-CACAAAGCGCCTTCCCC 
3155-3353 198 
R-GCGATTAGAATGGGTACAAT 
 
The products generated from primary PCR amplification are then digested with a 
restriction enzyme which has had a restriction site removed or added by the presence of 
the mutation, yielding different fragment lengths for mutant and wild-type. The 
restriction enzymes used for each mutation and the cut site information are shown in 
Table 3.4. 
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Table 3.4 Restriction enzymes for RFLP analysis. The restriction enzyme required to 
differentiate between wild-type and mutant mtDNA for the MELAS (m.3243A>G) 
mutation, the cut site and the size of the fluorescently labelled fragment. 
Mutation 
(Position) 
Restriction 
Enzyme 
Restriction 
Buffer 
Cut Site Fragment Sizes 
MELAS 
(m.3243A>G) 
HaeIII 2 
GG / CC 
CC / GG 
A (WT) 160 
G (Mut) 86 
3.2.5 Pyrosequencing analysis of heteroplasmic mutations 
The primary PCR for pyrosequencing analysis was a 30 µL GoTaq Hot Start 
Polymerase (Promega) reaction (Section 2.5.2). Primers used in the primary PCR (F- 
and R-) and sequencing (Seq-) reactions are shown in Table 3.5.  
Table 3.5 Primary PCR and sequencing primers for pyrosequencing. Primary PCR 
and sequencing primers for pyrosequencing. Showing size and position of primers or 
fragments. *BIO indicates biotinylated primers. 
Primer Sequence and Modification Position of Primer Size (bp) 
(m.3243A>G) 
F-*BIO-TAAGGCCTACTTCACAAAGCG 
3142-3353 211 
R- GCGATTAGAATGGGTACAATGAG 
Seq-ATGCGATTACCGGGC 3258-3244  - 
(m.8344A>G) 
F-*BIO-CATGCCCATCGTCCTAGAAT 
8203-8495 292 
R- TTTTTATGGGCTTTGGTGAGG 
Seq-TAAGTTAAAGATTAAGAGA 8325-8343 - 
 (m.8993T>G) 
F-AGGCACACCTACACCCCTTA 
8919-9171 252 
R-*TGTGAAAACGTAGGCTTGGAT 
Seq-CATTCAACCAATAGCCC 8976-8922 - 
 
3.2.6 Compilation of published heteroplasmy data 
Blood heteroplasmy data was collated by myself and Dr. Passorn Wonnapinij from  
published studies for five mtDNA mutations: m.3243A>G, m.8344A>G, m.8993T>G, 
m.11778G>A and m.3460G>A (Appendix B.1). When possible, muscle heteroplasmy 
levels were also recorded for comparison to blood heteroplasmy levels; however, were 
not used to generate O-M values to study variance.  
3.2.7 Statistical analysis 
Descriptive statistics were calculated for each frequency distribution, including: the 
minimum and maximum values; inter-quartile ranges; mean and median and standard 
deviation (Std. Dev) and standard error of the mean (SEM).  
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The selected normality test was the D’Agostino & Pearson omnibus. It first computes 
the skewness and kurtosis to quantify how far from Gaussian the distribution is in terms 
of asymmetry and shape. The normality test was passed if the combined p-value < 0.05.  
A one-sample t-test was performed to assess whether the data were sampled from a 
Gaussian population with a mean equal to the hypothetical value of 0 (no selection 
bias). Results were considered significant if p-value < 0.05 (*), <0.01 (**), <0.001 
(***).  
3.3 Assay development 
There are several methods for quantifying mtDNA heteroplasmy level, which rely on 
either mutation-specific restriction enzyme digestion or sequencing. I have chosen to 
assess fluorescent restriction fragment length polymorphism (RFLP) and 
pyrosequencing, to determine which is the most sensitive and reliable technique. 
3.3.1 Optimisation of quantification of mtDNA heteroplasmy 
Both techniques require PCR amplification of a template surrounding the mutation site. 
If all available templates do not amplify reliably at each cycle, this could introduce 
shifts in heteroplasmy from the true value. Therefore a standard curve across the full 
range of m.3243A>G heteroplasmy levels was generated and assayed in triplicate from 
independent PCR reactions.  
The m.3243A>G mutation introduces an additional cut site for the HaeIII restriction 
enzyme, meaning the wild-type sequence generates a 160 bp tagged fragment, but the 
mutant sequence generates an 86 bp tagged fragment. Using a capillary DNA analyser, 
the relative fluorescence of each peak can be measured and used to quantify the 
heteroplasmy level (Figure 3.1A).  
Pyrosequencing can distinguish between nucleotides at a particular position in a 
sequence through sequential addition of dNTPs, which release pyrophosphate (PPi) 
when incorporated into a DNA fragment. The PPi is converted to ATP by ATP 
sulfurylase which is used in a luciferase-mediated reaction to generate light. Detection 
of the light signal after each dNTP addition allows quantification of each base at the 
mutation site (Figure 3.1B). 
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Figure 3.1 m.3243A>G heteroplasmic control standards. m.3243A>G heteroplasmy 
quantification using (A) fluorescent RFLP and (B) pyrosequencing in artificially 
generated standard samples with known mutation load. 
There is mild deviance from the expected heteroplasmy (indicated by the black lines) 
when using both RFLP (Figure 3.2A) and pyrosequencing (Figure 3.2B). However, the 
measured heteroplasmy levels correlate well with each other (Figure 3.2C), and the 
deviance from the expected heteroplasmy is therefore likely to be introduced during 
dilution of the wild-type and mutant clones. Although both techniques provide accurate 
quantification of heteroplasmy levels, pyrosequencing has better reproducibility 
between technical replicates.  
0%            ~25%     ~50%                  ~75%           100% 
160: WT 86: Mut
WT:T  C: Mut
Sequence: (T/C)CTGCC
        0%          ~35%             ~50%                  ~65%       100% 
A. 
B. 
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Figure 3.2 Comparison of RFLP and pyrosequencing heteroplasmy measurements. 
The graph shows the scatter of measured heteroplasmy for both (A) RFLP and (B) 
pyrosequencing in triplicate, compared to the predicted heteroplasmy values. Error bars 
represent the SD of triplicate reactions.  
3.3.2 Correction of blood heteroplasmy measurements 
The heteroplasmy level of m.3243A>G measured in blood has been consistently lower 
than that measured in post-mitotic tissues such as skeletal muscle and brain (Ciafaloni et 
al., 1991). Measurement of m.3243A>G heteroplasmy level at two time points showed 
a decrease in mutation load over time in 28 of 29 patients assayed across two studies 
(Pyle et al., 2007, Rahman et al., 2001, t Hart et al., 1996). The greatest decrease in 
mutant load is observed in younger patients, consistent with an exponential loss of 
mutated DNA in blood leukocytes. The proposed mechanism is selection against 
haematopoietic (precursor) cells with high mutation loads.  
By simulating the segregation of mtDNA in precursors cells, Rajasimha and colleagues 
derived an equation to correct for the loss of the m.3243A>G mutation in blood 
(Rajasimha et al., 2008).  
Published data from individuals with heteroplasmy measurements made in both blood 
and muscle were compared for three mtDNA mutations: m.3243A>G; m.8344A>G and 
m.8993T>G. As expected, the uncorrected heteroplasmy level of m.3243A>G in blood 
correlates poorly with that measured in muscle (blood mean, 33.41; muscle mean, 
64.86; p <0.0001 unpaired t test).The correlation is improved by age-correction using 
the formula derived by Rajasimha and colleagues (Figure 3.3A) (blood-corrected mean, 
58.42; ns). Exclusion of patients with <15% mutation load measured in blood further 
improved the correlation between blood and muscle heteroplasmy levels (blood >15% 
uncorrected, 66.97, ns), suggesting there may be a threshold effect where blood 
precursor cells with a low mutation load are no longer strongly selected against (Figure 
3.3B). 
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Figure 3.3 Correction of m.3243A>G heteroplasmy level in blood. The mutation 
load of m.3243A>G measured in both blood and muscle (A) correlate well with each 
other when age-corrected and (B) is improved through exclusion of those with <15% 
measured blood heteroplasmy.  
Although there are some cases where the m.8344A>G blood heteroplasmy level is 
lower than that measured in muscle, the majority correlate well with each other (blood 
mean, 65.25; muscle mean, 77.78; p < 0.05 unpaired t test) (Figure 3.4A). There are few 
incidences where both blood and muscle heteroplasmy have been measured in an 
individual patient, but heteroplasmy levels remain consistent between tissue (blood 
mean, 86.5; muscle mean, 89.2; ns). 
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Figure 3.4 Uncorrected m.8344A>G and m.8993T>G heteroplasmy levels in blood. 
The mutation load of (A) m.8344A>G and (B) m.8993T>G is more consistent between 
blood and muscle. 
Data including heteroplasmy measurements from both blood and muscle are limited, 
since usually only one tissue is assayed in each study. However, the reduction in 
m.3243A>G mutant load in blood during aging is also evident when plotting blood 
heteroplasmy against the patient’s age at sampling (Figure 3.5A). The distribution of 
corrected m.3243A>G heteroplasmy across age groups is comparable to that of 
m.8344A>G and m.8993T>G (Figure 3.5B-D). Analysis of the published data for the 
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LHON mutations demonstrates that high m.11778G>A heteroplasmy levels are 
maintained in patients above 80 years of age (Figure 3.5E), but there is an apparent 
decline of mutant load in blood with aging for the m.3460G>A mutation (Figure 3.5F). 
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Figure 3.5 Heteroplasmy level distribution across patient ages. The mutant load of 
(A) m.3243A>G, (B) m.3243A>G age-corrected, (C) m.8344A>G, (D) m.8993T>G, 
(E) m.11778G>A and (F) m.3460G>A in patients across varying ages in published 
studies.  
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There are two possible explanations for the reduced m.3460G>A heteroplasmy level 
observed in older individuals. If heteroplasmy levels correlate to clinical severity, it is 
plausible that those with lower mutant load will survive longer than those with high 
mutant load, seeming to suggest a decrease in heteroplasmy with age. The aetiology of 
LHON is complex, with strong indication that other genetic and/or environmental 
factors influence penetrance of the mtDNA mutations. Although unaffected individuals 
may be homoplasmic for m.3460G>A, the mutant load in affected individuals has been 
discovered to affect manifestation of the disease phenotype (Black et al., 1996). 
In an analysis of tissue segregation patterns in 27 members of a family with 
m.3460G>A, 18 had >95% mutation load in all tissues, and the other nine had lower 
heteroplasmy levels in blood than in hair follicles (Kaplanova et al., 2004). This 
discrepancy leads to seemingly skewed segregation patterns when analysing 
heteroplasmy levels from blood but not hair follicles. Decreasing blood m.3460G>A 
heteroplasmy was confirmed by a longitudinal study of five heteroplasmic individuals 
from one maternal pedigree, showing a decrease of ~1% year (Howell et al., 2000).  
As m.3460G>A is a rare mutation, it has not been fully established whether 
heteroplasmy levels decrease in blood across a wide range of pedigrees, and no 
correction method has been established. This will have to be taken into consideration 
when interpreting any segregation data for this mutation.  
3.4 Results and Discussion 
3.4.1 Analysis of O-M variance in measured heteroplasmy data 
The shift in heteroplasmy level between generations is calculated by subtracting the 
mother’s mutant load from that of her child (O-M value). If plotted on a frequency 
histogram, a mutation with inheritance governed by random drift will be normally 
distributed around a mean of 0. Frequency histograms were generated for the 
m.3243A>G (n=57), m.8344A>G (n=19) and m.8993T>G (n=12) (Figure 3.6). 
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Figure 3.6 Frequency histograms of O-M values for m.3243A>G, m.8344A>G and 
m.8993T>G transmissions. O-M values represent the shift in heteroplasmy between 
generations of (A) m.3243A>G, (B) m.8344A>G and (C) m.8993T>G. 
The descriptive statistics for each mutation are listed in Appendix A.1. The mean O-M 
values for the tRNA mutations are close to 0 (m.3243A>G, 5.77 %; m.8344A>G, -
3.15 %) but the mean for m.8993T>G is 33.33 %. There is greater potential for an 
increase than decrease in heteroplasmy for the transmissions measured for the 
m.8993T>G mutation (Min, -50.3 %; Max, 89.3 %). Although heteroplasmy can either 
increase or decrease to a similar degree for the tRNA mutations, there is greater 
potential for change with m.3243A>G (min, -84.3 %; max, 79.2 %) than for 
m.8344A>G (min, -57 %; max, 55.3 %). This may reflect a different width of mtDNA 
bottleneck. If a smaller proportion of the mother’s total mtDNA repopulates the oocyte, 
there is a greater potential for change in heteroplasmy level. 
Each distribution was subjected to D’Agostino-Pearson omnibus test for normality. The 
distribution for m.8993T>G shows the greatest level of skew (-0.86), but all mutation 
distributions passed the normality test (Appendix A.2). A one-sample t-test shows that 
m.3243A>G and m.8344A>G do not significantly differ from a theoretical mean of 0. 
The discrepancy -33.03 (p <0.05 one-sample t test) for the m.8993T>G mutation is 
significant; however, the 95% confidence interval is large, with a minimum value of just 
3.25 (Appendix A.3). 
There are several sources of bias which might affect the reliability of the results. There 
is a potential for ascertainment bias, since all samples used in the study have been 
brought to the attention of clinicians through diagnosis of an affected individual 
(proband). Any transmissions including the proband case have been removed from the 
m.3243A>G data set, to determine whether ascertainment bias has affected the 
distribution of O-M values (Figure 3.7B). 
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Where inheritance of mtDNA is governed by random genetic drift, the heteroplasmy 
variance is critically dependent on the initial heteroplasmy level in the mother. This 
means that mothers with ~50% heteroplasmy may have greater shifts in mutant load 
than mothers with extreme heteroplasmy values (close to 0 or 100 %). Previously, any 
measured variance in heteroplasmy has been normalised by the mother’s heteroplasmy 
levels to avoid misinterpretation of data (Samuels et al., 2010). However, in this study 
the variance within a population is not being measured. Instead, the transmissions where 
heteroplasmy has shifted in one direction to a greater degree than it could potentially 
shift in the other direction have been removed (Figure 3.7C).  
As previously determined from analysis of published data, the age-based correction 
method for blood heteroplasmy levels may not work as reliably when the measured 
mutant load is below 15 %. Any transmission where either the mother or child have a 
measured heteroplasmy below 15 % was removed (Figure 3.7D).  
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Figure 3.7 Removal of potential bias influencing transmission data for 
m.3243A>G. Comparison of frequency distributions between (A) total m.3243A>G 
transmission data and after (B) exclusion of transmissions containing probands, (C) 
removal of bias caused by differences in mothers’ heteroplasmy levels and (D) removal 
of any transmission including individuals with a measured heteroplasmy below 15 %. 
The descriptive statistics for each distribution after removal of potential sources of bias 
are listed in Appendix A.4. The largest difference was between the total data set and 
upon exclusion of the proband cases (total mean, 5.77 %; excl. probands, 16.71 %). In 
this data set, 13 transmissions included mothers (6 individuals) who were probands and 
11 transmissions contained children who were probands. After removal of proband 
cases, there was only 1 of 11 mothers with heteroplasmy levels >50 %, as the women 
with the highest heteroplasmy values tended to be the affected proband. Removal of the 
proband cases did not have the same effect on the remaining children (9/15 > 50 %), 
since siblings of proband cases could also have high heteroplasmy levels and remain 
included in the study.  
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All distributions pass the D’Agostino-Pearson omnibus test for normality (p > 0.05) and 
have low values of skewness and kurtosis (Appendix A.5). The one-sample t-tests show 
none of the distributions differ significantly from a mean of 0 (p > 0.05) (Appendix 
A.6). 
3.4.2 Meta-analysis of published heteroplasmy data 
Heteroplasmy data for mother to child transmissions were compiled from published 
studies for five mutations: m.3243A>G (n=111), m.8344A>G (n=96), m.8993T>G 
(n=118), m.11778G>A (n=118) and m.3460G>A (n=74). The blood heteroplasmy for 
m.3243A>G was corrected as previously stated and the O-M values for all mutations 
were generated. Frequency histograms were plotted for each mutation, and a Gausssian 
curve fitted to each plot (Figure 3.8). 
 
Chapter 3  
106 
 
-1
0
0
-5
0 0
5
0
1
0
0
1 0
2 0
3 0
m .3 2 4 3 A > G
O -M  v a lu e
%
 F
r
e
q
u
e
n
c
y
A .
-1
0
0
-5
0 0
5
0
1
0
0
1 0
2 0
3 0
m .8 3 4 4 A > G
O -M  v a lu e
%
 F
r
e
q
u
e
n
c
y
B .
-1
0
0
-5
0 0
5
0
1
0
0
1 0
2 0
3 0
m .8 9 9 3 T > G
O -M  v a lu e
%
 F
r
e
q
u
e
n
c
y
C .
-1
0
0
-5
0 0
5
0
1
0
0
1 0
2 0
3 0
m .1 1 7 7 8 G > A
O -M  v a lu e
%
 F
r
e
q
u
e
n
c
y
D .
-1
0
0
-5
0 0
5
0
1
0
0
1 0
2 0
3 0
m .3 4 6 0 G > A
O -M  v a lu e
%
 F
r
e
q
u
e
n
c
y
E .
 
Figure 3.8 Frequency histograms of O-M values for transmission of five 
heteroplasmic mutations generated from meta-analysis of published data. O-M 
values represent the shift in heteroplasmy between generations of (A) m.3243A>G 
(n=111), (B) m.8344A>G (n=96) and (C) m.8993T>G (n=118), (D) m.11778G>A 
(n=118) and (E) m.3460G>A (n=74) compiled from previously published studies. 
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The mean values of the distributions measured by pyrosequencing are remarkably 
similar to those compiled from published data (m.3243A>G measured, 5.77 %; 
m.3243A>G published, 3.32 %; m.8344A>G measured, -3.15 %; m.8344A>G 
published, -4.96 %; m.8993T>G measured, 33.33 %; m.8993T>G published, 32.67 %). 
The mean value for m.11778G>A is 15.4 % and the mean for m.3460G>A is 22.02 %. 
Further descriptive statistics for the frequency distributions from published data can be 
found in Appendix B.2. 
The only distribution which did not pass the D’Agostino-Pearson omnibus normality 
test was that of m.3460G>A (p <0.01) (Appendix B.3). The one-sample t-test shows the 
distributions for the tRNA mutations, m.3243A>G and m.8344A>G, do not 
significantly differ from a theoretical mean of 0. However, the mutations in protein-
coding genes, m.8993T>G, m.11778G>A and m.3460G>A, have distributions which all 
significantly differ from 0 (p <0.0001 one-sample t test) (Appendix B.4).  
The apparent selection for mutations in protein-coding genes is evident in the fixation 
frequency in the mother-child pairs from published data. For the purposes of this 
analysis and due to limitations in the techniques for measuring heteroplasmy in some 
studies, fixation has been defined as instances where heteroplasmy ≤ 30 %, ≤ 60 % and 
≤ 90 % in the mother has increased to ≥ 95 % in the child. The mutations were also lost 
during some transmissions, defined as instances where heteroplasmy ≥ 10 %, ≥ 40 % 
and ≥ 70 % heteroplasmy in the mother has decreased to ≤ 5 % heteroplasmy in the 
child. Transmissions in which fixation was not reached have been defined as either a 
negative change (lower heteroplasmy in child than in mother), neutral ± 5 % (the 
common sensitivity on most techniques) or positive (higher heteroplasmy in child than 
in mother). 
Fixation rate for the tRNA mutations was low (m.3243A>G, 1.8 %; m.8344A>G, 0 %) 
but was higher for all three protein-coding gene mutations (m.8993T>G, 21.2 %; 
m11778G>A, 23.7 %; m.3460G>A, 23.0 %) (Figure 3.9). Loss of the mutation was 
highest in m.8344A>G (17.3 %), with moderately high levels of m.3243A>G (9.0 %) 
and m.3460G>A (9.5 %) loss. Frequency of m.8993T>G and m.11778G>A loss was 
lower, at only 3 % and 0.8 % respectively. 
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Figure 3.9 Fixation rate of mutations from published transmissions. Mutations were 
categorised by whether there was a negative, neutral or positive change between mother 
and child. Positive changes were further characterised by fixation to over 95 % 
heteroplasmy in the child from a heteroplasmy of under 30 %, between 30-60 % and 
between 60-90 % in the mother. The tRNA mutations m.3243A>G (~2 %) and 
m.8344A>G (0 %) have a low frequency of fixation but the protein-coding mutations 
m.8993T>G, m.11778G>A and m.3460G>A have ~20% frequency of fixation. 
From the published studies, individuals were only included if there was recorded data of 
transmission from a heteroplasmic mother to her child. In addition to these individuals, 
there are those without their mother’s heteroplasmy measurements and those who are 
homoplasmic for the mtDNA mutation. The rate of fixation is evident in the mutant load 
in the total participants (Figure 3.10). Homoplasmy frequency (≥95 %) is low for tRNA 
mutations (m.3243A>G blood, 11.7 %; m.3243A>G muscle, 9.4 %; m.8344A>G, 
6.2 %). The higher rate of m.3243A>G homoplasmy in blood compared to muscle is 
likely due to imperfect age-based correction of measured blood heteroplasmy levels. 
There is a higher frequency of individuals who are homoplasmic (≥95 %) for protein-
coding mutations (m.8993T>G, 33.3 %; m.11778G>A, 81.3 %; m.3460G>A, 46.5 %). 
There is a high frequency of wild-type homoplasmy for m.8344A>G (23.8 %), 
m.8993T>G (34.6 %) and m.3460G>A (18.0 %). There is a moderately high frequency 
of m.3243A>G homoplasmy in blood (15.8 %) which is not observed in muscle (1.9 %) 
and lower frequency of homoplasmy for m.11778G>A (3.0 %). 
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Figure 3.10 Heteroplasmy levels of mtDNA mutations in published data. The 
heteroplasmy levels reported in published studies of (A) m.3243A>G in blood (B) 
m.3243A>G in muscle, (C) m.8344A>G, (D) m.8993T>G, (E) m.11778G>A and (F) 
m.3460G>A. Higher levels of homoplasmy are evident in the protein-coding mutations, 
which showed a significant deviance away from neutral transmission.  
The severity of the tRNA mutations prevents survival of those with near homoplasmic 
mutant load, explaining why the frequency for m.3243A>G in muscle and m.8344A>G 
peaks at 70-80 % but declines above this threshold. Despite having the largest 
discrepancy in distribution mean, m.8993T>G has the lowest homoplasmy frequency of 
the protein-coding mutations. This is also likely due to the relative severity of the 
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mutations. The high numbers of individuals with 0 % m.8993T>G in the published 
studies are mostly from pedigrees where the mutation has occurred de novo on one 
lineage, rather than a loss of mutation from a heteroplasmic female. Both m.11778G>A 
and m.3460G>A cause Leber’s Hereditary Optic Neuropathy (LHON), but with 
incomplete penetrance. LHON typically presents during mid-life as acute or subacute 
bilateral visual loss, occasionally with additional clinical presentations (Nikoskelainen 
et al., 1995). In this study, there are heteroplasmic individuals for both of these 
mutations above the age of 80, including those with heteroplasmy > 90 % above the age 
of 70. The m.8993T>G mutation can cause Leigh Syndrome (LS) or neuropathy, ataxia, 
and retinitis pigmentosa (NARP), and disease severity broadly correlates to 
heteroplasmy level (White et al., 1999a). Disease onset is earlier, with a wide variety of 
clinical presentations, and often causes premature death. In this study, the oldest 
recorded patient studied for m.8993T>G was 52, and all individuals with >90 % 
heteroplasmy level were below 10 years of age. Thus, although m.8993T>G 
transmission is most offset from neutral, the opportunity to assay homoplasmic 
individuals is limited, as those with highest heteroplasmy have the worst prognosis. 
3.4.3 Absence of m.3243A>G heteroplasmy decline in blood.  
The heteroplasmy level of m.3243A>G was investigated extensively in the blood and 
muscle of seven families with variable clinical phenotypes (Hammans et al., 1995). In 
one of these families, all four members had higher than expected heteroplasmy level in 
blood. Upon sequencing, a homoplasmic mutation was identified in the tRNA
Leu
 gene, 
m.3290T>C, in addition to m.3243A>G. When the age-correction formula is applied to 
these individuals, all of their estimated heteroplasmy levels correct to above 100 % 
(107, 149, 164 and 279 %). It was postulated that the additional mutation was affecting 
the clinical phenotype. In light of more recent evidence that the mutation load of 
m.3243A>G decreases in age with blood, this mutation may also modify selection 
against the mutant molecules in blood precursor cells. 
Correction of all publicised blood heteroplasmy data revealed a further three families 
from independent studies which correct to above 100 % (Campos et al., 1995, Iwanishi 
et al., 1995, Morovvati et al., 2002). Some of these studies include more than one 
pedigree, yet all members of one family and none of the others correct to above 100 %, 
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suggesting strong evidence of a genetic basis of resistance to purifying selection in 
blood.  
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Figure 3.11 Over-correction of blood m.3243A>G heteroplasmy in published data.  
The m.3243A>G heteroplasmy data from four published studies showing (A) a family 
in each with higher than normal mutant load in blood which (B) over-corrects to above 
100 %.  
In two of the studies, there was no further sequence analysis completed to identify 
evidence of modifying mutations; however, Morovvati and colleagues (2002) identified 
two mutations specific to the family which had higher than expected m.3243A>G 
heteroplasmy levels. These were m.1520T>C in the 12S rRNA gene and m.12153C>T 
in the tRNA
His
 gene. Both mutations are listed as rare SNPs (>0.2 % of total GenBank 
sequences) on www.mitomap.org. Aside from mtDNA changes, it is also plausible that 
a nuclear factor is instead providing protection for these mutations and allowing 
maintenance of high levels of heteroplasmy in blood cells.  
From the samples whose heteroplasmy was measured locally by pyrosequencing, only 
one corrected to above 100 %. This was a 54 year-old woman with two children. Her 
measured heteroplasmy level was 40.7 %, which age-corrects to 119.8 %. Her children’s 
heteroplasmy levels were only 20.7% (at age 27 corrected to 35.5 %) and 30.7 % (at age 
22 corrected to 47.6 %). Although their heteroplasmy levels do not correct to above 
100 %, it is possible they have always had lower heteroplasmy levels which have 
remained constant.  
The mother’s mtDNA was sequenced to identify any additional mutations which may be 
modifying the behaviour of the mutant mtDNA molecules in blood precursor cells. 
Sequence changes from the rCRS in the RNA and protein-coding genes are listed in 
Table 3.6.  
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Table 3.6 mtDNA sequence changes in a female with m.3243A>G. The mtDNA 
coding and RNA sequence variants in a female with m.A3243A>G whose measured 
blood heteroplasmy over-corrects to above 100%. The loci and effect on amino acid 
coded for is given for each sequence variant. The SNP status and GenBank Frequency 
were collated from www.mitomap.org. Haplogroup associations were collated from 
www.phylotree.org and identifies the woman as haplogroup K. 
Base 
Nucleotide 
Change 
Loci Syn? SNP 
GenBank 
Frequency 
% 
Haplogroup 
Association 
994 A>G 12S RNA - Y 1 <0.01 - 
1189 T>C 12S RNA - Y 323 1.8 K1 
1438 A>G 12S RNA - Y 749 4.1   
1811 A>G 16S RNA - Y 1450 7.9 U2-8 (K) 
2706 A>G 16S RNA - Y 13893 75.7   
3243 A>G tRNA Leu (H) - N - - - 
3480 A>G ND1  Y Y 951 5.2 Ub8 (K) 
4646 T>C ND2 Y Y 240 1.3 K1b1a1a 
4769 A>G ND2 Y Y 17964 97.8   
5913 G>A COI Asp>Asn Y 109 0.6 K1b 
7028 C>T COI Y Y 14259 77.7   
8860 A>G ATP6 Thr>Ala Y 18178 99.0   
9055 G>A ATP6 Ala>Thr Y 997 5.4 Ub8 (K) 
9698 T>C COIII Y Y 961 5.2 U8 (K) 
9962 G>A COIII Y Y 57 0.3 K1b1 
10289 A>G ND3 Y Y 75 0.4 K1b2 
10398 A>G ND3 Thr>Ala Y 7972 43.4 K1 
10550 A>G ND4L Y Y 915 5.0 K 
11299 T>C ND4 Y Y 1045 5.7 K 
11467 A>G ND4 Y Y 2465 13.4 U (K) 
11719 A>G ND4 Y Y 13641 74.3   
11923 A>G ND4 Y Y 47 0.3 K1b1a 
12308 A>G tRNA Leu  - Y 2454 13.4 U (K) 
12372 G>A ND5 Leu>Leu Y 2654 14.5 U (K) 
13967 C>T ND5 Thr>Met Y 79 0.4 K1b1a1 
14053 A>G ND5 Thr>Ala Y 80 0.4   
14167 C>T ND6 Y Y 920 5.0 Ub8 (K) 
14766 C>T CYTB Thr>Iso Y 13539 73.7   
14798 T>C CYTB Phe>Leu Y 1472 8.0 K 
15257 G>A CYTB Asp>Asn Y 242 1.3 K1b1a 
15326 A>G CYTB Thr>Ala Y 18123 98.7   
15946 C>T tRNA Thr - Y 38 0.2 K1b1 
 
The majority of sequence changes are associated with haplogroup K and its subtypes 
(K1b1a1a), identified using www.phylotree.org. All sequence changes are listed as 
SNPs on www.mitomap.org, excluding m.3243A>G. There is one sequence on 
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GenBank which has identical RNA and protein-coding sequence changes to this female 
(JQ704057.1) and only some alternative changes in the D-loop (data not shown) and the 
m.3243A>G mutation. This suggests a moderately close genetic relationship, with no 
additional pathogenic mutations evident.  
In the published pedigrees, the additional mutations which may have influenced 
selection against m.3243A>G were in the tRNA
Leu
 gene itself (Hammans et al., 1995), 
and 12S rRNA or tRNA
His
 (Morovvati et al., 2002). Although lacking an additional 
mutation in the tRNA
Leu
 gene, there is a rare SNP in the 12S rRNA gene, m.994A>G.  
A longitudinal study of heteroplasmy levels in the individuals of this pedigree is needed 
to determine whether their mutant load is stable in blood, before any conclusion can be 
drawn on the significance of the presence of m.994A>G. 
3.5 Concluding Remarks 
The heteroplasmy levels of m.3243A>G, m.8344A>G and m.8993T>G from mother-
child pairs were accurately measured by pyrosequencing. The tRNA mutations showed 
Gaussian distributions centred around a mean transmission of 0, suggesting neutral 
transmission governed by random drift. The transmission of the MT-ATP6 mutation, 
m.8993T>G, had a mean significantly different to 0 (33.33 %, p <0.05 one-sample t 
test), suggesting there may be positive selection of this mutation. These results were 
corroborated by analysis of previously published data, which show positive deviance 
from 0 for m.8993T>G and also two other protein-coding mutations, m.11778G>A and 
m.3460G>A.  
m.8993T>G and m.11778G>A show high frequencies of fixation to ≥95 % 
heteroplasmy and have low frequencies of mutation loss to ≤ 5 % heteroplasmy, 
supporting the notion of selection in favour of these mutations. 
Although m.3460G>A has a high frequency of fixation, it also shows moderate 
frequency of mutation loss. This suggests a narrow bottleneck with a greater capacity 
for change in mutation load, but does not necessarily support positive selection. The 
deviance from 0 in the mean O-M variance could be artefactual, caused by the apparent 
decrease in blood heteroplasmy with age, which could not be corrected. 
The means of O-M variance for both the tRNA mutations, m.3243A>G and 
m.8344A>G, are not significantly different from 0 and are normally distributed (one-
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sample t test). Although both mutations show higher frequencies of mutation loss than 
mutation fixation, high mutation loads of m.3243A>G and m.8344A>G are not 
tolerated and will therefore not be measurable in the population. 
In addition to the family mentioned in observed by Hammans and colleagues (1995), a 
further three pedigrees with m.3243A>G have been identified from independent studies 
which show higher than normal blood heteroplasmy levels. The heteroplasmy of these 
individuals over-correct to above 100 % when the age-based formula is applied, which 
does not occur in any individual from other pedigrees from these studies. This strongly 
suggests a genetic factor rather than a technical artefact. Additional mutations in 
tRNA
Leu
, 12S rRNA and tRNA
His
 were identified in these families.  
Only one individual’s heteroplasmy measured by pyrosequencing age-corrected to over 
100 %. No additional tRNALeu mutations were identified in this individual; however, 
there was a rare homoplasmic SNP in 12S rRNA (m.994A>G). Further study is needed 
to establish whether this mutation influences the selection of m.3243A>G in blood 
precursor cells. 
Future study in this field would benefit from increased avaialability of DNA samples 
from tissue other than blood, such as muscle. Since preimplantation genetic diagnosis 
(PGD) is becoming a more widely used diagnostic tool, it allows the possibility to study 
the transmission of different heteroplasmy mutations across many embryos from 
individual females (Sallevelt et al., 2013).     
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4.1 Introduction 
The mtDNA bottleneck was first hypothesised after observations of a homoplasmic 
mtDNA mutation occurring in a proportion Holstein cows dispersed across a single 
lineage (Hauswirth and Laipis, 1982, Olivo et al., 1983). The mutation is unlikely to 
have occurred multiple times independently across the lineage. Consequently they 
proposed that the founder female contained both the wild-type and mutant mtDNA 
genotypes, and random segregation or unequal amplification accounted for the fixation 
to either genotype in subsequent generations.  
Since then, much work has been undertaken to identify the mechanism and timing by 
which heteroplasmy values shift between generations. The majority of this work has 
relied upon mice as a model organism, where embryogenesis is comparable to humans, 
and transgenic lines allow identification and manipulation of the germ line (Payer et al., 
2006, Sugimoto and Abe, 2007).  
Many stages of embryonic development and germ-line formation provide potential sites 
for the mtDNA bottleneck. Unequal partitioning of mtDNA during cleavage of the pre-
implantation embryo, or reduction in mtDNA copy number in PGCs during post-
implantation development, could account for a prenatal mtDNA bottleneck. Replication 
of a sub-population of mtDNA genomes during maturation of primary oocytes could 
potentially cause shifts in heteroplasmy during postnatal development. Understanding 
mouse embryogenesis and development of the female germ-line is critical to uncovering 
the timing and mechanism of the mtDNA bottleneck, and the implications it has for 
transmission of mitochondrial disease. 
4.1.1 Mouse embryogenesis 
After fertilisation of the oocyte, the embryo undergoes a series of cellular cleavages 
(Figure 4.1A). The embryo remains a constant size, but contains a progressively higher 
numbers of smaller blastomeres (Cockburn and Rossant, 2010). Once the embryo 
reaches the 8-cell stage compaction occurs, where there is increased intracellular 
adhesion and cells become flattened, but continue to divide. Once at the 32-cell stage, 
the cells closest to the outside become committed to the trophectoderm lineage. Within 
the embryo a fluid-filled blastocoele cavity forms, allowing development of the inner 
cell mass (ICM) (Pedersen et al., 1986). The formed blastocyst develops over the 
following 24 hours, and implants in the uterine wall by 4.5 d.p.c. 
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Figure 4.1 An overview of early mouse embryogenesis. After fertilisation of the 
oocyte (A) pre-implantation begins with cleavage of the embryo, dividing into more 
blastomeres until compaction and formation of the blastocyst at ~ 3.5 d.p.c. At 4.5 d.p.c. 
the blastocyst implant in the uterine wall and begin (B) post-implantation development. 
At 6.25 d.p.c. the first cells form that will become lineage-restricted to PGCs, and by 
7.25 d.p.c. the population has expanded to ~40 cells and express the germ-cell specific 
marker, Stella (Dppa3). As the PGC population expands, the PGCs migrate from the 
endoderm to the genital ridges. After mitosis they form germ-cysts and eventually 
colonise the gonad primordium, as oogonia, by 13 d.p.c. * Prenatal bottleneck predicted 
by Cree and colleagues (2008) and supported by Freyer and colleagues (2012).   
Gastrulation occurs within the first 48 h of post-implantation development (Figure 
4.1B), and embryos can be staged by morphological landmarks relating to the formation 
of the primitive streak and the development of the different germ layers (endoderm, 
ectoderm and mesoderm) (Downs and Davies, 1993). At 6.25 d.p.c., a subset of 
pluripotent proximal epiblast cells respond to signals from the extra-embryonic 
ectoderm and the visceral endoderm, and begin to express Fragilis (Ifitm3) (Saitou et al., 
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2002). Of these, ~ 6 cells will begin to express Blimp1 (Prdm1) and become lineage-
restricted to PGC precursors (Ohinata et al., 2005). By 7.25 d.p.c., the PGC population 
has expanded to ~40 cells and expression of Stella (Dppa3) is detectable (Saitou et al., 
2002). At 8.5 d.p.c. the endoderm invaginates, and the PGCs migrate along the length of 
the forming hindgut. By 9.5 d.p.c., the PGCs are directed from the hindgut to the dorsal 
body wall, until eventually colonising the genital ridges (McLaren, 2003). At this stage 
they begin expressing other PGC-specific biomarkers, such as Vasa (Ddx4) (Toyooka et 
al., 2000), germ cell nuclear antigen 1 (Gcna1) (Enders and May, 1994) and Germ cell-
less homolog 1 (Gmcl1) (Kimura et al., 1999).  
Once at the genital ridge, PGCs undergo mitosis and cluster together, forming germ-
cysts containing many oogonia (Figure 4.2A). At 13.5 d.p.c. the oogonia enter meiotic 
prophase, becoming oocytes, and arrest in diplotene at 18.5 d.p.c., near the time of birth. 
At this point, ~30% the oocytes in the clusters begin to form primordial follicles, 
gaining a surrounding layer of granulosa cells; the remainder are destroyed through 
apoptosis (atresia) (Pepling et al., 2010). The primordial follicles remain inactive until 
selected through initial recruitment for follicle maturation. Thecal cells are recruited to 
secondary follicles and further stimulate growth and maturation to antral follicles, at 
which point there is a surge in gondadotrophin (particularly luteinising hormone (LH)) 
secretion (Figure 4.2B). This induces ovulation, and the oocyte is released from the 
follicle, ready for fertilisation. The follicle, stimulated by LH, differentiates into a 
corpus luteum, essential for the early stages of pregnancy (Uzumcu and Zachow, 2007). 
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Figure 4.2 An overview of mouse folliculogenesis and ovulation. At the genital 
ridges (A) a proportion of formed oogonia are selected for formation of primordial 
follicles. These recruit first granulosa cells, then thecal cells as the follicles grow and 
mature. (B) Once at the antral stage, a surge in gonadotrophin (LH) secretion stimulates 
maturation of the primary to a secondary oocyte and it is released for fertilisation. 
* Jenuth and colleagues (1996) predict a mtDNA bottleneck caused by unequal 
segregation during expansion of the oogonia population. † Marchington and colleagues 
(1997) support the hypothesis that heteroplasmic variation has formed by oocyte 
maturation. 
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4.1.2 Mechanisms of the mtDNA bottleneck 
To test these hypotheses, Jennuth and colleagues (1996) generated mice with 
heteroplasmic polymorphisms by electrofusing cytoplasts from one mouse breed into 
the one-cell embryo of another breed. A post-fertilisation mtDNA bottleneck was 
eliminated through comparison of mature, unfertilised oocytes to progeny of the same 
female, finding no difference in variance of heteroplasmy levels. Similarly, comparison 
of immature primary oocytes and mature secondary oocytes from the same mouse 
showed similar variance in heteroplasmy, suggesting the mtDNA bottleneck has 
occurred by folliculogenesis at postnatal day 3. PGCs isolated at 8.5 d.p.c. showed little 
heteroplasmic variance. They proposed that this indicated the mtDNA bottleneck is 
caused by unequal segregation during the mitotic divisions undergone by the oogonial 
population prior to primary oocyte formation. By modelling the divisions required to 
generate this population of oogonia and the variance achieved, they estimated the 
number of independent segregating units to be 185. This calculated value is remarkably 
close to the primitive estimate of 200, based upon mitochondria per oogonia (40) and 
average number of genomes per mitochondria (5) (Nass, 1969, Nogawa et al., 1988). 
 Variance in the heteroplasmy of polymorphic tracts in mature human oocytes supported 
the conclusion that at least part of the heteroplasmic variance is generated by oocyte 
maturation (Marchington et al., 1997). By assaying polymorphic tracts and mtDNA 
rearrangements, they calculated the number of segregating units for a single selection 
point to be ~9, but if accounting for 23 divisions, it would be 210 segregating units 
(Marchington et al., 1998). Although ~200 segregating units accounts for how 
heteroplasmy levels shift due to genetic drift, it would not allow de novo mutations to 
reach the high heteroplasmy levels often seen (Lebon et al., 2003). This suggests the 
estimates of the number of segregating units are only a mean value, and mtDNA copy 
number in individual cells may vary greatly, including some cells with extremely low 
heteroplasmy values.   
Although alluding to the timing and size of the bottleneck, these studies did not uncover 
the mechanism, or mechanisms, by which the mtDNA bottleneck is formed (Figure 4.3).  
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Figure 4.3 Proposed mechanisms for generation of heteroplasmy variance (the 
mtDNA bottleneck). Potential mechanisms for formation of the mtDNA bottleneck 
include (A) unequal segregation of homoplasmic nucleoids, (B) reduced mtDNA copy 
number followed by unequal segregation of single mtDNA molecules and (C) 
replication of a subpopulation of mtDNA causing a skew in heteroplasmy levels.  
Rather than relying on statistical modelling to estimate the size of the mtDNA 
bottleneck, Cao and colleagues (2007) directly measured mtDNA copy number in 
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mouse cells from developing embryos using qPCR techniques. During pre-implantation, 
the mtDNA copy number per blastocyst halved at each cell division, but remained 
constant in the overall embryo. The majority of cells had a measured copy number of 
over 620 genomes. When assaying PGCs, identified by alkaline phosphatase staining, 
from 7.5 to 13.5 d.p.c. they found few cells with lower than 600 genomes per cell, 
which remained consistent as the PGC population expanded. Their evidence led them to 
conclude that the mtDNA bottleneck occurs without a reduction in mtDNA copy 
number, and that limiting the number of segregating units occurs through aggregation of 
mtDNA genomes into homoplasmic nucleoids or through replication of a sub 
population of genomes (Figure 4.3A).  
This finding was later disputed by a further two studies which independently measured 
a dramatic reduction in mtDNA copy number in the early PGC population (Cree et al., 
2008, Wai et al., 2008). As alkaline phosphatase was shown to interfere with mtDNA 
copy number measurements, these studies instead used PGC-specific GFP-reporter 
transgenic mice to identify and separate PGCs from somatic cells. Using an adapted 
population genetic model, Cree and colleagues (2008) calculated that the reduction in 
mtDNA copy number observed at 7.5 d.p.c. can account for 70% of the heteroplasmy 
variance observed in the progeny of heteroplasmic mice, with the remaining 30% 
generated through massive mitochondrial proliferation as the PGC population expands 
(Figure 4.3B). However, Wai and colleagues (2008). analysed heteroplasmic PGCs at 
various stages of prenatal oogenesis, and reported no increase in heteroplasmy variance 
during oogenesis. By using the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU), 
they demonstrated only a small percentage of mtDNA molecules in primary oocytes are 
replicating, and suggested this as the major mechanism responsible for generation of 
heteroplasmic variance (Figure 4.3C). These results were further disputed (Samuels et 
al., 2010), and there is therefore a need to confirm the precise timing of the bottleneck 
using an independent, validated technique. 
 Mice with defective polymerase gamma (Pol γ) (D257A PolgA exo− or mtDNA-
mutator mice) allowed generation of mouse lines with a range of mtDNA mutations 
(Trifunovic et al., 2004). This included a mouse line with heteroplasmic levels of the 
pathogenic mutation m.3875delC in tRNAMet, found to remain stable across all tissues 
of the body and through inheritance to further generations (Freyer et al., 2012). There 
was an absence of mice with >86% mutation level, and no reduction in fecundity in 
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female mice with higher heteroplasmy, indicating a purifying selection before formation 
of the offspring. By crossing these mice with the GFP-Stella reporter line (Payer et al., 
2006), they were able to isolate heteroplasmic PGCs at 13.5 d.p.c. Measurements of the 
mutation levels in these PGCs demonstrated that the heteroplasmic variance observed in 
oocytes and live offspring is already generated by 13.5 d.p.c. in PGCs. These findings 
support the hypothesis of a prenatal bottleneck caused by the dramatic reduction in 
mtDNA copy number during early post-implantation development.  
4.1.3 mtDNA replication during embryonic development 
For the mtDNA copy number to increase dramatically as the PGC population expands, 
the rate of mtDNA replication must be greatly increased compared to pre-implantation 
development. The mtDNA copy number in a total embryo does not vary throughout 
embryonic development (McConnell and Petrie, 2004, Thundathil et al., 2005). 
However, the use of BrdU identified mtDNA replication occurring in fertilised oocytes 
and in 2-cell mice embryos, indicating a higher turnover rate at these stages (McConnell 
and Petrie, 2004). Contrary to this, Thundathil and colleagues (2005) measured 
increased expression of known replication-related genes (Polg-A, Polg-B, Ssb and 
RNase MRP) from the 8-cell stage to the blastocyst stage. Measuring the transcript 
levels of mt-Nd2 and mt-Nd6 transcripts demonstrated higher expression of 
mitochondrial genes at the morulae (compaction) and blastocyst stages. This correlated 
with an increase in Tfam expression, but not with increased expression of Nrf1, Tfb2m 
and Tfb1m. This agreed with the original measurements of mitochondrial transcripts 
made by Piko and Taylor (1987), who determined the egg and 2-cell embryo are 
transcriptionally silent relative to cleavage stages. 
The expression of mitochondrial replication genes has also been correlated to mtDNA 
accumulation during oocyte growth, with Tfam, Polg and Polg2 expression being 
highest between 12-15 days and then decreasing as oocyte growth halts and mtDNA 
replication rate lowers (Mahrous et al., 2012).  
4.1.4 Research Aims 
Recent research supports a prenatal mtDNA bottleneck forming before 13.5 d.p.c. 
(Freyer et al., 2012). Since expression of mtDNA replication factors is critical to 
regulation of mtDNA copy number, we will assess the expression of these genes during 
pre- and post-implantation development to determine the stage at which mtDNA 
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replication rate increases. We will expand the scope of genes assessed, and explore how 
mitochondrial dynamics, replication, transcription, and biogenesis contribute to 
regulation of mtDNA copy number during embryogenesis.  
4.2 Materials and Methods 
4.2.1 Mouse tissue isolation 
Sample isolation was performed by Dr L.M. Cree or Dr. V. Floros under license 
(Institute of Genetic Medicine, Newcastle University) and in accordance with the UK 
Home Office Animal Act (1986).  
C57BL/6J.CBA females were mated with Stella-GFP BAC–homozygous 
C57BL/6J.CBA males (Payer et al., 2006). For collection of pre-implantation zygotes, 
females were superovulated with pregnant mares’ serum (PMS) (Sigma- Aldrich) and 
human chorionic gonadotrophin (hCG) (Sigma-Aldrich). Single-cell embryos were 
recovered by flushing the oviducts with pre-warmed M2 medium (Sigma-Aldrich) and 
transferred to pre-warmed M16 media (Sigma-Aldrich). Embryos were incubated at 
37 °C in a humidified atmosphere containing 5 % CO2 until they reached the required 
cleavage stage. For each sample, 15 embryos were pooled and transferred to sterile PCR 
tubes and lysed in TRIzol
®
 Reagent (Invitrogen, Life Technologies) and stored at -80 °C 
until extraction.  
For isolation of PGCs from post-implantation samples, Stella-GFP heterozygous 
embryos were collected in supplemented DMEM, (Invitrogen, Life Technologies) at 
7.5, 8.5, 9.5 and 11.5 d.p.c. (counting from midnight on the evening of mating). The 
posterior region of the 7.5, 8.5, and 10.5 d.p.c. embryos and the genital ridges of 
11.5 d.p.c. embryos were dissected, pooled and dissociated. The tissue was resuspended 
in one volume of FBS and then centrifuged at low speed. The final pellet was 
resuspended in further supplemented DMEM and kept on ice until fluorescence-
activated cell sorting (FACS). PGCs were uni-directionally sorted using a BD 
FACSAria (Becton Dickinson) into TRIzol
®
 Reagent (Invitrogen, Life Technologies) to 
a total of 150 cells in each biological replicate. Samples were stored at -80 °C until 
extraction.  
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4.2.2 RNA isolation, amplification and cDNA synthesis 
RNA isolation was performed was performed by Dr L. M. Cree (Institute of Genetic 
Medicine, Newcastle University) using PureLink
®
 RNA Mini Kit (Ambion, Life 
Technologies), which can extract ultrapure total RNA from samples lysed with TRIzol
®
 
Reagent using silica-based spin columns. RNA extraction was performed as described 
in the PureLink
®
 RNA Mini Kit manual using chloroform (Sigma-Aldrich) to separate 
organic, interphase and aqueous layers and RNase-Free DNase (QIAGEN) for the 
optional on-column DNase treatment.  
The purity and quality of the extracted RNA was analysed on the NanoDrop 2000 UV-
Vis Spectrophotometer and Agilent 2100 Bioanalyzer respectively, as described in 
Section 2.9.5). 
RNA extracted from pre-implantation samples was converted to cDNA exclusively 
using WT-Ovation
®
 RNA Amplification System (NuGEN). Post-implantation sample 
cDNA synthesis was tested with both WT-Ovation
®
 RNA Amplification and One-
Direct Systems (NuGEN) and SuperScript III First-Strand Synthesis System 
(Invitrogen, Life Technologies) described in Section 2.11. The post-implantation RNA 
samples were also amplified using Arcturus
®
 RiboAmp
®
 HS PLUS RNA Amplification 
Kit (Section 2.10). 
4.2.3 TaqMan Low Density Array (TLDA) cards 
The selected card layout for these experiments was ‘Format 32’, allowing measurement 
of 31 target assays in addition to the mandatory internal reference gene (18S rRNA). All 
measurements were made in triplicate, allowing for four unique samples per card (one 
sample in two ports). Gene selection was based on previously published studies. The 
details for the Taqman
®
 assays used are shown in Table 4.1.  
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Table 4.1 Assay information for mouse gene expression TLDA cards. The 31 
selected genes (and reference gene) on the TLDA cards, including information on the 
sequence, assay ID and the amplicon positional information.  
Gene 
Symbol 
Accession 
Number 
Assay ID  Location Exons Position* 
Amplicon 
Length 
Gapdh NM_008084.2 Mm99999915_g1 75 1-1 5' 107 
18S X03205.1 Hs99999901_s1 609 -- 3'-M 187 
B2m NM_009735.3 Mm03003532_u1 160 2-2 5'-M 247 
Bax NM_007527.3 Mm00432051_m1 592 5-6 3' 84 
Dnm1l NM_001025947.1 Mm01342903_m1 1707 13-14 3' 71 
Fis1 NM_001163243.1 Mm00481580_m1 445 2-3 3' 60 
Hif1a NM_010431.2 Mm01283758_g1 791 3-4 M 141 
Hist2h2 NM_013549.1 Mm00501974_s1 47 1-1 5' 57 
Lrpprc NM_028233.2 Mm00511512_m1 3546 30-31 3' 64 
Mfn1 NM_024200.4 Mm00612599_m1 980 7-8 M 88 
Mfn2 NM_133201.2 Mm00500120_m1 622 4-5 5'-M 61 
Nrf1 NM_001164226.1 Mm00447996_m1 632 4-5 M 69 
Opa1 NM_001199177.1 Mm00453879_m1 2270 21-22 M 80 
Pdx1 NM_008814.3 Mm00435565_m1 523 1-2 M 74 
Peo1 NM_153796.3 Mm00467928_m1 1815 1-2 5' 74 
Phb2 NM_007531.2 Mm00476104_m1 443 3-4 5' 102 
Polg NM_017462.2 Mm00450527_m1 975 2-3 5' 99 
Polg2 NM_015810.2 Mm00450161_m1 577 1-2 5' 132 
Polrmt NM_172551.3 Mm00553272_m1 216 2-3 5' 118 
Pop5 NM_026398.4 Mm00503231_m1 422 3-4 3' M 102 
Pparg NM_001127330.1 Mm01184322_m1 757 5-6 3' 101 
Ppargc1a NM_008904.2 Mm00447187_g1 2036 9-10 3' 81 
Ppargc1b NM_133249.2 Mm01258518_m1 2734 9-10 3' 83 
Pprc1 NM_001081214.1 Mm00521078_m1 4406 9-10 3' 123 
Rnaseh1 NM_011275.2 Mm00488036_m1 328 2-3 5' 68 
Sirt5 NM_178848.3 Mm00663721_m1 656 5-6 M 70 
Sod2 NM_013671.3 Mm00449726_m1 433 2-3 5' 67 
Sp1 NM_013672.2 Mm00489039_m1 1940 4-5 3' 75 
Tfam NM_009360.4 Mm00447485_m1 327 2-3 5' 81 
Tfb1m NM_146074.1 Mm00524825_m1 669 5-6 3' 88 
Tfb2m NM_008249.4 Mm01620397_s1 41 1-1 5' 125 
Txn1 NM_011660.3 Mm00726847_s1 668 5-5 3' 113 
*M=Middle. 
4.2.4 Gene expression analysis 
As the samples of the study are five independent stages of embryogenesis, the Ct values 
generated for reference and target genes were used to calculate the expression of the 
target gene as a percentage of the reference.
 
                                (
    
     ⁄ )  
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4.2.5 Real-Time qPCR 
For assessing the relative quantity of RNA transcripts in mouse samples, a standard 
25 µL qPCR reaction mix (Section 2.12.1) was used with the following primers in Table 
4.2. 
Table 4.2 Mouse gene expression primers. β-actin gene expression primers to assess 
the quantity of cDNA in post-implantation samples.  
Primer Sequence  Fragment Size 
Actb  
F-TTGCTGACAGGATGCAGAAG 
86 bp 
R-CTCCTCCTGAGCGCAAGTAC 
4.3 Assay Development 
4.3.1 Selection of reference genes 
The TLDA cards are designed with an assay for 18S rRNA as a control gene. In addition 
to 18S rRNA, three other genes were selected as reference genes to allow the option of 
selecting the most stably expressed gene as the reference. The additional genes selected 
were beta-2-microglobulin (B2m), glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 
and histone cluster 2, H2aa1(Hist2h2aa1). 
To assess the reliability and stability of the gene expression for each gene the Ct values 
for all four reference genes were subjected to BestKeeper analysis (Pfaffl et al., 2004). 
This software uses pair-wise correlations to calculate the stability of Ct values for each 
‘reference gene’ across all experimental conditions, on the assumption that equal 
amounts of total RNA/cDNA have been loaded into the reaction. It also generates an 
averaged index value between all samples for genes deemed stably expressed. If 
normalising against a control sample using the ΔΔCt method to generate a fold change 
value, this index can be used as a more reliable reference source than using a single 
gene Ct value.  
The descriptive statistics indicate that 18S rRNA has the least amount of variance and 
the highest correlation with the BestKeeper index and would be the most suitable choice 
for a reference gene (Appendix C.1 and Appendix C.2). The standard deviation is still 
high (1.3), as the BestKeeper software suggests rejecting any reference gene with a 
higher than one standard deviation. However, the BestKeeper software relies on the 
equal loading of RNA/cDNA quantity, and it is possible that the variance observed is 
due to unequal loading rather than expression instability.  
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Since the Ct values in most cases are lower for 16-32 cell and blastocyst samples, this 
could indicate a higher amount of starting material loaded (Appendix C.3). As the ratio 
of the target gene and reference gene should remain consistent with variable 
concentrations of starting materials, I have chosen to accept the slightly high standard 
deviation of the 18S Ct values and use this gene as my reference.  
4.3.2 Optimisation of post-implantation RNA analysis 
RNA was supplied by Dr L.M. Cree from 150 PGCs collected by FACS at various 
stages of post-implantation embryogenesis (7.5, 8.5, 9.5 and 11.5 d.p.c.).  
Post-implantation sample quantification and quality control 
The RNA was not quantifiable via standard spectrophotometry (using NanoDrop 2000 
UV-Vis Spectrophotometer) or by analysis by the Agilent 2100 Bioanalyzer RNA 6000 
Nano kit, with the lower sensitivity rating of 5 ng. 
 
Figure 4.4 Agilent 2100 Bioanalyzer Nano Gel Image. Gel image produced from the 
Agilent 2100 Bioanalyzer software showing the quality of control and sample RNA.  
As the RNA was at low concentration, cDNA was generated using the One-Direct 
System (NuGEN) which is capable of amplifying cDNA from as little as 10 pg of RNA. 
However, qPCR results from the TLDA cards showed much lower signal intensity for 
all genes in the post-implantation samples. The average Ct value for 18S rRNA in pre-
implantation blastocyst samples was 18.43, but for post-implantation samples was 36.5. 
A ΔCt of 18.06 is equivalent to ~275,000 fold less signal in post-implantation samples. 
[Controls]  [    Samples   ]
  ~250 ng  ~5 ng     7.5       7.5      8.5       9.5      9.5      11.5     11.5      B 
28S 
18S   
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The other reference genes, such as B2m and Gapdh also failed to amplify successfully 
(Figure 4.5). 
  
Figure 4.5 TLDA trace comparisons for selected reference genes. The pre-
implantation samples from blastocysts (3) show successful amplification of (A) 18S 
rRNA, (B) B2m and (C) Gapdh reference genes. However, samples extracted from post-
implantation PGCs (7.5, 8.5, 9.5 and 11.5 d.p.c. in duplicate) show (D) poor 
amplification for 18S rRNA, (E) no amplification for B2m and (F) variable amplification 
success for Gapdh reference genes. 
RNA amplification 
RNA amplification allows generation of microgram amounts of anti-sense/amplified 
RNA (aRNA) from low amounts of input total RNA. Lang and colleagues (2009) tested 
three methods of RNA amplification: Modified T7 amplification, the Arcturus
®
 
RiboAmp
®
 HS RNA Amplification Kit and the Balanced PCR method. They found the 
RiboAmp
®
 HS kit gave the most reliable amplification from sub-nanogram amounts of 
total RNA.  
A. B. C. 
D. E. F. 
18S rRNA B2m Gapdh 
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Table 4.3 Signal comparison before and after RNA amplification. The table shows 
the Ct value for Actb (at a threshold of 500 RFU) of control and post-implantation 
samples before and after amplification, indicating where applicable the improvement.  
Sample Before Amp. After Amp. Improvement Fold Change 
Control 29.79 20.95 8.84 451.50 
7.5 No Signal No Signal - - 
8.5 31.28 26.28 5.00 31.73 
8.5B N/A 23.60 - - 
9.5 N/A 24.66 - - 
11.5 N/A No Signal - - 
 
Samples amplified with RiboAmp kit were found to be incompatible with the NuGen 
WT-Ovation and One-direct kits, which successfully increased the signal of an 
unamplified pre-implantation sample by ~380 fold (Table 4.4).  
Table 4.4 Comparison between WT-Ovation and Superscript III cDNA synthesis 
kits. The table shows that aRNA does not produce cDNA with the NuGen WT-Ovation 
system but does with Superscript III. However, unamplified samples (Blasto) show 
much higher signal for Actb with the WT-Ovation system compared to Superscript III.  
Sample WT-Ovation Superscript III Difference Fold Change 
Blasto. 21.49 30.08 8.59 379.82 
8.5A No Signal 27.53 - - 
8.5B No Signal 25.62 - - 
9.5 No Signal 23.15 - - 
 
This would indicate more signal is lost by not being able to generate cDNA with the 
NuGen kit than has been gained by amplifying the RNA. 
Post-implantation TLDA results after RNA amplification 
Post-implantation samples that have undergone RNA amplification were also loaded 
into TLDA cards and analysed. Although there was an improvement in 18S rRNA signal 
with the RNA amplification method, the signal for mRNA transcripts was lower or 
unreliable (across technical replicates). The signal for the pre-implantation blastocyst 
sample was also dramatically lower for both 18S rRNA and mRNA transcripts. This 
would suggest that the WT-Ovation
®
 RNA One-Direct Systems (NuGEN) can amplify 
the signal of mRNA transcripts more efficiently than the Arcturus
®
 RiboAmp
®
 HS 
PLUS RNA Amplification Kit.  
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Table 4.5 Comparison of post-implantation TLDA results. The table shows the 
TLDA results obtained using either the WT-Ovation
®
 RNA One-Direct Systems 
(NuGEN) for cDNA synthesis or Arcturus
®
 RiboAmp
®
 HS PLUS RNA Amplification 
Kit. Both methods produce unreliable signal from post-implantation samples.  
  
NuGEN cDNA synthesis RNA amplification 
8.5A 8.5B 9.5A Blasto  8.5A 8.5B 9.5A Blasto  
18S 34.35 35.96 34.26 18.47 26.84 29.47 25.15 26.78 
B2M   
  
26.80   
  
  
Bax   21.16 36.46 26.49 28.66 32.60 27.55   
Dnm1l   29.29 
 
27.73   
  
36.27 
Fis1   
  
31.26 33.23 28.22 
 
  
Gapdh 32.58 25.35 27.57 23.42   33.71 26.44 31.31 
Hif1a   
  
30.03   
  
  
Hist2h2   
  
28.65   
  
  
Lrpprc   
  
24.97   
 
30.35 34.14 
Mfn1   
 
31.51 23.84   
  
33.84 
Mfn2   
  
    
  
  
Nrf1   
  
26.75   
  
35.61 
Opa1 35.20 
  
27.08   
  
37.08 
Pdx1   
 
30.62     
  
  
Peo1 27.15 
  
    
  
  
Phb2   
 
26.73 27.53   
 
34.32 34.75 
Polg   
  
    
  
  
Polg2   
  
    
  
  
Polrmt   
  
    
  
  
Pop5   35.30 
 
26.31   
 
33.68   
Pparg   
  
    
  
  
Ppargc1a   
  
    
  
  
Ppargc1b   
  
33.13   
  
36.42 
Pprc1   29.02 
 
27.80   
 
34.17 34.14 
Rnaseh1   
  
    
  
  
Sirt5   
  
    
  
  
Sod2 23.23 
 
34.8 27.09   
  
34.39 
Sp1   
 
23.28 27.46   
  
  
Tfam 36.03 
  
33.28   
  
35.92 
Tfb1m   
  
28.99   
  
36.39 
Tfb2m   
  
    
  
  
Txn1       29.46         
 
4.3.3 RNA extraction from somatic cells collected by FACS 
The previously extracted post-implantation samples are at unacceptably low RNA 
concentration, with no way of identifying the quality of the samples. For potential 
further studies, it is important to identify the number of cells required for successful 
gene expression analysis of RNA from samples gathered using FACS. 
As fluorescently marked PGCs are extremely limited, I have chosen to analyse a 
reference gene in RNA extracted from somatic cells acquired through FACS. The 
Arcturus
®
 PicoPure
®
 RNA Isolation Kit (Life Technologies) has been shown to 
successfully recover high-quality RNA from fewer than 10 cultured cells. Since there 
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are approximately 50 PGCs at early post-implantation stages, cells from separate FACS 
sessions may need to be pooled. After lysis, the samples in the extraction buffer can be 
stored at -80 °C before being pooled and extracted on one column at a later date. To test 
the efficiency of this method, five aliquots of 50 cells were pooled to a total of 250 
cells. A range of cells from 10 to 1000 were collected into the RNA extraction buffer 
from the Arcturus
®
 Picopure
®
 kit (Figure 4.6).  
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Figure 4.6 Actb signal in somatic mouse cells. The Ct values at 200 RFU for RNA 
extracted from somatic cells collected using FACS. The signal gets stronger with 
increasing number of cells up to 500 and 1000, which have similar signal. The duplicate 
RNA extracted from 10 and 50 cells show some variance. RNA from approximately 250 
pooled cells shows similar signal to that of 50 and 100 individual cells.  
Using the same cDNA synthesis and qPCR technique (with a threshold of 200 RFU), 
successfully analysed pre-implantation blastocyst samples had a Ct of 28.11. The 
biological duplicates for 100 cells had an average Ct value of 29.18, a much stronger 
signal than any previously analysed post-implantation samples extracted from Trizol
®
 
Reagent using the PureLink
®
 RNA Mini Kit. However, when pooling aliquots of 50 
cells, 250 cells had lower signal than 100 cells (30.15), suggesting a greater number of 
cells may be required if 100 cells cannot be collected from one FACS session. Since the 
previously collected samples were 150 pooled PGCs, this suggests either PGCs contain 
considerably less RNA than a mixed population of somatic cells, or the previously used 
RNA extraction technique was not optimal for use with limited input tissue. 
Unfortunately, the fecundity of the mice became reduced and severely limited the 
availability of GFP-Stella expressing PGCs, making further analysis of post-
implantation samples at this stage impossible. However, the success of extraction using 
the Arcturus
®
 PicoPure
®
 RNA Isolation Kit indicates that combining this technique with 
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the WT-Ovation
®
 RNA Amplification and One-Direct Systems (NuGEN) for cDNA 
synthesis would generate sufficient material for analysis using the TLDA cards in future 
studies. 
4.4 Results and Discussion 
4.4.1 Pre-implantation TLDA results 
RNA was supplied by Dr L.M. Cree from pooled pre-implantation embryos at the 2-
cell, 4-cell, 6-8-cell, 16-32-cell and blastocyst stages of development. 
Replication genes 
The expression of the replication genes Peo1, Polg, Polg2 and Rnaseh1 were measured 
during pre-implantation . Peo1, the mitochondrial helicase, is most highly expressed at 
the 2-cell stage, with very low expression throughout the rest of pre-implantation 
development (Figure 4.7A). Polg is detected at low levels at both the 2-cell and 
blastocyst stage, and at higher levels in 16-32-cell stage, but only in one replicate 
(Figure 4.7B). Polg2 was only detected in one blastocyst replicate (Figure 4.7C). 
Rnaseh1 is detected in only one sample at the 2-cell stage, but detected at higher and 
more consistent levels throughout the remainder of pre-implantation development 
(Figure 4.7D). No differences were statistically significant (unpaired t test). 
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Figure 4.7 The expression of mitochondrial replication genes relative to 18S. The 
bar charts represent the gene expression of mitochondrial replication genes (A) Peo1, 
(B) Polg, (C) Polg2 and (D) Rnaseh1 as a percentage of 18S gene expression. The error 
bars are representative of the standard deviation between biological replicates. As the 
signal was not present in all samples for all genes, the number above each bar represents 
the number of biological replicates contributing to the mean (maximum 3). 
The higher levels of expression of  Peo1 and Polg at the 2-cell stage of development 
could indicate increased rate of replication. This would correlate with the increased rate 
of mtDNA turnover discovered at this stage by McConnell and Petrie (2004). The low 
frequency of detection for Polg2 is likely to be due to the low level of expression of this 
gene (0.003% of 18S expression). Thundathil and colleagues (2005) reported an 
increase in the expression of replication genes as pre-implantation development 
progresses, it is plausible that the increased loading concentration of RNA at the 16-32 
cell and blastocyst stages, suggested by previous analysis of reference gene expression, 
could account for Polg and Polg2 only being detectable at these later stages. The higher, 
and more consistent levels of Rnaseh1 are explained by the majority of the protein being 
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localised to the nucleus, and only approximately 10% associated with mitochondrial 
function (Figure 4.7D) (Suzuki et al., 2010). 
Mitochondrial transcription genes 
The expression of the mitochondrial transcription genes Tfam, Tfb2m,  Polrmt,  Nrf1, 
Lrpprc and Sp1 were measured during pre-implantation development.  
Tfam and Tfb2m both show increased expression from the 8-cell stage onwards, though 
are not always detected in all replicates (Figure 4.7A-B). Polrmt has increased 
expression in all three replicates at the 8-cell stage, but dropped dramatically in the 16-
32-cell and blastocyst stages (Figure 4.8C). Nrf1 is expressed higher in the 2- and 4-cell 
stages, compared to the later stages of development (Figure 4.8D). Lrpprc also shows 
higher expression from the 8-cell stage onwards (Figure 4.8E). Although increased at 
the 8-cell stage, similarly to Polrmt, the levels reduce again at the 16-32-cell stage and 
blastocyst stage (Figure 4.8F). None of the gene expression changes were statistically 
significant (unpaired t-test). 
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Figure 4.8 The expression of mitochondrial transcription genes relative to 18S. The 
bar charts represent the gene expression of mitochondrial transcription genes (A) Tfam, 
(B) Tfb2m, (C) Polrmt, (D) Nrf1, (E) Lrpprc and (F) Sp1 as a percentage of 18S gene 
expression. The error bars are representative of the standard deviation between 
biological replicates. As the signal was not present in all samples for all genes, the 
number above each bar represents the number of biological replicates contributing to the 
mean (maximum 3). 
Thundathil and colleagues (2005) measured steadily increasing expression of 
mitochondrial genes from the 8-cell stage onwards during pre-implantation 
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development. Tfam and Tfb2m both show increased expression from this stage onwards, 
indicating they are good markers for mitochondrial transcription. LRPPRC has been 
shown to not directly interact with POLRMT as a transcription factor. It modifies 
mitochondrial gene expression post-transcriptionally through increasing mRNA 
stability, modulating transcript polyadenylation and coordination of mitochondrial 
translation (Harmel et al., 2013). Lrpprc also shows higher expression from the 8-cell 
stage onwards, suggesting expression of this gene is tightly linked to mitochondrial 
transcription rate.  
Mitochondrial dynamics genes 
The expression of the mitochondrial dynamics genes Dnm1l, Fis1, Mfn1 and Mfn2 were 
measured in pre-implantation samples. 
The expression levels of Dnm1l, Fis1, and Mfn1 do not change significantly over the 
course of pre-implantation development (Figure 4.9A-C). Mfn2 is expressed at the 
highest levels from the 6-8 cell stage onwards (Figure 4.9D), and is significantly 
different between the 8- cell stage (0.08 %; SD±0.003 %) and the blastocyst stage 
(0.02 %; SD±0.002 %; p <0.01 unpaired t test), though only detected in two of the 
replicates. 
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Figure 4.9 The expression of mitochondrial dynamics genes relative to 18S. The bar 
charts represent the gene expression of mitochondrial dynamics genes (A) Dnm1l (B) 
Fis1 (C) Mfn1 (D) Mfn2 and (E) Opa1 as a percentage of 18S gene expression. The 
error bars are representative of the standard deviation between biological replicates. As 
the signal was not present in all samples for all genes, the number above each bar 
represents the number of biological replicates contributing to the mean (maximum 3). 
** p < 0.01 unpaired t test. 
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Continuous mitochondrial fission and fusion allows the exchange of replication factors 
between mitochondrial compartments. Impairing mitochondrial dynamics through 
knockdown of fission proteins, DNM1L and FIS1, or knockout of fusion proteins 
MFN1, MFN2 and OPA1 has been shown to cause mtDNA depletion in cultured cells 
and skeletal muscle respectively (Chen et al., 2010, Malena et al., 2009). Mfn2 is 
expressed at the highest levels from the 6-8 cell stage onwards, similar to Tfam and 
Tfb2m, suggesting it could contribute to an increase in mitochondrial transcription rate.  
Mitochondrial biogenesis genes 
The expression of the mitochondrial biogenesis genes, Ppargc1b, Ppargc1a, Ppargc1b 
and Pprc1 was measured throughout pre-implantation development. 
Ppargc1a (encoding PGC1α) was not detectable at any stage during pre-implantation. 
Pparg is expressed in just one replicate at the 2-cell and 16-32-cell stages, but reliably 
detected at low levels in blastocysts (Figure 4.10A). Ppargc1b (encoding PGC1β) is 
expressed at high levels in all three replicates at the blastocyst stage and in one replicate 
at 16-32-cell stage (Figure 4.10B). Pprc1 is expressed consistently throughout pre-
implantation development (Figure 4.10C). No expression changes were statistically 
significant (unpaired t test). 
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Figure 4.10 The expression of mitochondrial biogenesis genes relative to 18S. The 
bar charts represent the gene expression of mitochondrial biogenesis genes (A) Pparg, 
(B) Ppargc1b and (C) Pprc1 as a percentage of 18S gene expression. The error bars are 
representative of the standard deviation between biological replicates. The number 
above each bar represents the number of biological replicates contributing to the value 
(maximum 3). 
Many of the molecular pathways which influence mitochondrial biogenesis do so 
through induction or activation of PGC1α (see Section 1.4.6). However, Ppargc1a 
(encoding PGC1α) was not detectable at any stage during pre-implantation. The 
expression of Pparg and Ppargc1b was most reliable in blastocysts, suggesting an 
increase in mitochondrial biogenesis at the later stage of pre-implantation development. 
PGC1β has similar transcriptional responses to PGC1α, and may be the main regulator 
of mitochondrial biogenesis in blastocysts. Pprc1 has recently shown to be critical to 
early mouse development, with homozygous knockout mice failing to implant correctly 
in the uterine wall (He et al., 2012), but is not regulated during these stages. 
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Mitochondrial stress and apoptosis genes 
The expression of genes involved in mitochondrial stress response (Sod2 and Hif1a) and 
in apoptosis (Bax) were measured during pre-implantation. 
There was a slight increase in Sod2 expression as development progresses (Figure 
4.11A). Hif1a expression is increased at both the 2-cell stage and at the blastocyst stage 
(Figure 4.11B). Bax expression was significantly lower at the 2-cell stage compared to 
the blastocyst stage (p < 0.05 unpaired t test) (Figure 4.11C).  
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Figure 4.11 The expression of mitochondrial stress and apoptosis genes relative to 
18S. The bar charts represent the gene expression of mitochondrial stress and apoptosis 
genes (A) Sod2, (B) Hif1a and (C) Bax as a percentage of gene expression. The error 
bars are representative of the standard deviation between biological replicates. The 
number above each bar represents the number of biological replicates contributing to the 
value (maximum 3). * p < 0.05 unpaired t test. 
In some tissues, it was reported that manganese superoxide dismustase (MnSod; 
encoded by Sod2) correlates with mtDNA copy number, to maintain low levels of 
oxidative stress markers (Aiken et al., 2008). Although mtDNA copy number remains 
stable in the total embryo during pre-implantation development, the slight increase in 
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Sod2 expression as development progresses, which potentially correlates with the 
increase in transcription and biogenesis. Increased mitochondrial ROS production can 
lead to activation of hypoxia-inducible factor 1-α (encoded by Hif1a) inducing 
downstream transcriptional responses to compensate for physiological stress such as 
hypoxia (Guzy and Schumacker, 2006). Hif1a expression was increased at the stages 
when replication rate and mitochondrial biogenesis were highest. 
Apoptosis has been found to be repressed in 2-cell embryos, through increased anti-
apoptotic proteins (Bcl) and reduced pro-apoptotic proteins (Bax), which prevent 
mitochondrial depolarisation (Hansen and Fear, 2011). Although transcript levels of Bax 
were not found to be affected by stage in bovine embryos, there was a detectable 
reduction observed in murine 2-cell embryos. There has been little speculation on why 
apoptosis is repressed at the 2-cell stage, but it is possibly linked to the increased 
mtDNA replication observed at the 2-cell stage.  
Overview of pre-implantation results 
Biological variability can be introduced through the uncertain timing of fertilisation and 
the staging of embryos, which have to be determined by eye. By pooling 15 embryos in 
batches, it is possible the average time since fertilisation in each biological replicate is 
different. The main technical limitation of the study was low amounts of starting 
material, with lower expressed genes unable to be detected or at the limit of detection 
(LOD) where expression isn’t reliable. In some cases one of the technical replicates was 
also undetectable, most likely due to the nature of loading the TLDA cards by 
centrifugation into nano-sized reaction chambers. 
4.4.2 Analysis of published microarray data 
The mtDNA bottleneck has been shown to have occurred by 13.5 d.p.c. (Freyer et al., 
2012). Our analysis attempted to study mitochondrial gene expression from PGCs as 
early as possible, using GFP-Stella mice (7.5 d.p.c.) to identify the stage at which 
mtDNA replication and biogenesis is at the highest levels. We hypothesised this would 
indicate the point where the PGCs began recovering from their lowest mtDNA copy 
number (the critical stage of the mtDNA bottleneck).  
To identify new genes, specifically expressed in female and male germ cells, Sabour 
and colleagues (2011) isolated PGCs at 8.5 to 18.5 d.p.c. from OG2/CD1 (△PE-GFP) 
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mice. Their data is publically available online, allowing for analysis of our genes of 
interest during post-implantation. Unfortunately, they were only able to perform 
microarray analysis from 11.5 d.p.c. onwards, after the predicted stages, 8.5-9.5 d.p.c., 
when mtDNA copy number in PGCs has been discovered to increase (Cree et al., 2008, 
Wai et al., 2008).  
The expression patterns of the mtDNA replication genes Peo1, Polg, Polg2 and 
Rnaseh1 are variable during post-implantation (Appendix D.1). Expression levels of 
Polg and Polg2 would suggest a slightly higher replication rate up to and including 
13.5 d.p.c., before decreasing for a few days, fitting with the prediction that mtDNA 
replication rate has already increased. The expression of mitochondrial transcription 
genes, in particular Tfb2m, Polrmt and Nrf1 (Appendix D.2), would suggest the 
transcription rate increases from approximately 14.5 d.p.c., after when we know the 
mtDNA bottleneck has already been formed. The genes regulating mitochondrial 
dynamics steadily increase throughout post-implantation development, peaking between 
14.5 and 16.5 d.p.c., before decreasing again (Appendix D.3). However, Pparg 
expression increases from 11.5 d.p.c., peaking at 14.5 d.p.c. before decreasing again, in 
a similar pattern to both Polg and Polg2, suggesting it could be linked to the increased 
mitochondrial biogenesis required to repopulate the dividing population of PGCs 
(Appendix D.4A). Ppargc1a and Ppargc1b are detected at low levels throughout post-
implantation development, without a clear pattern of expression (Appendix D.4B-C). 
4.5 Concluding remarks 
Despite the limitations of the study there is evidence that during pre-implantation 
development, the mtDNA replication and transcription rate correlates to that suggested 
in previous research (McConnell and Petrie, 2004, Piko and Taylor, 1987, Thundathil et 
al., 2005). Lrpprc has only recently been implicated in post-transcriptional regulation of 
mitochondrial expression, and this study has shown it also increases during cleavage of 
the pre-implantation embryo. Although Mfn2 also shows a similar expression pattern to 
the components of the transcription machinery, none of the other genes regulating 
fission or fusion follow a particular expression pattern. This means there is no clear 
evidence that mitochondrial dynamics regulates mitochondrial copy number during pre-
implantation development. 
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5.1 Introduction 
The availability of sufficient material for large gene expression analysis has limited our 
study of regulation of mtDNA content. Cellular models offer an alternative to primary 
tissue for studying basic cell biology and biochemistry. Cell culture conditions are 
simple to manipulate, allowing investigation of different physiological conditions or 
drug treatments. 
5.1.1 Regulation of mtDNA content  
The majority of research investigating regulation of mtDNA content relies on 
hypothesis-driven selection of a gene of interest. Expression of various POLG-fusion 
proteins confirmed the mitochondrial localisation of POLG protein, established the 
necessity of the 3’-5’-exonuclease in preventing accumulation of mutations and showed 
that although POLG mutations cause mtDNA depletion, increased activity of POLG 
does not elevate mtDNA content (Spelbrink et al., 2000). Overexpression and knockout 
of TFAM in mice demonstrated that TFAM protein levels correlate directly with 
mtDNA content, but that increased mtDNA content does not necessarily increase 
mitochondrial gene expression or biogenesis (Ekstrand et al., 2004). Overexpression of 
the mitochondrial helicase Twinkle (encoded by C10orf2) in transgenic mice caused 3-
fold upregulation of mtDNA content in some tissues, and siRNA knockdown of Twinkle 
in cultured 143B human osteosarcoma cells immediately reduced mtDNA copy number 
(Tyynismaa et al., 2004).  
However, changes in mtDNA content upon overexpression, knockout or knockdown of 
a gene does not necessarily mean that the expression of that gene is altered in 
physiological relevant situations where mtDNA copy number is regulated. We want to 
identify which genes are regulated in order to control mtDNA content, and to potentially 
screen for new factors influencing mtDNA copy number. To do this, we need to 
generate a model whereby mtDNA replication rate is increased, independent of 
manipulating gene expression. Altering the expression of these genes during 
embryogenesis may influence how the mtDNA bottleneck skews inheritance of mtDNA 
mutations. 
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5.1.2 The mtDNA repopulation assay 
The mtDNA repopulation assay uses ethidium bromide (EtBr), a dsDNA-intercalating 
drug, to reversibly inhibit mitochondrial transcription and replication, depleting cultured 
cells of mtDNA (King and Attardi, 1989). Upon drug removal, mtDNA replication can 
resume, allowing cells to recover their mtDNA levels. 
The mtDNA repopulation assay has been used to show how primary sequence and 
molecule size can affect the mtDNA replication rate (Diaz et al., 2002, Moraes et al., 
1999). It can also be used as a tool for investigating whether pathogenic, nuclear 
mutations in mtDNA maintenance genes affect the rate of mtDNA replication (Stewart 
et al., 2011). 
Upon depletion of mtDNA, protein levels of the mitochondrial transcription machinery, 
TFAM and POLRMT, also become dramatically reduced (Seidel-Rogol and Shadel, 
2002). Importantly, they found that after removal of EtBr, mitochondrial transcription 
occurs prior to recovery of mtDNA and transcription machinery levels. Resumption of 
high transcription rates is clearly critical to increasing mtDNA replication rates, as the 
fastest replication rate occurs when accumulation of TFAM and POLRMT is most 
dramatic. Depletion and repopulation in four cell lines (143B, D16.10.40, and HP4) was 
found not to significantly alter the expression of POLG, TFAM, POLRMT and SSBP 
transcripts, when analysed by northern blot (Moraes et al., 1999). However, only the 
final time point after 15 days of depletion and then after 15 days of repopulation were 
studied, and therefore initial responses to changes in EtBr concentration may have been 
overlooked.  
Myoblasts are primitive muscle cells, which fuse together to generate multi-nucleated 
myotubes, which will eventually develop into striated muscle fibres. Myoblasts are 
derived from muscle biopsies, making this cell-type one of the most physiologically 
relevant to mitochondrial disorders. In previous research from our group, it was found 
that myoblasts failed to thrive after 10 days of treatment with 50 ng/ mL EtBr (Stewart, 
2008). Therefore, depletion of mtDNA in myoblasts will need to be optimised before 
the full assay can be completed.  
Treatment of human immunodeficiency virus (HIV)-infected patients with nucleoside 
reverse transcriptase inhibitors (NRTIs) induces many phenotypes similar to those 
observed in mitochondrial disease. As nucleoside analogues, they not only block viral 
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reverse transcriptase, but also endogenous DNA polymerases, such as mitochondrial 
polymerase γ (Martin et al., 1994). Myoblasts have proved sensitive to mtDNA 
depletion by some NRTIs, particularly Didanosine (2',3'-dideoxyinosine; ddI) and 
Zalcitabine (2'-3'-dideoxycytidine, ddC) (Birkus et al., 2002) and provide an alternative 
to EtBr. However, even at low concentrations, NRTIs can negatively affect cellular 
proliferation over long treatment courses (Benbrik et al., 1997). An optimal 
concentration which both effectively depletes mtDNA without preventing cellular 
proliferation must be found.  
5.1.3 Research aims 
We will use the mtDNA repopulation assay to model the reduction and subsequent 
increase in mtDNA copy number observed during embryogenesis, forming the mtDNA 
bottleneck (Cree et al., 2008, Wai et al., 2008). We will assess gene expression 
throughout the depletion/repopulation phase, identifying which genes are regulated to 
induce an increase in mtDNA copy number. With regular sampling, we will be able to 
identify a more accurate timing of the gene expression changes which occur. 
If the repopulation assay proves a suitable model for studying mtDNA replication, we 
will then perform a non-hypothesis-driven analysis of gene expression to identify new 
regulatory factors, and explore how manipulation of these genes can affect the 
segregation of mutant mtDNA molecules. 
5.2 Materials and Methods 
5.2.1 Myoblast and fibroblast primary cell lines 
The information for myoblast and fibroblast primary cell lines are found in Table 5.1. 
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Table 5.1 Cell line information. The identifier, gender and age of patients used to 
generate myoblasts and fibroblasts. 
I.D Cell type Identifier Gender Age 
Control 1 Myoblast C018 Male 22 
Control 2 Myoblast C049 Male 21 
Control 3 Myoblast C010 Male 42 
MERRF Myoblast  M028 Male 12 
Control Fibroblast F010 - Embryonic 
5.2.2 Depletion of mtDNA in myoblasts and fibroblasts 
The drugs chosen to deplete mtDNA were EtBr (Sigma-Aldrich) and ddC (Sigma-
Aldrich). Several concentrations were chosen to identify the conditions able to produce 
maximum depletion with minimal toxicity. EtBr concentrations used were 10 ng/ mL 
and 25 ng/ mL, and ddC concentrations were 0.2 µg/ mL, 0.6 µg/ mL and 1 µg/ mL.  
5.2.3 Galactose (glucose-free) media treatment 
Galactose medium for fibroblast culture was created by the addition of 5 mM D-(+)-
galactose (Sigma-Aldrich), 10% dialysed FBS (Gibco), 500 units/ mL 
Penicillin/Streptomycin (Gibco) and 50 µg/ mL uridine (Sigma-Aldrich) to glucose-free 
DMEM (Gibco). 
5.2.4 qPCR for quantification of mtDNA copy number per cell 
Relative mtDNA copy number per cell was calculated using the ΔCt technique, using a 
mitochondrial gene fragment (MT-ND1) and a nuclear gene fragment (B2M).  
Generation of templates for the mtDNA copy number assay 
DNA templates for real-time qPCR standards were created using standard 25 µL 
Immolase reaction (Section 2.2.2).  
Table 5.2 Primers to create templates for copy number real-time standards. Primer 
sequences to generate large DNA fragments which are purified by gel extraction, 
quantified and which serve as templates for standard curves analysed by qPCR. 
Gene Genome Primer Sequence 
Fragment 
Size (bp) 
ND1 Mitochondrial 
F-TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG 
1040 
R-CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC 
B2M Nuclear 
F-CGCAATCTCCAGTGACAGAA 
1092 
R-GCAGAATAGGCTGCTGTTCC 
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PCR products were electrophoresed (Section 2.2.3) and the product bands were excised. 
The DNA was extracted using the standard QIAquick Gel Extraction Kit (QIAGEN) 
protocol.  
The concentration of the extracted DNA is determined using a NanoDrop 2000 UV-Vis 
Spectrophotometer. The copy number/ µL can be determined by calculating the 
molecular weight of each DNA fragment and using the concentration to estimate the 
DNA content of the purified samples. 
                                                      
     
  ⁄  
          ⁄
  
 
           
  ⁄         ⁄         
                 ⁄   
qPCR reaction 
A standard 25 µL qPCR reaction mix (Section 2.12.1) was used with the following 
primers in Table 5.3.  
Table 5.3 Primers to amplify DNA from MT-ND1 and B2M templates. Primer 
sequences to generate mitochondrial and nuclear fragments for use in qPCR to quantify 
mtDNA copy number.  
Gene Fragment Primer Sequence Fragment Size (bp) 
ND1 Mitochondrial 
F-ACGCCATAAAACTCTTCACCAAAG 
111 
R-GGGTTCATAGTAGAAGAGCGATGG 
B2M Nuclear 
F-CACTGAAAAAGATGAGTATGCC 
231 
R-AACATTCCCTGACAATCCC 
 
5.2.5 Real-time PCR for assessing gene expression 
RNA was extracted using the RNeasy
®
 Mini Kit (QIAGEN) (Section 2.9.2). cDNA was 
generated using the standard Superscript III reaction (Section 2.11). A standard 25 µL 
qPCR reaction mix (Section 2.12.1) was used with the following primers in Table 5.4.  
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Table 5.4 qPCR primers for assessing gene expression. Primer sequences for use 
with cDNA templates for gene expression analysis by qPCR, listing the related function 
and fragment sizes. 
Gene Related Function Primer Sequence Fragment Size (bp) 
ACTB Reference gene 
F-GATGCAGAAGGAGATCACTGC 
131 
R-ACATCTGCTGGAAGGTGGAC 
GAPDH Reference gene 
F-CTGACTTCAACAGCGACACC 
133 
R-ATGAGGTCCACCACCCTGT 
B2M Reference gene 
F-CACCCCCACTGAAAAAGATG 
112 
R-TTCAAACCTCCATGATGCTG 
TFAM Transcription 
F-GCTCCCCCTTCAGTTTTGTGT 
140 
R-TTTTGCATCTGGGTTCTGAGCT 
POLG Replication 
F-AGAGTTTATGACCAGCCGTGTGA 
101 
R-CAAACTCTTCAAACAGCCACTTCA 
POLG2 Replication 
F-CAATGTGTCTAAATTACATGGCCGAG 
81 
R-CGGTCTAGGTCCCCATTTACAGA 
NRF1 Transcription 
F-TTGCTTCGGAAACTTCGAGCC 
146 
R-GTACTTACGCACCACATTCTCC 
OPA1 Fusion 
F-GTTCAACTGGCGGAAGACC 
117 
R-TGCAGAGCTGATTATGAGTACGA 
PEO1 Replication 
F-ATATGATCACTGGGCTGACC 
150 
R-AACTGCAGGTTGTCGATGAT 
FIS1 Fission 
F-AGGAGGAACAGCGGGATTAC 
130 
R-AGTTCCTTGGCCTGGTTGTT 
POLRMT Transcription 
F-ACTTCATCCACTCGCTGGAC 
133 
R-ACCTGGTTCATGACGGAGAC 
PPARG Biogenesis 
F-TTGAATGTCGTGTCTGTGGAG 
138 
R-GGATCCGACAGTTAAGATCACA 
SOD2  ROS 
F-GGGTTGGCTTGGTTTCAATA 
130 
R-GTAGTAAGCGTGCTCCCACA 
COII (mt) 
Mitochondrial 
respiratory 
subunit 
F-CCATCCCTACGCATCCTTTA 
108 
R-GCCGTAGTCGGTGTACTCGT 
COX4I1 
Nuclear 
respiratory 
subunit 
F-CTAGTTGGCAAGCGAGCAAT 
102 
R-ACGCCGATCCATATAAGCTG 
PGC1a Biogenesis 
F-TCTGGAACTGCAGGCCTAACT  
179 
R-CCTTTCTTGGTGGAGTTATTGC 
 
Gene Expression analysis 
Fold change was generated using the equation developed for the Relative Expression 
Software Tool (REST
©
), which accounts for the individual efficiency of each primer 
pair (Pfaffl et al., 2002). 
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E = Efficiency as a ratio of 1  Ref = Reference Gene Tar = Target Gene 
BestKeeper analysis 
To assess the stability of selected reference genes, samples were chosen from a range of 
treatments and time points. The concentration of each sample was measured using the 
NanoDrop 2000 UV-Vis Spectrophotometer. The same amount of RNA (400 ng) was 
converted into cDNA using Superscript III
®
 (Section 2.11). Each sample was analysed 
by qPCR for ACTB, GAPDH, and B2M. The stability of Ct values across samples was 
assessed using the BestKeeper software (Pfaffl et al., 2004).  
5.2.6 Immunohistochemistry of myotubes 
Myoblasts were differentiated into myotubes following the protocol in Section 2.7.6. 
Differentiation was assessed using antibodies for Slow Myosin Heavy Chain (ab11083; 
Abcam, Cambridge, UK).  
5.2.7 SDS-PAGE and western blotting 
SDS-PAGE and western blotting were completed using the standard protocol in Section 
2.14. All mitochondrial subunits were analysed with β-Actin on a 14% acrylamide gel. 
POLG protein was analysed with β-Actin on an 8% acrylamide gel. Antibodies for 
western blotting are listed in Table 5.5. 
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Table 5.5 Antibodies used for western blotting. The table below lists the antibodies 
used for determining mitochondrial protein expression, indicating the species in which 
the antibody was raised (Ms, mouse; Rb, rabbit; Sw, Swine) and the clonality (mAb, 
monoclonal; pAb polyclonal), the size of the target protein, the concentration (Conc.) of 
the antibody used when probing the blot and the distributor information. 
Type Antigen Species 
Size 
(kDa) 
Conc. used 
(µg/ mL) 
Distrib. Code 
1° Anti-β-Actin (Loading Control) Ms mAb 42 0.1 Sigma A1978  
1° VDAC1 / Porin (Mito Mass) Ms mAb 39 0.1 Abcam ab14734 
1° SDHA (CII Nuclear) Ms mAb 70 0.2 Abcam ab14715 
1° COX4 (CIV Nuclear) Ms mAb 20 1 Abcam ab110261 
1° 
Cytochrome C oxidase subunit II 
(CIV Mitochondrial) 
Ms mAb 26 1 Abcam ab110258 
1° DNA Polymerase gamma Rb pAb 130 2 Abcam ab97661 
2° Anti-Mouse (Ms) Rb pAb - 0.5 DAKO P0260 
2° Anti-Rabbit (Rb) Sw pAb - 1.5 DAKO P0399 
5.3 Assay Development 
Before the expression of mitochondrially-related genes can be studied, the optimum cell 
culture conditions must be established. This includes the drug and concentration to use, 
treatment and recovery times and viability of the cells. 
5.3.1  Determination of drug concentrations 
Using data from previous publications (Birkus et al., 2002, Saitoh et al., 2008, Stewart 
et al., 2011), a range of concentrations to test was established. For EtBr, these were 
10 ng/ mL and 25 ng/ mL. For ddC, these were 0.2 µg/ mL, 0.6 µg/ mL and 1 µg/ mL. 
Two control myoblast cell lines were either cultured in standard media or treated for 11 
days and then allowed to recover in standard media for a further nine days. Cells were 
harvested at each passage, and the mtDNA copy number calculated using relative qPCR 
technique, comparing the signal of an mtDNA amplicon to a nuclear amplicon (Figure 
5.1).  
Myoblasts treated with either 10 or 25 ng/ mL had 5-15% mtDNA copy number after 11 
days of treatment. In both control cell lines, treatment with the lower concentration of 
EtBr allowed an earlier onset of recovery (Control 1-Day 18, 10 ng/ mL EtBr 13.8 % 
(SD±3.2 %) , 25 ng/ mL EtBr 7.2 %  (SD±0.1 %); Control 2-Day 21, 10 ng/ mL EtBr 
13.1 % (SD±2.4 %), 25 ng/ mL EtBr 7.2 %  (SD±1.3 %). Culturing myoblasts with 
1 µg/ mL ddC depletes mtDNA levels as rapidly as either EtBr concentration (Control 1-
Day 12, 11.7 % (SD±1.1 %); Control 2-Day 12, 6.5 % (SD±0.1 %). Cells began 
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recovering their mtDNA levels at the same rate, or more rapidly after depletion with 
1 µg/ mL ddC than those depleted with 10 ng/ mL EtBr (Control 1-Day 18, 16.0 % 
(SD±0.2 %); Control 2-Day 18, 16.8 % (SD±4.5 %). The lower concentrations of ddC 
failed to regularly deplete mtDNA levels to the same extent (Control 1-Day 12, 
0.2 µg/ mL ddC 61.6 % (SD±2.9 %), 0.6 µg/ mL ddC 20.9 % (SD±0.02 %); Control 2, 
0.2 µg/ mL ddC 31.6 % (SD±0.63 %), 0.6 µg/ mL ddC 14.2 % (SD±0.4 %)). 
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Figure 5.1 MtDNA depletion and repopulation curve using different drugs with a 
range of concentrations. The mtDNA depletion and repopulation rates in two control 
cell lines caused by treatment with EtBr or ddC at varying concentrations. Each mtDNA 
copy number is presented as a percentage of the untreated condition. Error bars 
represent standard deviation of biological duplicates. 
As the depletion rate is the same for both concentrations of EtBr and 1 µg/ mL ddC, 
there may be a plateau effect whereby increasing concentrations of the inhibiting drugs 
cannot deplete cells in culture any faster. Since the mechanism of the drugs is to block 
replication of new mtDNA molecules, rather than destroy existing mtDNA, this could 
represent the natural turnover rate of mtDNA, and implies that mtDNA replication has 
been completely blocked by these treatments. As the lower concentrations of ddC had 
slower depletion rates, this suggests mtDNA replication is only partially blocked. Since 
1 µg/ mL ddC depletes mtDNA at the maximal rate whilst allowing more rapid recovery 
from treatment, this is the optimal condition taken forward for further study. 
Throughout the experiment the mtDNA copy number in the untreated condition was 
steadily increased. This means, by the end of the repopulation phase, the mtDNA copy 
number was higher than the starting copy number, but still only a fraction of the 
untreated condition. This is a concern, since through the depletion/repopulation there 
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needs to be a state in which replication rate is increased in treated cells compared to the 
untreated condition.  
5.3.2 Stability of mtDNA copy number  
The stability of the copy number in untreated cells is crucial to establishing a detectable 
gene expression difference in repopulating cells. The increased copy number could also 
be a stress response to inadequate tissue culture conditions, which would compromise 
the integrity of the results. To establish whether increasing copy number is a regular, 
repeatable occurrence, one control (Control 2) and one MERRF myoblast cell line were 
cultured for 18 days without drug treatments from two independent aliquots of frozen, 
stored cells (e.g. Control-A and Control-B; MERRF-A and MERRF-B). Cells were 
passage four at Day 0 and were passage 10 by Day 18. At the beginning of cell culture, 
both cell lines had similar mtDNA copy number (Control 387 (SD±64); MERRF 352 
(SD±32.8). At the point of greatest increase, control myoblasts reached 334 % 
(SD±61 %) of their original mtDNA copy number and MERRF myoblasts reach 235 % 
(SD±19 %). 
 
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
T im e  P o in t  (D a y )
m
tD
N
A
 c
o
p
y
 n
u
m
b
e
r
C o n tro l-A
C o n tro l-B
M E R R F -A
M E R R F -B
 
Figure 5.2 mtDNA copy number in untreated cultured myoblasts. mtDNA copy 
number measurements in one control and one MERRF myoblast line cultured without 
drug treatment for 18 days. Increased mtDNA copy number is observed in both control 
and MERRF myoblasts. Error bars represent standard deviation of biological duplicates. 
Independent aliquots of the same cell line increased in mtDNA copy number to a similar 
extent. This suggests that whatever influences the rise in mtDNA copy number may 
affect cell lines differently or could relate to the condition of particular cells, rather than 
being an artefact of the tissue culture process.  
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5.3.3 Modulating FBS concentration and passage confluency 
To investigate the possible causes for the increase in mtDNA copy number during 
myoblasts culture, modulation of growth conditions was applied to the control and 
MERRF cell lines. Firstly, the cells might have been reaching confluency and ceasing to 
divide, which could lead to an accumulation of mtDNA in cells. To avoid this, cells 
were passaged every two days instead of 3, but reseeding with the same number of cells 
to avoid becoming too sparse and impairing growth. Secondly, increasing concentration 
of FBS to 15% may provide a richer growth medium for the cells to grown in (Figure 
5.3). The best combination of conditions was for both cell lines to be passaged every 
three days with 15 % FBS. The second best condition was cells to be passaged every 
two days with 15 % FBS with both passage frequencies in 10 % FBS having the greatest 
increase in mtDNA copy number. 
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Figure 5.3 mtDNA copy number in untreated myoblasts using variable conditions. 
The mtDNA copy number trends in (A) a Control and (B) a MERRF myoblast cell line 
passaged either every two days (blue lines) or 3 days (green lines) and either cultured 
using 10% (light) or 15% (dark) FBS. The greater the number of passages, the more 
pronounced the increase in mtDNA copy number is; however, 15% FBS improves the 
stability of mtDNA copy number in myoblasts. Error bars represent standard deviation 
of biological duplicates. 
Passaging cells every two days only led to a more pronounced increase in mtDNA copy 
number, suggesting that the increase could be a stress response related to passaging the 
cells. In both cell lines, 15% FBS gave the lowest rate of increase, with the best-case 
scenario being passaging every three days and 15% FBS supplementation. Even so, the 
effect of increased FBS concentration was minimal, and an increase in mtDNA copy 
number was still observed. 
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The trend in data observed by passage number (during the experiment) rather than by 
the day point was much more similar between cell lines passaged every two days or 
three days when accounting only for the first eight passages (Figure 5.4). The lowest 
slope observed was cells passaged every two days in 15 % FBS and the highest slope 
was cells passaged every three days in 10 % FBS. 
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Figure 5.4 Copy number in myoblasts normalised for passage number. The copy 
number trends in (A) a Control and (B) a MERRF myoblast cell line passaged either 
every two days (blue lines) or three days (green lines) and either cultured using 10% 
(light) or 15% (dark) FBS. When ordered by passage number, the difference in mtDNA 
copy number between cell lines passaged every two or three days is reduced. Error bars 
represent standard deviation of biological duplicates. 
The cell lines which have the lowest rate of mtDNA copy number increase have 
changed to cells passaged every two days with 15% FBS, reflecting not only the benefit 
of higher FBS concentration, but also that each passage has a greater effect than simply 
length of time in culture. It is probable that length of time in culture does have some 
effect, as the first eight passages of the cell lines passaged every two days only 
represents the first 15 days of culture, as opposed to the entire 21 days of culture for the 
cell lines passaged every three days. The worst-case scenario is now being passaged 
every three days in 10% FBS, suggesting that general time in culture does contribute to 
the increase in mtDNA copy number, but not as severely as passaging cell lines. 
The passage of mitotic cells in culture for a long period of time is unavoidable. 
Although the culture of post-mitotic cells such as myotubes (differentiated from 
myoblasts) for a long enough period of time is possible (Ferrer-Martinez et al., 2006), it 
would rely on sampling non-passaged replicates at each time point rather than a fraction 
of the cells during subculture. This means there is no guarantee that cells sampled at a 
later date were behaving in a similar way to those sampled at earlier time points, and 
thus increases the likelihood of misleading results.  
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5.3.4 Assessing differentiation in myoblasts 
Primary myoblast cultures have the potential to differentiate into myotubes if the serum 
levels are reduced, or the cells remain fully confluent for a long period of time (Capers, 
1960). To exclude the possibility of unintentional differentiation of the myoblasts 
during culture, the cells were probed for Myosin Heavy Chain Slow (MYHC–Slow). 
MYHC-Slow is specifically expressed in type I myotubes and not myoblasts (Figure 
5.5).  
 
Figure 5.5 Immunocytochemistry assessing differentiation of myoblasts. (A) 
Control myoblasts show no staining for MYH-Slow (Green) and individual single 
nucleated cells (Blue). (B) Myoblasts differentiated into myotubes showing staining for 
MYH-Slow in Type I myotubes and show long multi-nucleated fibres. (C) Myoblasts at 
day 18 are observed as individual nucleated cells with no MYH-Slow staining, 
suggesting that they are not differentiating into myotubes. 
Myoblasts at the end of experimentation (Day 18) are still observed as individual nuclei 
(DAPI stained) with no MYHC-Slow staining, suggesting they have not differentiated 
into myotubes, though further markers are required to determine whether myoblasts are 
in the early stages of differentiation. 
5.4 Results and Discussion 
5.4.1 Gene expression during depletion/repopulation in myoblasts 
With the optimum concentrations for EtBr and ddC established, and the modulation of 
FBS concentration increased to 15% to reduce mtDNA copy number increase in 
untreated cells, the expression of genes with known importance to mtDNA replication 
was measured. Control and MERRF myoblasts were depleted for six days with 
25 ng/ mL EtBr or 1 µg/ mL ddC, and allowed to repopulate for 12 days afterwards (total 
B. Myotube controls C. Late-passage myoblasts A. Myoblast controls  
DAPI; MYHC-Slow  
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of 18 days). Cells were subcultured every third day and samples collected for DNA and 
RNA extraction. First, copy number measurements were made to select for the optimum 
depletion/repopulation curve (Figure 5.6). Control myoblasts treated with 25 ng/ mL 
failed to repopulate by Day 18 (6.12 %; SD±1 %). Myoblasts treated with 1 µg/ mL ddC 
began repopulation at Day 15 (Control, 48.4 % (SD±12.8 %); MERRF, 99.8 % 
(SD±8.55 %)).  
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Figure 5.6 Depletion and repopulation of mtDNA in control and MERRF 
myoblasts. mtDNA copy number as a percentage of starting value on Day 0, in (A) 
control and (B) MERRF myoblasts. Cells were either untreated (green), treated with 
EtBr (red) or treated with ddC (blue) until day six. The drugs are removed at day six, 
allowing  mtDNA to repopulate for a further 12 days. Error bars represent standard 
deviation of biological triplicates. 
The control cell line failed to repopulate with EtBr treatment, but both cell lines 
repopulated to varying degrees with ddC treatment. Therefore, cell lines depleted only 
with ddC were chosen to study gene expression patterns.  
The fold change in ddC-treated compared to untreated cell lines was calculated using 
the ΔΔCt technique, comparing the expression of a target gene (e.g. TFAM) to a 
reference gene (e.g. ACTB), and then comparing this ratio in a target sample (e.g. 
treated) to a control sample (e.g. untreated). A fold change of one represents no 
difference in gene expression between the two compared samples (shown at day 0 as 
there was only one sample, with no treated condition) (Figure 5.7).  
TFAM gene expression levels show a reduction correlating with mtDNA copy number 
during at the lowest point of depletion (Control-Day 9, 0.79 (SD±0.06); MERRF-Day 9, 
0.56 (SD±0.06)) and a subsequent increase in expression after repopulation (Control-
Day 18, 1.62 (SD±0.11); MERRF-Day 18, 1.42 (SD±0.02), p < 0.05 unpaired t test). 
There was a decline in POLG expression in control myoblasts only (Control-Day 6, 
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0.46 (SD± 0.43); MERRF-Day 6, 1.31 (SD±0.31) and after repopulation, POLG gene 
expression is no different from the untreated condition (Control-Day 18, 0.99 
(SD±0.33); MERRF-Day 18, 0.94 (SD±0.1). POLG2 also shows slight reduction in 
expression after depletion (Control-Day 6, 0.61 (SD±0.2); MERRF-Day 6, 0.78 
(SD±0.05) with recovery to normal or higher levels (Control-Day 18, 2.04 (SD±0.00), p 
< 0.005 unpaired t test; MERRF 1.23 (SD±0.1). NRF1 levels do not appear to correlate 
with depletion and repopulation. 
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Figure 5.7 Gene expression in myoblast cell lines normalised against untreated. 
The gene expression of (A) TFAM, (B) POLG, (C) POLG2 and (D) NRF1 using ACTB 
as a reference gene in control and MERRF myoblast cell lines. Fold change calculated 
between treated (1 µg/mL ddC) and untreated cells at each time point. Error bars are 
based on the standard deviation of fold changes calculated when treated biological 
triplicates are normalised against the mean untreated Ct values. * p < 0.005 unpaired t 
test. 
When comparing treated to untreated cell lines at each time point, there seems to be a 
slight, non-significant reduction in gene expression of TFAM, POLG and POLG2 
between Day 0 and Day 6-9 with a steady increase either back to normal (POLG) or 
slightly higher levels (TFAM and POLG2). NRF1 has an unstable gene expression 
profile which does not seem to correlate well between cell lines or conditions. 
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The highest fold change observed is below 2.5 fold, which is not a high enough 
difference to be valuable if performing whole transcriptome profiling, and especially not 
when hoping to identify novel genes involved with mtDNA replication regulation which 
may have more subtle expression changes to genes such as POLG and TFAM.  
5.4.2 Gene expression during mtDNA depletion/repopulation in fibroblasts with 
and without galactose 
Cells in standard culture media containing glucose can rely on glycolysis for the 
majority of their energy demands. This means there is little pressure on cells to 
repopulate their mtDNA after depletion when in glucose media. To make cells reliant on 
mitochondria, it is possible to culture them on a glucose-free media supplemented with 
galactose. To utilise galactose for glycolysis, it must first be converted into a component 
of glycolysis, glucose-6-phosphate (G6P), in a 4-step process. Although the net yield of 
ATP per galactose molecule is the same as for glucose (+2ATP), the flux rate at which 
G6P can be produced from galactose is much slower than for glucose (Demir and Aksan 
Kurnaz, 2006, Pritchard and Kell, 2002). The slow production of ATP through 
glycolysis when metabolising purely galactose is not sufficient to supply the energy 
demands of the cell, meaning a higher reliance on ATP production through oxidative 
phosphorylation in the mitochondria. This phenomenon allows the use of galactose-only 
media as a test of mitochondrial dysfunction in patient cell lines (Robinson et al., 1992). 
Reliance on oxidative phosphorylation may be a way to drive mtDNA replication in 
repopulating cells and observe a more extreme transcriptional response to depletion. In 
this model, fibroblasts were cultured for six days with 1µg/mL ddC in high-glucose 
media; upon removal of ddC some cells were placed in galactose media whilst others 
returned to standard glucose media (Figure 5.8). 
Fibroblasts were depleted of mtDNA to below 10 % by Day 9 (Glucose, 5 % 
(SD±1.34 %); Galactose, 7 % (SD±0.53 %)). Repopulation rate is initially similar in 
glucose and galactose conditions (Glucose-Day 12, 53.46 % (SD±14.33); Galactose-
Day 12 48.21 % (SD±13.96 %)). By Day 15, however, fibroblasts in the galactose 
condition have a dramatically increased mtDNA copy number compared to those in 
glucose (Control-Day 15, 86.68 % (SD±9.62); MERRF-Day 15, 410.09 % 
(SD±36.50 %).  
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Figure 5.8 Fibroblast mtDNA repopulation with and without galactose. Fibroblasts 
were depleted for six days with 1 µg/ mL ddC and allowed to repopulate in either 
standard glucose media or 5 mM galactose media. (A) Copy number is significantly 
higher in fibroblasts cultured with galactose. Brightfield microscopy images taken on 
Day 9 showing (B) untreated and (C) 1 µg/ mL ddC treated fibroblasts having no 
significant morphological differences, but (D) fibroblasts cultured in galactose for three 
days after depletion showing growth defects.  
There was early evidence of culture in galactose after depletion having a negative effect 
on cellular growth and morphology (Figure 5.8D). Without cells dividing, it is difficult 
to gauge the replication rate since mtDNA can accumulate without compensation for 
mtDNA copy number halving upon division. The dramatic reduction in cell number 
towards the end of the experiment also meant a reduction in DNA recovered for use in 
the qPCR assays to determine mtDNA copy number. The signal for the nuclear gene 
(B2M) was close to the limit of sensitivity of the assay, which could account for the 
apparent dramatic increase in mtDNA copy number and larger standard deviation in 
galactose treated fibroblasts on Day 18. 
The gene expression of TFAM, POLG, POLG2 and NRF1 were also measured relative 
to ACTB in both glucose and galactose culturing conditions (Figure 5.9). There is 
B. Untreated control        C. ddC, Glucose                 D. ddC, Galactose 
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significant difference of POLG expression at Day 3 and NRF1 expression at Day 6; 
however at this stage of the experiment the two samples were in the same media 
conditions. There was a significant difference between glucose and galactose condition 
in the gene expression of TFAM at Day 9 (Glucose, 1.34 (SD±0.30); Galactose, 2.11 
(SD±0.37) and Day 18 (Glucose, 0.78 (SD±0.24); Galactose, 1.68 (SD±0.38). There is 
also significant difference of POLG expression at Day 9 (Glucose, 1.17 (SD±0.17); 
Galactose 1.65 (SD±0.23)), Day 12 (Glucose, 1.04 (SD±0.31); Galactose, 2.44 
(SD±0.7)) and Day 18 (Glucose, 0.88 (SD±0.15); Galactose, 2.92 (SD±0.79)). POLG2 
expression is significantly different between media conditions at Day 12 (Glucose, 1.59 
(SD±0.22); Galactose 4.09 (SD±1.0) and Day 15 (Glucose, 2.04 (SD±0.33); Galactose 
4.00 (SD±1.08). NRF1 expression is significantly different between media conditions at 
Day 9 only, and then reduces in expression in the galactose condition whilst increasing 
in the glucose condition (Glucose, 0.38 (SD±0.2); Galactose, 2.07 (SD±0.21). 
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Figure 5.9 Gene expression in control fibroblasts. The gene expression of (A) TFAM, 
(B) POLG, (C) POLG2 and (D) NRF1 using ACTB as a reference gene. Fold change 
calculated between treated (1µg/mL ddC) and untreated cells at each time point. Error 
bars are based on the standard deviation of fold changes calculated when treated 
biological triplicates are normalised against the average of untreated biological 
triplicates. † Signal for POLG2 and NRF1 was below the sensitivity range of the assay 
on Day 18. * p < 0.05, ** p < 0.01, *** <0.001 unpaired t test. 
All genes show significantly increased expression induced by culturing with galactose 
instead of glucose at one or more time points after repopulation resumes. However, with 
the growth of cells compromised, it is not a valid model to study gene expression as any 
changes observed may be due to cellular stress rather than simply increased replication 
rate. 
5.4.3 Culture in variable concentrations of galactose-based media 
Fibroblasts were depleted for six days with 1 µg/ mL ddC. Between Day 6 and 9, 
fibroblasts were subjected to different percentages of galactose/glucose ranging from 
between 0% (glucose only) and 100% (galactose only) in 25% increments. Daily, 
between Day 9 and 12, the galactose concentration was increased, and glucose 
concentration reduced, by 25% (Figure 5.10A). The mtDNA copy number was 
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measured at each passage and the cell number determined by haemocytometer (Figure 
5.10B-C). 
At Day 15, only the 75 % galactose condition shows a significantly higher mtDNA copy 
number than the glucose control condition (Glucose, 121.9 % (SD±16.9 %); 75 % > 
Galactose, 203.0 % (SD±22.1 %); p < 0.01 unpaired t test). Cells grown for three days in 
galactose directly after drug removal showed a decreased cell number (52.5 % 
(SD±22.9 %)). Between Days 9 and 12, any cells exposed to pure glucose also showed a 
decrease in cell number (25% > Gal, 35.76 (SD±16.9 %); 50 % > Gal, 65.5 % 
(SD±21.5 %); 75 % > Gal, 47.7 % (SD±10.3 %)). 
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Figure 5.10 Fibroblast depletion and repopulation with galactose. Fibroblasts were 
depleted for 6 days with 1µg/mL ddC. From Day 6 fibroblasts were exposed to variable 
ratios of glucose and galactose. A) Demonstration of when the glucose: galactose ratio 
changes. B) mtDNA copy number measurements shows no difference in repopulation 
rates between cell lines. C) Cell counts normalised to untreated showing depleted cells 
are not viable in 100% galactose. † Denotes cells in galactose for at least one day. 
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Fibroblasts depleted of mtDNA have reduced proliferation rates in galactose media as 
they cannot generate sufficient energy for cell division through limited glycolysis. 
However, by Day 15 mtDNA copy number in all depleted lines have recovered beyond 
that observed in the untreated condition, yet fibroblasts moved to pure galactose media 
at this point still fail to thrive.  
Although there was no difference in mtDNA repopulation rate, the gene expression of 
the four replication/transcription genes was assayed to determine whether the variable 
galactose concentration has induced any gene expression changes (Figure 5.11). 
Although there are many statistically significant differences between time points for 
TFAM, POLG2 and NRF1, the only significant difference between media conditions 
was for NRF1 expression on day 12 (Glucose, 1.16 (SD±0.1); 0 > 75% Gal, 1.48 
(SD±0.02), p < 0.05 unpaired t test). 
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Figure 5.11 Gene expression under variable galactose concentrations. The gene 
expression of A) TFAM, B) POLG, C) POLG2 and D) NRF1 using ACTB as a reference 
gene. Mean fold changes calculated between treated biological triplicates (1µg/mL ddC) 
and the mean of untreated triplicates at each time point. Error bars represent the SD.      
* p < 0.05 unpaired t test. 
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NRF1 expression is not significantly affected by media conditions at Day 9 and the 
difference observed at Day 12 represents a fold change difference of just 0.32 fold. It is 
clear that although fibroblasts can proliferate in up to 75% galactose, there is little 
difference in either the mtDNA copy number repopulation rate or associated gene 
expression. 
5.4.4 Mitochondrial protein levels during depletion/repopulation 
In the previous experiment, mtDNA copy number was repopulated to between 35-85% 
by Day 12 in variable concentrations of galactose. By Day 15, all conditions had 
recovered to above that of the untreated condition, yet the fibroblasts could not 
proliferate in pure galactose media.  
For the respiratory chain to be functional, the mitochondrial-encoded proteins must be 
translated and incorporated into the respiratory complexes. It may be that although 
mtDNA has fully repopulated, the mitochondrial-encoded protein levels have not 
returned to sufficient levels to restore adequate mitochondrial function. 
To investigate when translation of mitochondrial-encoded proteins recommences, 
protein lysates from untreated and treated (1µg/mL ddC) fibroblasts were analysed by 
SDS-PAGE and western blotting. Membranes were probed with antibodies against a 
reference protein (β-Actin), a mitochondrial outer membrane protein unrelated to 
respiration (Porin/VDAC), a subunit from the entirely nuclear-encoded Complex II 
(SDHA) and Complex IV subunits. COXII is a Complex IV subunit encoded on the 
mtDNA, whereas CIV SIV is nuclear encoded (Figure 5.12). 
SDHA is one of four nuclear subunits comprising Complex II. Although expression of 
SDHA is significantly lower in ddC-treated fibroblasts at Day 12 (Untreated, 0.21 
(SD±0.02); ddC, 0.12 (SD±0.01), p < 0.05 unpaired t test), it is detectable at all stages 
after depletion. However, COXII, which is mitochondrially encoded, is not detectable in 
ddC-treated fibroblasts until Day 15 (Untreated, 0.08 (SD±0.03); ddC, 0.05 (SD±0.03), 
ns). Despite the lack of mitochondrial complexes, the nuclear subunit of complex IV, 
SIV, is expressed at consistent levels at both Day 9 and Day 12. Porin/VDAC shows 
increased expression in ddC-treated fibroblasts from Day 12 (Untreated, 0.06 
(SD±0.03); ddC, 0.28 (SD±0.07); ns) and is at over 10-fold expression by Day 15 
(Untreated, 0.04 (SD±0.01); ddC, 0.49 (SD±0.01); p < 0.001 unpaired t test).  
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Figure 5.12 Protein expression during repopulation. A) mtDNA copy number during 
repopulation. B) Western blot images comparing protein expression in untreated 
fibroblasts compared to ddC-treated fibroblasts, showing lack of expression of 
mitochondrial COXII after mtDNA depletion and an increase in mitochondrial 
biogenesis (indicated by VDAC/Porin) as the cell repopulates. C) Densitometry 
quantification of the expression levels of Complex II SDHA (CII), VDAC/Porin and 
Complex IV subunit II (COXII) relative to β-Actin during repopulation, from biological 
duplicates. ¤ COXII not detectable in Days 6-12. † CIVSIV was not analysed at Day 9 
or Day 15. * p < 0.05, *** p < 0.001 unpaired t test. 
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Depletion of mtDNA prevents translation of mitochondrial-encoded proteins. However, 
this does not affect the expression of nuclear-encoded proteins, even those from 
complexes with mitochondrial-encoded subunits, such as Complex IV. 
The increased expression of Porin/ VDAC from Day 12 suggests there might be general 
upregulation of mitochondrial biogenesis to compensate for reduced respiration capacity 
cause by mtDNA depletion. 
Polymerase gamma protein levels 
To determine whether the increase in mtDNA copy number could be regulated at the 
protein level rather than the mRNA level, the expression of polymerase gamma protein 
was assessed between Day 6 and Day 15.  
POLG protein is reduced between Day 6 and Day 12 (ddC-Day 6, 0.64 (SD±0.2), ns; 
ddC-Day 9, 0.49 (SD±0.13), ns; ddC-Day 12, 0.42 (SD±0.12), p < 0.005 unpaired t test) 
but begins to recover by Day 15 (ddC, 0.82 (SD±0.08)). 
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Figure 5.13 Analysis of Polymerase Gamma protein levels. A) mtDNA copy number 
during repopulation. B) Western blot images comparing protein expression in untreated 
fibroblasts to compared to ddC-treated fibroblasts, showing decreased expression of 
mitochondrial polymerase gamma after mtDNA depletion until recovery at Day 15. C) 
Densitometry quantification of the expression levels of polymerase gamma relative to  
β-Actin during repopulation, from biological duplicates. * p < 0.05 unpaired t test. 
Previous analysis of polymerase gamma in 143B (TK-) ρ0 cells, containing no mtDNA, 
indicate no decrease in either protein or mRNA levels from that observed in the parental 
(ρ+) cell lines (Davis et al., 1996). However, after just six days in ddC the Polg protein 
levels are ~60% of that in untreated cells, dropping to ~40% before recovering. mtDNA 
depletion has previously been shown to cause reduction in TFAM protein levels 
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(Larsson et al., 1994). It is possible that reduction of mtDNA and TFAM protein 
compromises nucleoid structure, causing the decrease in other components of nucloids, 
such as POLG.  
5.4.5 Investigation of alternative functions at intermediate time points 
Previously, gene expression was only sampled at 3-day intervals, upon passaging the 
fibroblasts. It is possible that some important gene expression signals are being 
overlooked between these time points. The only genes analysed have functions related 
to mitochondrial transcription and replication, but there are many other biological 
functions which contribute to regulation of mtDNA copy number. To address these 
potential problems, fibroblasts will be sampled daily after removal of ddC, and the 
range of genes analysed will be expanded to include a other possible functions that are 
critical to regulation of mtDNA replication, such as mitochondrial dynamics or 
biogenesis. 
To ensure the most appropriate reference gene is being used, the stability of expression 
of various ‘housekeeping’ genes were analysed by the BestKeeper software, using 
samples under variable conditions (Appendix E.1). Although ACTB is considered 
acceptable, GAPDH shows lower deviation between samples and will be used as a 
reference gene instead. 
Fibroblasts were treated with 1 µg/ mL ddC for six days, as in previous experiments. To 
allow for sampling fibroblasts every day without passaging, at each three-day interval 
1/3 of a t75 was sampled for DNA/RNA extraction, whilst the remaining fibroblasts 
seeded one t75 and three t25s. The day after passaging, two t25s were sampled for 
extraction, and the second day after, one t25 was sampled.  
Treated fibroblasts at Day 9 have lower mtDNA copy number than at Day 6 (Day 6, 
5.51 % (SD±0.62 %); Day 9, 4.53 % (SD±0.85 %)), though the lowest point of depletion 
is actually Day 8 (3.64 % (SD±1.09 %)), meaning recovery has already begun at Day 9. 
mtDNA copy number peaks at Day 13 (72.93 % (SD±8.14 %), before decreasing in both 
the untreated and treated conditions.  
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Figure 5.14 Measuring mtDNA depletion and repopulation in fibroblasts each day. 
Fibroblasts were depleted with 1µg/mL ddC for six days and allowed to repopulate for a 
following 12 days in standard glucose media. Cells were passaged every three days but 
samples collected each day to make mtDNA copy number measurements. 
Investigating intermediate time points reveals that mtDNA replication has resumed by 
Day 9. Without the intermediate time points, it would be possible for the resumption of 
mtDNA replication to have occurred at any stage from Day 8 to Day 12, making 
interpretation of results difficult. It has also revealed a peak in mtDNA copy number 
after Day 12, which has decreased again by Day 15.  
Gene expression was analysed during the optimal stages of repopulation, between Day 6 
and Day 13. Fold change was calculated using the ΔΔCt method, normalising treated 
biological triplicates against the average for untreated samples. Statistical significance 
was calculated between the treated samples, and the untreated samples normalised 
against the average.  
There was no statistically significant difference at any time point for TFAM, POLG, 
POLG2 or NRF1 (Figure 5.15).  
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Figure 5.15 Gene expression in fibroblasts during mtDNA repopulation. The fold 
change of (A) TFAM, (B) POLG, (C) POLG2 and (D) NRF1 relative to GAPDH reveals 
no change in gene expression in intermediate points of mtDNA repopulation. Error bars 
based on standard deviation when the fold change is calculated from treated biological 
triplicates against the average of untreated controls.  
The gene expression of mitochondrial subunits for Complex IV was also measured. 
There is a statistically significant decrease in transcription of mitochondrial-encoded 
MT-COII from Day 7. Similarly to mtDNA, the lowest level of MT-COII transcript was 
at Day 8 (Untreated,1.02 (SD±0.26); ddC, 0.15 (SD±0.004)) (Figure 5.16A). Expression 
of COX4I1, a nuclear subunit of Complex IV, in treated fibroblasts is only significantly 
higher than that of untreated fibroblasts at Day 10 (Untreated, 1.00 (SD±0.02);         
ddC, 1.22 (SD±0.12)) (Figure 5.16B). 
Chapter 5  
176 
 
6 7 8 9
1
0
1
1
1
2
1
3
0 .0
0 .5
1 .0
1 .5
2 .0
M T -C O II
T im e  P o in t  (D a y )
F
o
ld
 c
h
a
n
g
e
 (
t
r
e
a
t
e
d
 v
. 
u
n
t
r
e
a
t
e
d
)
A .
**
** **
****
**
**
*
6 7 8 9
1
0
1
1
1
2
1
3
0 .0
0 .5
1 .0
1 .5
2 .0
C O X 4 I 1
T im e  P o in t  (D a y )
F
o
ld
 c
h
a
n
g
e
 (
t
r
e
a
t
e
d
 v
. 
u
n
t
r
e
a
t
e
d
)
B .
*
 
Figure 5.16 Gene expression of Complex IV subunits during mtDNA repopulation. 
Shows how depletion of mtDNA causes a (A) reduction in gene expression relative to 
GAPDH of the mitochondrially encoded subunit MT-COII until Day 8 which begins to 
recover by Day 9. (B) Nuclear encoded subunit COX4I1 transcript levels show no 
depletion by Day 6 and remain stable throughout repopulation. * p < 0.05, ** p < 0.01, 
**** p < 0.0001 unpaired t test. 
The depletion and repopulation of MT-COII transcript follows the same pattern as for 
mtDNA, though does not deplete to the same extent. This suggests that either more 
transcripts are being generated from each mtDNA molecule in depleted fibroblasts, or 
mitochondrial transcripts are long-lived and depletion lags behind that of mtDNA.  
Further genes were analysed to assess the contribution of replication (PEO1/Twinkle), 
transcription (POLRMT), fission and fusion (OPA1, FIS1), mitochondrial biogenesis 
(PPARG) and reactive oxygen species (SOD2) to regulation of mtDNA copy number. 
There were no statistically significant differences between untreated and treated cells 
from Day 6 to Day 12 for any genes (Figure 5.17).  
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Figure 5.17 Gene expression of additional genes during repopulation. Expression of 
(A) FIS1 (fission), (B) OPA1 (fusion), (C) PEO1 (replication), (D) POLRMT 
(transcription), (E) PPARG (biogenesis) and (F) SOD2 (oxidative stress) show no 
response to mtDNA depletion by Day 6 and remain stable throughout repopulation. 
 
Chapter 5  
178 
 
Kao and colleagues (2012) investigated the effect of six weeks treatment with EtBr and 
chloramphenicol (inhibitor of mitochondrial protein synthesis) on mitochondrial 
biogenesis. After six weeks of EtBr treatment, the expression of TFAM, NRF1 and 
POLG was decreased (TFAM, 0.42-fold; NRF1, 0.19-fold; POLG, 0.10-fold). After two 
weeks without EtBr, TFAM and NRF1 expression had increased beyond that of 
untreated cells (TFAM, 5.09-fold; NRF1, 2.92-fold) and POLG expression had returned 
to normal (1.15-fold) (Kao et al., 2012). Some mild depletion and recovery of gene 
expression has been observed over the course of experimentation with six days ddC 
treatment. Even though mtDNA copy number was depleted to <10%, longer exposure to 
the ddC may be needed to induce more dramatic compensatory mechanisms.  
5.5 Concluding remarks 
The instability of mtDNA copy number in myoblasts or fibroblasts during long periods 
of culture suggests there are other factors, such as cellular stress, contributing to 
regulation of mtDNA replication or content. Although there have been significant 
changes in gene expression induced by depletion of mtDNA with ddC, the results are 
not always regularly repeatable and do not provide large changes in gene expression. 
Fibroblasts cannot be forced to rely on mitochondrial function through culture in 
galactose medium after depletion of mtDNA. Recovery of normal levels of 
mitochondrial-encoded proteins is too slow to allow proliferation of fibroblasts in 
medium without glucose.  
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6.1 Introduction 
6.1.1 Gene expression analysis in mitochondrial disease 
The analysis of mitochondrial gene expression profiles was first done by northern blot 
and revealed dramatic transcript level rises, including increased amounts of unprocessed 
transcripts, in the tissues of patients with mitochondrial syndromes such as Kearns-
Sayre Syndrome (KSS), Myoclonic Epilepsy with Ragged-Red Fibre (MERRF) and 
Mitochondrial Encephalomyopathy, Lactic acidosis, and Stroke-like episodes (MELAS) 
(Heddi et al., 1993, Heddi et al., 1994). This includes, but is not restricted to, both 
mitochondrial- and nuclear-encoded OXPHOS subunits, with altered expression of 
ancillary genes such as adenine nucleotide transporter 1 (ANT1) and E1α subunit of 
pyruvate dehydrogenase (E1αPDH) (Heddi et al., 1999).  
The advent of microarray technology has allowed analysis of thousands of gene 
transcripts in parallel, without the requirement for preselecting target genes. This 
provides a powerful tool for the analysis of mitochondrial disease. However, particular 
care must be taken during experimental design and data analysis, as misleading gene 
expression alterations can be induced easily. Sources of experimental variability have 
been shown to be minor, if the correct quality control measures are in place, but large 
variability can be caused by tissue heterogeneity, sample limitations and inter-individual 
variation (Bakay et al., 2002). For example, agonal duration and brain pH has been 
shown to influence expression of mitochondrial genes in control post-mortem brain 
samples analysed by microarray (Vawter et al., 2006). Also, generation of 
transmitochondrial cytoplasmic hybrid (cybrid) cell lines by depletion and repopulation, 
a commonly used assay for studying mtDNA mutations in a common nuclear 
background (King and Attardi, 1989), has been shown to induce over 1,500 significant 
expression changes compared to non-manipulated cell counterparts (Danielson et al., 
2005). 
Regardless of such concerns, microarrays have consistently noted the general 
downregulation of transcription in mitochondrial disease, since it is a heavily energy- 
dependent process, and implicated several biochemical processes as causes or effects in 
the pathogenesis of mitochondrial disease. 
As previously discussed, ROS levels are increased in the tissues of patients with 
mitochondrial disease (Piccolo et al., 1991, Smits et al., 2010a). This leads to an 
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increased expression of antioxidant enzymes, such as manganese-superoxide dismutase 
(Mn-SOD), in the attempt to alleviate the ROS burden in mitochondrial disease patient 
tissues (Rusanen et al., 2000, Wani et al., 2008). However, catalase (CAT) and 
gluatathione peroxidise (G-Px) levels are not always upregulated alongside Mn-SOD, 
which can result in an accumulation of H2O2, as it is produced faster than it can be 
detoxified (Kunishige et al., 2003, Lu et al., 2003).  
Oxidative stress has been shown to have a regulatory effect on cytoskeletal remodelling. 
Upregulation of oxidative stress markers and matrix metalloproteinases (MMPs) with 
concomitant downregulation of cytoskeleton proteins in the fibroblasts of MERRF 
(m.8344A>G) patients, causes disruption to the dynamics of mitochondrial networks 
(Ma et al., 2005).  
Increased ROS production and levels of misfolded or damaged proteins caused by 
mtDNA deletions has been shown to have a inhibitory effect on the ubiquitin-
proteasome system. This has a negative impact on the amino acid salvage pathway, 
causing a global drop in amino acid levels within cells, and triggers autophagy through 
the mTOR pathway (Alemi et al., 2007, Kadowaki and Kanazawa, 2003).  
Comparison of transcription levels in various cell types from patients with different 
mitochondrial disease identified shared responses to mitochondrial deficiency are 
upregulation of the unfolded protein response (UPR) and cell cycle pathway, with a 
secondary effect of inhibition of vesicular secretion and protein synthesis. The UPR is 
related to endoplasmic reticulum (ER) disruption, resulting in protein folding and 
processing errors. Perturbation of the ER through mitochondrial dysfunction was 
confirmed by the use of rotenone as a mitochondrial inhibitor, which also caused 
upregulation of the UPR regulators ATF4 and CHOP (Cortopassi et al., 2006).  
Gene expression profiling has been completed in the skeletal muscle of a number 
mitochondrial encephalomyopathy (MEM) patients, including those with MELAS
 
or 
Progressive, External Opthalmoplegia (PEO) caused by the m.3243A>G point mutation, 
or PEO caused by macrodeletions (Crimi et al., 2005). Their results indicate that shared 
biochemical processes upregulated in all MEM patients include fatty acid metabolism 
and the urea cycle. ARG2 is localised to the mitochondria, and converts arginine to 
ornithine and is essential for amino acid metabolism. Reduction of arginine levels 
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because of ARG2 overexpression triggers apoptosis through conversion of nitric oxide 
(NO) to peroxynitrite, a metabolite toxic to mitochondria (Wiesinger, 2001).  
Other predominant biological processes dysregulated in skeletal muscle of MEM 
patients, identified by Crimi and colleagues (2005) includes cell cycle regulation, 
genetic information processing, protein biosynthesis, metabolism, development and 
signal transduction.  
6.1.2  Ragged-red fibres (RRFs) 
RRFs visualised in skeletal muscle sections are a classic hallmark of mitochondrial 
disease and often used as an aid to diagnosis (Taylor et al., 2004). However, although 
common to some diseases such as MERRF and MELAS, they are rarely observed in 
others such as LHON and NARP (Bourgeois and Tarnopolsky, 2004). They are also 
observed in normal aged muscle tissue (Cao et al., 2001), other diseases such as 
inclusion body myositis (Horvath et al., 1998) and can be induced by use of anti-
retroviral drugs, such as zidovudine, which clonally expand pre-existing age-related 
mutations (Dalakas et al., 1990, Payne et al., 2011).  
Single-fibre analysis indicates that RRFs demonstrate higher heteroplasmy levels 
compared to the ‘normal’ fibres from the same patient. The threshold level for fibres to 
become ragged-red is dependent on the mutation, the individual and even varies 
between fibres within some patients, showing overlap of the heteroplasmy levels in 
‘normal’ and ‘ragged-red’ fibres. However, the threshold for a fibre to become ragged-
red is generally considered to be >80% (Campos et al., 2001, Nishigaki et al., 2003, 
Ozawa et al., 1998) 
Research from Durham and colleagues (2006) indicates that with some mutations, but 
not m.3243A>G, maintenance of an absolute value of wild-type mtDNA molecules, as 
opposed to a heteroplasmy threshold, is crucial for retaining cytochrome c oxidase 
(COX)-activity in individual fibres. They also demonstrated highly variable mtDNA 
copy numbers in fibres of different sizes; together, this data could account for how there 
is variability in threshold levels for conversion to RRFs (Durham et al., 2006). 
COX-positive and -negative RRFs 
RRFs can be either COX-positive or COX-negative. RRFs observed in MERRF patients 
are usually COX-negative; however, muscle samples of patients with different 
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mitochondrial diseases, such as MELAS, often show both COX-positive and COX-
negative RRFs (Bourgeois and Tarnopolsky, 2004, Nishigaki et al., 2003, Petruzzella et 
al., 1994). 
When Petruzella and colleagues (1999) investigated single-fibre analysis of 
m.3243A>G heteroplasmy levels in MELAS and PEO, they noticed that in both cases 
RRFs had much higher heteroplasmy levels compared to ‘normal’ fibres, and that COX-
negative fibres had a slightly higher heteroplasmy than COX-positive fibres. MELAS 
(m.3243A>G) has a generally higher proportion of mutant mtDNA compared to PEO 
(m.3243A>G) in total; however, the homogeneous distribution of heteroplasmy levels 
means that in MELAS fewer fibres exceed the critical threshold of mutant levels to 
produce COX-negativity in fibres. In PEO, the distribution of mutant mtDNA is more 
heterogeneous, meaning, despite a lower overall mutation level, more fibres cross the 
threshold and lose COX activity (Petruzzella et al., 1994). 
The effect of fibre type on RRF and COX activity 
The population of fibres in muscle tissue is diverse and can be generally categorised 
into three groups. Type I fibres are heavily reliant on oxidative phosphorylation and are 
slow twitch (tonic), providing sustainable but moderate strength. Type IIx fibres are 
reliant almost entirely on glycolysis and are fast twitch (clonic), providing rapid, high 
strength action but only for short durations before experiencing fatigue. Type IIa are an 
intermediate between type I and type IIx fibres, relying on both glycolysis and oxidative 
phosphorylation with moderately fast action but higher sustainability. Each fibre type 
expresses predominantly one myosin heavy chain isoform; myosin-7 (slow I); myosin-2 
(fast IIa); and myosin-1 (fast IIx), with some overlapping expression evident in a subset 
of fibres (Scott et al., 2001).  
Categorising fibres in MELAS patients as either type I or type II, as well as whether 
they are ragged-red or not, allowed Tokunaga and colleagues (1994) to show a higher 
percentage of type I fibres to be ragged-red than observed in type II fibres. It was also 
apparent that type I RRFs are generally COX-positive whereas type II RRFs are 
generally COX-negative. Interestingly, the difference in heteroplasmy level between 
type I and II ragged-red fibres was not statistically significant. Despite higher 
hybridisation signal for mtDNA in RRF compared to normal fibres, there was again no 
significant difference between RRF of different fibre types (Tokunaga et al., 1994).  
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RRF specific expression changes 
In situ hybridisation for mRNA and immunohistochemistry have been used to analyse 
the expression of particular genes and proteins specifically in RRFs. Myoglobin (Mb), 
involved in transport and storage of oxygen, was shown to have both mRNA transcript 
and protein upregulation in the RRF of mitochondrial disease patient biopsies 
(Kunishige et al., 1996). As Mb has been shown to increase production of hydroxyl 
radicals, this was later shown to correspond to upregulation of ROS response proteins 
such as Mn-SOD, CAT and G-Px (Kunishige et al., 2003). Similar 
immunohistochemical analysis has shown RRF specific upregulation of heat-shock 
60 kDa protein 1 (HSP-60) and ubiquitin (UB), involved in regulation of protein folding 
and degradation (Sparaco et al., 1993), and also neurotrophin-4 (NT-4), a signalling 
molecule predicted to be involved with skeletal muscle innervation (Walker and Schon, 
1998) (Figure 6.1). 
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Figure 6.1 Immunohistochemical analysis of ROS response proteins in RRFs. 
Muscle biopsy sections from (A-C) a CPEO patient (Adapted from Kunishige et al., 
2003), (D-F) a KSS patient (Adpated from Sparaco et al., 1993) and (G-H) a PEO 
patient (Adapted from Walker and Schon, 1998). (A, D, G) RRF identified by SDH 
staining, showing RRF specific upregulation of (B) myoglobin (Mb), (C) manganese-
superoxide dismutase (Mn-SOD), (E) heat-shock protein 60 (HSP-60), (F) ubiquitin 
(UB) and (H) neurotrophin-4 (NT-4). 
Figure 6.1 shows the dramatic upregulation of a set number of proteins in RRFs 
investigated with immunohistochemistry, comparable to in situ hybridisation to analyse 
mRNA levels. Unfortunately, analysis using these techniques requires predetermination 
of targets of interest and only semi-quantitative analysis of results. Microarray analysis 
allows investigation of a broad spectrum of genes; however, the use of tissue 
homogenates often does not reflect the gene expression in specific cell populations of 
interest (Betsuyaku et al., 2001, Fink et al., 2002). If attempting to elucidate the 
mechanism for RRF formation and identify novel related genes, it is important the 
signal is not diluted by gene expression from the unaffected fibres, typically 
representing the majority of fibres in a biopsy.  
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6.1.3 Identification of RRF and fibre types 
Common histochemical stains used in the diagnosis of mitochondrial disease are 
combined COX-SDH and modified Gomori trichome staining. RRF acquired their name 
from their appearance with modified Gomori trichrome staining, where mitochondria in 
the subsarcolemma sequester the red stain and give a ragged-red appearance to fibres 
with increased mitochondrial mass. RRFs are also easily identifiable using singular 
SDH histochemistry (Figure 6.2). 
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Figure 6.2 Histochemical stains of muscle sections in mitochondrial disease. 
Routine stains include (A) Gomori trichrome stain and (B) SDH stain identifying 
ragged-red fibres in muscle sections. (C) Normal COX staining in control muscle 
showing type I fibres with higher activity than type II fibres. (D) COX staining of 
patient muscle with mitochondrial disease showing many COX-negative fibres with no 
colouration, (E) highlighted by the use of sequential COX-SDH staining as COX-
negative fibres retain SDH activity. (F) A single COX negative fibre as a result of 
ageing (Adapted from Taylor et al., 2004). Scale bars = 30 µm. 
Identification of fibre types using myosin-ATPase staining relies on pH sensitivity 
rather than the ATP hydrolysis rates (Brooke and Kaiser, 1970). The standard ATPase 
stain at ~9.4 pH shows type I fibres as light and type II fibres as dark, though 
manipulation of pH treatment can result in alternative staining patterns for further 
resolution of fibre typing (Figure 6.3). 
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Figure 6.3 Myosin-ATPase staining for fibre typing. Myosin-ATPase staining at (A) 
standard alkali pH identifies all type II fibres by dark staining, whereas pretreatment 
with acid at (B) pH 4.6 distinguishes all three fibre types as IIa (light), I (medium) and 
IIx (dark) but (C) pH 4.3 identifies type I fibres by dark staining (Adapted from Brooke 
and Kaiser, 1970) 
Immunohistochemistry 
Although not regularly used in diagnostic investigation, it is possible to identify RRFs 
in muscle sections using immunohistochemistry. RRFs are characterised by having 
accumulation of mitochondria in the subsarcolemma of fibres and using antibodies 
targeted to mitochondrial proteins. This can show RRFs with more intense staining than 
surrounding fibres for some mitochondrial proteins. However, the heterogeneous nature 
of mitochondrial disease means mitochondrial protein expression can be variable 
between disease, patients and even fibres within the same patient (De Paepe et al., 
2009) (Figure 6.4). 
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Figure 6.4 Immunohistochemical analysis of mitochondrial proteins. (A-B) 
Antibody staining of mitochondrial proteins in control muscle sections shows 
heterogenous intensity due to variation in mitochondrial mass between fibre types. (C) 
Heterogenous distribution of Complex I subunits in MERRF muscle sections. (D-F) 
Complex IV –positive and –negative RRF identified using mitochondrial subunit 
targeted antibodies (Adapted from De Paepe et al., 2009). 
Type I fibres have higher mitochondrial activity than both type IIa and particularly type 
IIx fibres, which are predominantly glycolytic. This explains heterogeneous staining 
pattern for mitochondrial proteins, even in control tissue (Figure 6.4 (A-B)). This can be 
exacerbated in mitochondrial diseases where expression of mitochondrial proteins 
becomes even more irregular (Figure 6.4 (C-F)). 
Immunohistochemistry allows the use of multiple antibodies on one section when using 
fluorescently tagged antibodies, which is particularly useful when fibre typing muscle 
sections (Figure 6.5).  
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Figure 6.5 Immunohistochemical fibre typing and enzyme activities. Serial sections 
of human skeletal muscle. (A) using immunolabelling of different myosin isoforms to 
demonstrate fibre types (type I, myosin-7, blue; type IIa+a/x, myosin-2, green; type IIx, 
myosin-1, red). (B) SDH staining demonstrating high oxidative phosphorylation 
(OXPHOS) capacity in type I fibres, moderate in type IIa fibres and low in IIa/x and IIx 
fibres. (C) α-glycerophosphate dehydrogenase (GDP) staining demonstrating high 
capacity for glycolysis in all type II fibres, but lower in type I fibres (Adapted from 
Bloemberg and Quadrilatero, 2012). 
This allows the possibility of fibre typing and identification of RRFs within one section, 
avoiding the use of serial sections. The heteroplasmy distribution can change along the 
longitudinal length of muscle fibres, meaning the nature of fibres from serial sections 
may vary when many sections spanning a large region need to be used (Durham et al., 
2006, Elson et al., 2002). 
6.1.4 RNA integrity 
As short, single-stranded molecules, RNA is prone to degradation. RNA quality has 
been shown to have a dramatic impact on the qPCR measurement of gene expression, 
affecting both the signal intensity and the variability of RNA samples, with a minor 
effect on qPCR efficiency, giving a less reliable measurement of gene expression 
(Fleige et al., 2006, Vermeulen et al., 2011). 
To ensure the quality of gene expression data, Bustin and colleague (2009) determined a 
structured set of guidelines to govern the standards of qPCR experiments, the 
‘Minimum Information for Publication of Quantitative Real-Time PCR Experiments’ 
(MIQE) (Bustin et al., 2009). The MIQE guidelines implore authors to provide adequate 
details on experimental design, sample description and RNA quality control and make 
sure all are of satisfactory compliance with requirements to produce accurate, 
reproducible gene expression data. 
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The gold standard for RNA integrity determination was achieved by measuring the ratio 
between the 28S and 18S rRNA bands on an agarose gel, which should be 
approximately 2:1 ratio, with degraded RNA having a lower ratio as the larger, 28S 
rRNA fragment degrades more rapidly. A ratio of 1.8 was considered to indicate high 
quality RNA suitable for downstream analysis. However, calculation of the 28S/18S 
ratio is subjective to human interpretation and can give misleading results (Copois et al., 
2007). 
In recent years, the RNA integrity has been most regularly analysed using microfluidic 
capillary electrophoresis chips such as the BioRad Experion System or Agilent 2100 
Bioanalyzer. These systems generate information on RNA quantity and quality, 
providing not only the 28S/18S ratio but generating a RNA Integrity Number (RIN), 
based on the 28S/18S peak sizes and the appearance of short fragments in the ‘fast’ 
region (Schroeder et al., 2006).  
Microfluidic capillary electrophoresis specifically measures the integrity of rRNA 
genes, which are abundant enough to visualise. However, mRNAs are the target 
molecule of interest in most gene expression studies, and rRNA integrity might poorly 
reflect the state of mRNA transcripts. mRNA is known to degrade usually from the 5’ 
direction, leading to development of a qPCR based technique comparing the relative 
levels of each end of an mRNA transcript. Both the RIN score and 3’:5’ assay have 
been shown to correlate well with RNA integrity (Auer et al., 2003, Copois et al., 2007, 
Nolan et al., 2006a) 
 The final aspect of RNA quality is the purity of the sample, in relation to contaminants 
which may act as PCR inhibitors. These contaminants could be reagents from extraction 
or copurified components from the biological sample (Rossen et al., 1992). Nucleic acid 
purity is typically measured using UV spectrophotometric analysis of absorbance at 
different wavelengths, with nucleic acids absorbing specifically at 260 nm, but possible 
contaminants absorbing at 230 or 280 nm. The effect of PCR inhibitors are most 
pronounced with absolute quantification from qPCR data, but may also affect relative 
quantification if the assays used are variably affected. The presence of PCR inhibitors in 
samples can be tested by use of the SPUD assay, whereby a fragment of DNA with no 
homology to sample being tested is amplified in the presence of either water or the 
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sample. No product must amplify from the nucleic acids in the sample, but presence of 
an inhibitor will affect the amplification of the other product (Nolan et al., 2006b). 
Technical obstacles to overcome 
Formalin fixation and paraffin embedding is known to cause degradation and chemical 
modification of RNA transcripts (Goldsworthy et al., 1999, Masuda et al., 1999). 
Alternative solutions involve extraction from freshly frozen tissue samples (Guo and 
Catchpoole, 2003) using alcohol-based fixatives such as 70% ethanol or modified 
methacarn (8:1 ratio of methanol and acetic acid), which have been found to 
successfully preserve the morphology of tissue sections but also cause the least 
degradation to RNA within tissues (Cox et al., 2006).  
Recovery of intact RNA from immunolabelled or stained tissues is more difficult than 
for DNA or proteins, as immersion in aqueous solutions, for even short periods of time, 
makes RNA vulnerable to degradation by endogenous RNases (Tangrea et al., 2011). 
6.1.5 Research aims 
To dissect the specific expression differences between ragged-red and normal fibres of 
an individual. Optimise a technique to identify the fibre type and location of RRFs 
within patient muscle sections and dissect them for RNA extraction and gene expression 
analysis. Crucial to the experiment is the preservation of RNA quality and maintenance 
of a stable gene expression profile once fibres have been dissected. 
6.2 Materials and Methods 
6.2.1 Sample information 
The age and gender information for the control and patient tissue used in this study are 
found in Table 6.1. 
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Table 6.1 Muscle sample information. Two control and two MERRF patient muscle 
tissue was used in this study. The final samples for microarray analysis were age- and 
gender-matched. 
Type Purpose Sample I.D Gender Age 
Control Assay Development MCTB-0017 Male 52 
Control Microarray MTCB-064 Male 61 
MERRF Assay Development PFC-PM1947 Male 61 
MERRF Microarray M0086-11 Male 58 
6.2.2 Tissue processing and quality control 
Muscle blocks were transported at all times in liquid nitrogen or on dry ice and must not 
thaw between cryosectioning. The cryostat was cleaned with 100% ethanol prior to 
cryosectioning and a new blade was used between samples to avoid contamination. For 
each sample, a muscle section was taken directly after cryosectioning to assess the 
starting quality of RNA in each muscle block. A RIN score >8 was required in freshly 
cut tissue.  
Sections required for RNA extraction were stored at -80°C in individual 50 mL Falcon 
tubes to create an air and water tight seal and avoid cross contamination of sections.  
6.2.3 Immunohistochemistry 
Immunohistochemistry was used to determine the fibre type and the mitochondrial 
localisation in muscle sections. The antibodies used in these experiments are listed in 
Table 6.2. 
Table 6.2 Antibodies used for immunohistochemistry. The table below lists the 
antibodies used for determining fibre type and mitochondrial localisation, indicating the 
species in which the antibody was raised (Ms, mouse; Rb, rabbit; Dk, Donkey, Gt, 
Goat) and the clonality (mAB, monoclonal; pAb, polyclonal), the concentration (Conc.) 
or dilution of the antibody used and the distributor information.  
Type Description Antigen Species 
Conc. used 
(µg/ mL) 
Distributor Code 
1° Fibre Typing 
Slow Myosin 
Heavy Chain 
Ms mAb 1:5000* Abcam ab11083 
1° Mitochondria Cytochome c Rb pAb 0.1 Abcam ab90529 
1° Mitochondrial mass VDAC1 / Porin Ms mAb 0.1 Abcam ab14734 
1° 
Mitochondrial 
marker 
MTC02 Ms mAb 0.5 Abcam ab3298 
2° 
Alexa Fluor(R) 488 
Conjugate 
Anti-mouse (Ms) Gt pAb 1 Invitrogen A11001 
2° 
Alexa Fluor(R) 488 
Conjugate 
Anti-rabbit (Rb) Dk pAb 1 Invitrogen A21206 
*Dilution factor given as antibody is in acites fluid.  
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High salt buffer immunolabelling 
The addition of 2M NaCl to DEPC PBS has been shown to significantly increase RNA 
integrity from immunolabelled tissue sections through inhibition of endogenous RNases 
(Brown and Smith, 2009). All solutions were used ice-cold and the procedure carried 
out at 4 °C; all H2O in solutions was pre-treated with DEPC (see Section 2.9.1). Fresh 
frozen sections were rinsed in PBS and immediately fixed in 70% ethanol, rinsed in 
PBS, and moved to 2 M NaCl PBS buffer (salt buffer). Sections were incubated for 2 h 
in primary antibody, then were washed for 2 x 5 min in salt buffer and incubated with 
secondary antibodies for 2 h. All antibodies were diluted in salt buffer at the 
concentrations specified in Table 6.2. The sections were then washed first in salt buffer, 
then in PBS to remove the salt and dehydrated in 70% and 100% ethanol for 3 min each. 
The sections were then air dried at ambient room temperature for 5 min and were then 
ready for laser microdissection.  
Zenon
®
 immunolabelling 
Zenon
®
 labelling technology noncovalently labels primary antibodies with fluorophores 
to eliminate the need for secondary antibody incubation. Zenon
®
 fragments are 
specifically designed to target and bind to the Fc portion of the primary antibody only. 
As primary antibodies are pre-labelled separately, antibodies raised in the same species 
can be used together. 
Using the Zenon
®
 Tricolor Mouse IgG1 Labeling Kit #2 (for Blue, Green and Red 
Fluorescence Imaging), the Slow Myosin Heavy Chain antibody for fibre-typing was 
labelled with Alexa Fluor
®
 594 and the mitochondrial marker (MTC02) was labelled 
with Alexa Fluor
®
 488. Firstly, approximately 1 µg of primary antibody was diluted to 
10 µL in PBS. As the Slow Myosin Heavy Chain is in ascites fluid, a dilution of 1:10 
was used as an estimate and found to give efficient labelling. The dilution was 
incubated with 5 µL of the appropriate Zenon® mouse IgG labelling reagent for 5 
minutes. Zenon
®
 blocking reagent (at a ratio of 1:4) was used to quench any unbound 
labelled IgGs. Once the conjugate solution is blocked, it steadily loses potency as the 
fluorophore fragments unbind primary antibodies and become sequestered by the 
blocking proteins. Therefore, labelled but unblocked antibodies were stored at 4°C with 
the addition of 2 mM sodium azide and blocked in batches when required. Blocked 
antibodies were used within 30 minutes to prevent loss of signal. Conjugated Slow 
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Myosin Heavy Chain was used at a dilution of 1:1000, and conjugated mitochondrial 
marker (MTC02) was used at a dilution of 1:250. 
6.2.4 Laser microdissection 
The stage and slide mounts were cleaned with Ambion RNaseZap
® 
to destroy any 
surface RNases. Excess extraction buffer (15 µL) was loaded into the cap of a 0.5 mL 
tube to account for evaporation during dissection. Each section was processed within 
one hour to prevent collection of seriously degraded material. 
6.2.5 RNA extraction and cDNA synthesis 
RNA was extracted using Arcturus
®
 Picopure
®
 RNA Isolation Kit (Life Technologies). 
Some muscle sections were collected directly into 0.5 mL tubes after cryosectioning. 
Sections were kept on dry ice, stored at -80°C or processed immediately. 10 µL 
‘Extraction Buffer (XB)’ was added to sections in the tube and incubated at 42 °C for 
30 min to lyse cells. The lysate was stored at -80 °C or immediately processed further.  
When muscle sections were sampled from microscope slides, 20 µL ‘Extraction Buffer 
(XB)’ was pipetted directly onto the section, allowed to incubate for 15 s, agitated with 
the pipette tip and then moved to a 0.5 mL tube. The tubes were incubated at 42 °C for 
30 min to lyse cells and the lysate stored at -80 °C or immediately processed further. 
Cells were dissected directly into the extraction buffer and were lysed at 42 °C for 
30 min. If more cells were required, the lysate was stored at -80 °C, otherwise they were 
processed immediately.  
The rest of the protocol is followed as in Section 2.9.3, eluting the RNA in between 10-
20 µL ‘Elution Buffer (EB)’. 
In control experiments, cDNA was synthesised using Superscript
®
 III Reverse 
Transcriptase as described in Section 2.11. 
6.2.6 Real-time qPCR 
qPCR was performed as described in Section 2.12. 3’ primers were designed across the 
last exon boundary and the 5’ primers were designed around the first. High GC content 
in the 5’ of ACTB prevented design of a suitable primer. Primers used in control 
experiments are presented in Table 6.3. 
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The average Ct value of control samples was used as the calibrator when doing ΔΔCt 
analysis. Each other control sample is also normalised against the average and provides 
a standard deviation for the control group. 
Table 6.3 Primer information for real-time qPCR analysis of RNA quality. Primer 
sequences, positions and fragment sizes for use in control experiments to analyse the 
gene expression profile and transcript integrity of human reference genes.  
Gene Primer Sequence 
Exon Junction 
(No. exons) 
Dist. from 5’/ 
total bp 
 Size (bp) 
ACTB-3’ 
F-GATGCAGAAGGAGATCACTGC 
5-6 (6) 1019/1812  131 
R-ACATCTGCTGGAAGGTGGAC 
GAPDH-3’ 
F-CTGACTTCAACAGCGACACC 
8-9 (9) 952/1310 133 
R-ATGAGGTCCACCACCCTGT 
B2M-3’ 
F-CACCCCCACTGAAAAAGATG 
2-3 (3) 329/987 112 
R-TTCAAACCTCCATGATGCTG 
GAPDH-5’ 
F-CTCTGCTCCTCCTGTTCGAC 
1-3 (9) 29/1310  112 
R-ACGACCAAATCCGTTGACTC 
B2M-5’ 
F-GGCATTCCTGAAGCTGACA 
1-2 (3) 27/987 142 
R-TCTCTGCTGGATGACGTGAG 
6.2.7 Microarray gene expression analysis 
Microarray analysis was outsourced to AROS Applied Biotechnology AS (Skejby, 
Denmark).  
The NuGEN Ovation Pico WTA System V2 (NuGEN Technologies, Inc; San Carlos, 
USA) was used to generate cDNA the microarray gene expression study. It is a whole 
transcriptome amplification system for preparing cDNA from as little as 500 picograms 
total RNA. 
The GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix) is the most 
comprehensive whole human genome expression array, with probes covering over 
47,000 transcripts. Analysis was performed using the Affymetrix
®
 Expression Console
™
 
Software using the MAS5 algorithm, using the Affymetrix Micro Array Suite 5.0 (MAS 
5.0) algorithm to identify differentially expressed genes. 
Filtering process 
Probes which were not detected at > 50 signal and present (P) in at least one sample 
were removed from the analysis. The fold change between each sample pair was 
calculated and each probe was binned into 1 of 6 categories. A cut-off threshold of 3-
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fold up- or downregulation was established. Where the probes in normal and ragged-red 
fibres from the MERRF patient are similarly dysregulated compared to in the control, 
these were considered MERRF-specific. If probes in RRFs are dysregulated compared 
to those in normal fibres from the MERRF patient and control, these were considered 
RRF-specific. In instances where dysregulation is more prounounced in RRFs more 
than in normal fibres from the MERRF patient, these probes are considered 
‘exacerbated in RRF’. An overview of this filtering process can be found in Figure 6.6. 
Bioinformatic analysis of regulated processes and pathways 
Functional annotation and clustering was performed using The Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.7 (Dennis et al., 2003). Gene lists 
were always compared to the Homo Sapien background. 
Functionally enriched pathways were processed and adapted from KEGG: Kyoto 
Encyclopedia of Genes and Genomes (Kanehisa and Goto, 2000).  
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Figure 6.6 Filtering process for differentially expressed genes. Probes which were 
not detected at > 50 signal and present (P) in at least one sample were removed from the 
analysis. The fold change between each sample pair was calculated was allowed 
categorisation of probes first as up- or down-regulated and second, as ‘MERRF-
specific’, ‘exacerbated in RRF’ or ‘RRF-specific’. 
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6.3 Assay Development 
The stages of developing a technique to study gene expression specifically in RRFs 
involved optimisation of a laser microdissection technique and a method to identify both 
fibre type and RRFs with RNA from dissected fibres maintained at high quality. 
6.3.1 Analysis of RNA quality and quantity from laser microdissected cells 
The difficulty with obtaining RNA from laser-assisted microdissected tissues is the 
processing time at room temperature needed to collect a sufficient amount of material 
for analysis. When RNA from 1-100 laser microdissected cells was analysed on the 
Agilent Bioanalyzer, there was no detectable signal to analyse the RNA quality (data 
not shown). To pool more cells for RNA analysis means longer times dissecting cells 
from tissue, which could compromise the RNA integrity, or pooling cell lysates or RNA 
post-dissection. 
Ethanol Precipitation of RNA 
Ethanol precipitation allows concentration of DNA or RNA samples without using heat 
or vacuum centrifugation. Ethanol precipitation was carried out following the protocol 
in Section 2.9.4. Samples were precipitated from 20 and 50 µL to 10 µL, and the RNA 
concentration and purity measured on the NanoDrop 2000 UV-Vis Spectrophotometer 
(Table 6.4).  
Table 6.4 RNA purity and concentration before and after ethanol precipitation. 
Assessing the RNA purity and yield after ethanol precipitation to concentrate a sample. 
Values are given for volumes used, concentrations and absorbance ratios. 
Before Precipitation After Precipitation 
Vol.  
(µL) 
 Conc.  
(ng/ µL) 
260/280 
Ratio 
260/230  
Ratio 
Vol.  
(µL) 
 Conc.  
(ng/ µL) 
260/280 
Ratio 
260/230 
Ratio 
% 
20 86.4 2.05 0.64 10 161.6 1.72 2.27 93.5% 
50 86 2.07 0.66 10 410.5 1.86 2.32 95.5% 
 
The yield calculated indicates that ethanol precipitation with high concentration samples 
from small and large volumes is an efficient way to concentrate RNA samples. The 
absorbance ratios also suggested the process removed some contaminants absorbing at 
230nm (such as phenol, carbohydrates and EDTA), but has introduced some that absorb 
at 280nm (likely to be residual ethanol which can affect the absorbance at 280nm when 
measuring RNA in water). However, despite using ice-cold solutions and centrifugation 
Chapter 6  
201 
 
at 4 °C, it is possible that the process of ethanol precipitation could compromise the 
RNA integrity of the samples. The Agilent Bioanalyzer was used to investigate the 
effect of ethanol precipitation on rRNA integrity, and found that precipitation does not 
adversely affect the RNA integrity (Figure 6.7). Samples after precipitation were diluted 
to bring the RNA concentration within the limits of the machine specifications.  
 
Figure 6.7 Quality of RNA after ethanol precipitation. RNA analysed on the Agilent 
Bioanalyzer shows the integrity of the rRNA transcripts are maintained at high levels 
(A) before and (B) after ethanol precipitation.  
With ethanol precipitation providing a viable method of pooling RNA from many laser 
microdissection sessions, unstained control sections were prepared at room temperature 
with dehydration in 70% and 100% ethanol for 3 min each. Individual fibres were 
dissected with 100-200 cells from each section into dry 0.5 mL caps and RNA extracted 
individually. The ethanol precipitation protocol was then applied to a pool of the five 
RNA extractions and finally eluted in 10 µL of buffer. RNA was also collected from the 
remaining sections after laser microdissection, and the RNA from both analysed on the 
Agilent Bioanalyzer (Figure 6.8).  
A. Before precipitation 
 
B. After precipitation 
 
RIN: 10 
 
RIN: 9.8 
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Figure 6.8 RNA quality after laser microdissection. Electropherogram and 
‘reproduced’ gel images analysed by the Agilent Bioanalyzer of (A) RNA from sections 
post-laser microdissections and (B) RNA from 500 pooled laser microdissected fibres.  
Despite evidence of some degradation and the inaccuracies associated with measuring 
quality and quantity of such low amounts of RNA from dissected fibres, it was apparent 
that a reasonable amount of RNA can be obtained from 500 fibres. Improvement in 
techniques to preserve RNA quality should also impact in the amount of RNA extracted.  
The protocol was improved by dehydration in ice-cold ethanol solutions with the 
procedure carried out at 4 °C. Processing time for laser microdissection was restricted to 
1 h after dehydration, and cells were dissected directly into 15 µL lysis buffer.  
6.3.2 Analysis of RNA quality and quantity from stained tissue 
A method for identifying RRFs and fibre types whilst preserving RNA is essential to 
obtaining high quality material from specific cell populations. RNA was analysed from 
whole sections stained with SDH or modified Gomori trichrome used to identify 
ragged-fibres (Figure 6.9). 
RIN: 6.8 
6.4 ng/ µL 
 
RIN: 5.9 
302 pg/ µL 
 
A. Remaining section after LMD B. 500 LMD fibres 
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Figure 6.9 Quality of RNA extracted from unstained and stained muscle sections. 
Quality of RNA from (A) unstained muscle section is very high with a 8.5 RIN (B) 
RNA from SDH stained muscle sections shows only slight degradation, but lower 
concentration compared to unstained sections (C) RNA from Gomori trichrome stain 
muscle sections shows slightly higher degradation and a lower concentration compared 
to unstained sections. 
Despite the RNA integrity seeming to remain high with SDH and even Gomori 
trichrome staining, the concentration of the sample was severely compromised by the 
presence of the stains (Table 6.5).  
Table 6.5 RNA quality and quantity statistics from muscle sections. After 
electrophoresis and analysis on the Agilent 2100 Bioanalyzer the measured 
concentration and RIN number indicates that the histochemical stains have reduced the 
RNA quantity extracted but only slightly affected the quality of the RNA. 
Sample RNA Area: 
RNA Concentration 
(pg/ µl):  
rRNA Ratio  
[28s / 18s]: 
RNA Integrity Number 
 (RIN): 
Control Section 227.46 1000.86 1.46 8.5 
SDH 78.97 347.50 1.35 7.7 
Gomori Trichrome 89.11 354.54 1.24 7.1  
 
Studying the integrity of rRNA is only one technique to analyse the quality of RNA. It 
is also important to ensure manipulation of the samples is not affecting the relative 
RIN: 8.5 
A. Control  B. SDH stained 
C. Gomori Trichrome stained 
RIN: 7.7 
RIN: 7.1 
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expression profiles of mRNA transcripts. This can be done using the ΔΔCt technique 
which normalises one gene against another to account for loading control, and then 
compares the relative expression of those genes to a control sample (in this case, 
unstained tissue). A fold change of 1 indicates the same expression profile in control 
and stained samples (Figure 6.10). 
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Figure 6.10 Stability of reference gene mRNAs in unstained and stained muscle 
sections. Fold change of expression of reference genes in SDH and Gomori trichrome 
stained muscles sections relative to unstained tissue. Error bars derived from the 
standard deviations.  
Although B2M when normalised against ACTB remains satisfactorily close to a fold-
change of 1,  the decreased level of GAPDH compared to ACTB suggests a drop in 
signal for GAPDH in both SDH and Gomori trichrome stained sections.  
6.3.3 Optimisation of immunohistochemistry techniques 
The poor quality and quantity of RNA obtained from stained sections is likely due to the 
duration the section is exposed to aqueous solutions. Once sections are incubated in 
aqueous solutions, the endogenous RNases become activated and rapidly degrade RNA. 
This is also a challenge when looking to immunolabelling as a solution for rapid 
protocols for identifying RRF and fibre types. Even in the presence of an RNase 
inhibitor in PBS for only a 2 min incubation, there is some evidence of RNA 
degradation (Grimm et al., 2004).  
Firstly, it is essential to identify the most appropriate antibodies for identification of 
RRF and fibre types. The homology between myosin (MYH) genes makes selecting an 
antibody for fibre typing difficult. Since there are different subtypes of type II fibres,  
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antibodies for identifying fast-twitch fibres would need to recognise protein products 
from MYH1 and MYH2 (type II predominant) but not MYH7 (type I predominant). 
Anti-Slow Skeletal Myosin Heavy chain antibody (ab11083) is a monoclonal antibody 
which specifically reacts with adult human skeletal slow myosin in type I fibres, and is 
known to not react with fast-type myosin in type II fibres.  
The expression of mitochondrial subunit proteins is known to have a fibre-type 
dependent, heterogeneous staining patterning, also highly variable in disease tissue 
(Figure 6.4). Three antibodies were chosen as candidates for identifying ragged-red 
fibres without showing fibre type specific intensity: Cytochrome c, the electron carrier 
between Complex III and IV of the electron transport chain; VDAC (Porin), an outer 
mitochondrial membrane channel; and a ‘mitochondrial marker’ antibody generated 
using semi purified protein preparation (MTC02).  
Live fluorescent imaging on a microdissector can be less sensitive than conventional 
microscopy, and it is important that RRF are easily identifiable using both technologies. 
Muscle sections (12 µm) from control and MERRF patients on PEN-membrane slides 
were immunolabelled with these antibodies, targeted by an Alexa Fluor
®
 488 
conjugated secondary antibody, and visualised on the Leica AS LMD (Leica 
Microsystems) using the FITC filter (Figure 6.11).  
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Figure 6.11 Laser microdissector imaging of fluorescence immunohistochemistry 
in muscle sections. (A, C, E, G, I) Control muscle sections and (B, D, F, H, J) MERRF 
muscle sections stained on PEN-membrane slides for (A, B) mysosin-slow, (C,D) 
cytochrome c, (E,F) VDAC (Porin), (G,H) Mitochondrial marker (MTC02). Red arrows 
indicate RRF. Scale bar = 100 µm. 
Myosin-Slow shows clear staining of a subset of fibres, easily discerning type I from 
type II fibres. Cytochrome c shows mosaic staining in control tissues, though many 
more fibres than either type I or type II alone. This implies the intensely-staining cells 
are a combination of both oxidative type I and IIA fibres. The negatively-staining fibres 
are likely type IIx/d glycolytic reliant fibres. Both VDAC and ‘mitochondrial marker’ 
Control MERRF 
Myosin-Slow  
Type1 Fibres 
 
 
Cytochrome c 
Mitochondrial 
subunit 
 
B.  A.  
C.  D.  
VDAC (Porin) 
Mitochondrial 
channel 
 
 
E.  F.  
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Mitochondrial 
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G.  H.  
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antibodies showed similar staining patterns; however the intensity of ‘mitochondrial 
marker’ staining is higher and the increased signal aids in clear identification of 
individual cells with much higher mitochondrial mass (RRFs). 
Control and MERRF muscle tissue sections on glass slides were co-stained for nuclei 
(DAPI) with MYH-slow or ‘mitochondrial marker’ (MTC02). Imaging of control and 
MERRF tissue was completed on an AxioImager (Zeiss) using an ApoTome (Figure 
6.12).  
 
Figure 6.12 Fluorescent imaging in muscle sections. Immunolabelling in (A, C) 
control tissue and (B, D) MERRF tissue for (A-B) Myosin-slow and (C-D) 
‘mitochondrial marker’ and counter stained for nuclei (DAPI; blue). Red arrows 
indicate potential RRFs.  
In Figure 6.12A-B it is noticeable that there is a higher percentage of type I than type II 
fibres in MERRF patient muscle than in the control. Fibre type abnormalities are 
common to mitochondrial disorders, usually resulting in type I fibre predominance 
(T1FP), but sometimes in type II fibre predominance (T2FP), and often include 
variations in size and fibre atrophy (Enns et al., 2005, Makino et al., 2000). The 
pathogenesis of T1FP is postulated to be a compensatory mechanism to increase the 
energy capacity of the muscle by having a higher percentage of purely oxidative fibres 
(Koo et al., 1993).  
Control MERRF Patient 
Myosin-Slow 
(Type I Fibres) 
MTC02 
(Mitochondria) 
C. D. 
B. A. 
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There are clearly fibres with higher intensity of mitochondrial marker (MTC02) which 
are suspected to be RRF (indicated by red arrows in Figure 6.12B). It is important to 
establish that the fibres identified by immunohistochemistry are the same as would be 
conventionally considered as RRF, as identified by modified Gomori trichrome or SDH 
histochemistry. This is evident when using both visualisation techniques on serial 
sections of MERRF patient muscle (Figure 6.13). 
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Figure 6.13 Confirmation of immunhistochemical identification of RRFs. (A,C) 
Immunohistochemistry using mitochondrial marker antibody (MTC02; green), co-
stained for nuclei (DAPI; blue) and a serial section (B,D) with SDH histochemistry. 
(A,B) An individual RRF identified specifically by both immuno- and SDH 
histochemistry and (C,D) a large portion of section showing similar intensity patterns 
for MTC02 and SDH staining. Red arrows indicate the same fibre. Scale bar = 100µm. 
Despite subtle differences in staining intensity, explained by the heterogeneous nature 
of fibres along their longitudinal profile (Durham et al., 2007), the pattern for 
‘mitochondrial accumulation’ visualised by SDH and immunohistochemistry is 
comparable not only for individual fibres but across large areas of sections, as shown in 
Figure 6.13-C,D . 
MTC02 
MERRF 
Patient 
B. 
SDH 
C. D. 
A. 
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Preservation of RNA during immunohistochemistry 
Standard immunohistochemistry requires long antibody incubations in aqueous buffers, 
typically not compatible with preservation of RNA quality. One method developed for 
RNA preservation during immunolabelling uses the addition of salt (NaCl) into the 
buffers used for washes and antibody incubations. RNA quality was investigated using 
electrophoresis and rRNA integrity analysis, maintenance of stable gene expression 
profiles, and 5’ to 3’ signal assays and concluded 2 M NaCl included in buffers gave 
almost identical preservation to the commonly used RNase inhibitor RNAlater
®
 from 
Ambion (which was found to be incompatible with immunolabelling) and better than 
inclusion of RNaseOUT
®
 from Invitrogen (Brown and Smith, 2009). 
Another method of improving RNA preservation is to use much shorter antibody 
incubation times with fluorescently labelled primary antibodies, using direct labelling 
kits such as Zenon
®
 IgG Labelling Kits (Molecular Probes, Invitrogen).  
Serial sections were either sampled freshly from sections, after 3 min dehydration in 
70% and 100% ice-cold ethanol, after 5 h incubation in DEPC water, after 
immunolabelling in high-salt buffer, after using the standard Zenon
®
 protocol but with 
standard secondary antibodies rather than fluorescently-tagged primary antibodies or 
using a modified version of the Zenon
®
 protocol including 95 °C pretreatment of 
blocking buffer and only a 20 min antibody incubation period at 4 °C. RNA was 
extracted and analysed on the Agilent Bioanalyzer (Figure 6.14).  
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Figure 6.14 RNA integrity in immunolabelled sections. Control muscle sections were 
(A) sampled immediately after thawing, (B) after only dehydration, (C) after long 
incubation in just DEPC water, (D) after immunolabelling in high-salt buffer (High 
Salt), using the standard Zenon
®
 protocol (Zenon) or using a modified version of the 
Zenon
®
 protocol (Zenon mod.). Electropherograms and RIN scores indicate high 
preservation of RNA when using either the High-Salt or Modified Zenon
®
 protocol. 
The reference gene expression profile and 3’-5’ assay was performed on RNA extracted 
from immunolabelled sections (Figure 6.15). 
 
B. Dehydrated 
C. DEPC H
2
O  D. High Salt  
E. Zenon  F. Zenon mod. 
  
A. Fresh frozen  
RIN: 7.7 
  
RIN: 4.2 
  
RIN: 8.1 
RIN: 4.4 RIN: 8.3 
RIN: 7.7 
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Figure 6.15 mRNA profile integrity during immunhistochemistry. (A) The relative 
gene expression of the reference genes ACTB, GAPDH and B2M were measured in 
RNA (cDNA) extracted from muscle sections treated with different immunolabelling 
conditions. The ΔCt for combinations of these reference genes were normalised against 
a control sample from fresh, untreated tissue to obtain fold changes (ΔΔCt). (B) 5’ to 3’ 
assay for B2M and GAPDH comparing the relative fold change of each end of the 
mRNA transcript. Fold change ~1 (dashed line) indicates no difference in gene 
expression profile from the control sample. 
The 3’-5’ assay reveals loss of GAPDH 5’ sequence, even when only dehydrating the 
samples in ethanol, without immunolabelling. Both the high-salt buffer and modified 
Zenon
®
 protocol offer a good solution to preservation of RNA during 
immunohistochemistry compared to using standard aqueous solutions such as DEPC 
water or PBS.  
6.3.4 Analysis of RNA quality and quantity for immunolabelled and LMD fibres  
Immunohistochemistry with high-salt buffer was tested on control muscle with only 
MYH-Slow antibody staining for type I fibres. The staining pattern and intensity of 
fluorescent signal was comparable to that of tissue stained using the standard technique, 
and type I fibres were easily identified and dissected (Figure 6.16). 
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Figure 6.16 Laser microdissection of type I muscle fibres. Control muscle sections 
were labelled with MYH-Slow in high-salt buffer. (A) Mounted on glass slides and 
counterstained with DAPI for nuclei imaging. (B-C) Mounted on PEN-membrane slides 
and visualised (B) before and (C) after laser microdissection of Type I 
immunofluorescent fibres (numbered 1-8). Scale bar = 100µm. 
Sections were processed within a maximum of a 1 h period from ethanol fixation. 125 
fibres were pooled into each cap containing extraction buffer. After incubation at 42 °C 
lysates may be stored safely at -80 °C, which is crucial for the ability to pool samples 
from separate LMD sessions. Fibres were pooled either before application to the 
extraction column or were pooled via ethanol precipitation after extraction. The RNA 
was reverse transcribed to cDNA, and the gene expression profiles of three reference 
genes analysed by qPCR and the fold changes calculated (Figure 6.17A). Amplicons 
from the 5’ and 3’ of GAPDH and B2M were compared to assess RNA quality (Figure 
6.17B). 
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Figure 6.17 mRNA transcript profile and integrity during laser microdissection. 
(A) The expression of the reference genes GAPDH and B2M relative to ACTB were 
measured from muscle sections before and after laser microdissection (LMD). (B) 
Amplicons from the 5’ and 3’ region of both GAPDH and B2M were compared to assay 
for RNA quality. The ΔCt for these reference genes were normalised against a control 
sample from fresh, untreated tissue to obtain fold changes (ΔΔCt). A fold change of 1 
(dashed line) indicates no difference in gene expression profile from the control sample. 
Comparison of expression in laser microdissected tissue compared to muscle 
homogenates might not be appropriate for GAPDH as different fibre types have variable 
amounts GAPDH protein and only Type I fibres were dissected (Galpin et al., 2012). 
Zenon
®
 Molecular Probes 
Zenon
®
 Mouse IgG Labelling Kits allow direct labelling of primary antibodies with 
fluorophores to allow one-step immunolabelling of target proteins and the use of 
multiple antibodies raised in the same species. Since both the MYH-Slow and MTC02 
antibodies are raised in mice, this kit enabled us to target both proteins on the same 
section without having to find suitable alternative primary antibodies from a different 
species, and allows for a shorter incubation time which can aid preservation of the RNA 
in the muscle samples. 
The fluorophores are bound to a Fab fragment which is directed against the Fc portion 
of antibodies from a particular species. They are not covalently bound, and 
consequently the protocol for immunohistochemistry with the Zenon
®
 labelling kit 
recommends fixation with PFA after antibody incubation to prevent dissociation of the 
fluorophore from antibody. As direct labelling can sometimes have reduced fluorescent 
intensity the protocol also recommends incubation with a detergent such as triton X-100 
to increase the permeability of the section. The protocol developed for maintaining 
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RNA integrity during immunohistochemistry relies on the use of a high salt buffer and 
shorter incubation times, so it is important to establish whether the PFA fixation and 
triton X-100 treatment is necessary and also whether the fluorophore and antibody 
remain bound when used in a high-salt buffer instead of standard PBS (Figure 6.18).  
 
Figure 6.18 Immunohistochemistry using Zenon
®
 labelling kits. A comparison of 
immunohistochemistry for MYH-slow using (A) the standard Zenon
®
 fluorphore 
conjugated antibody labelling with tritonX-100 and PFA fixation and (B) labelling 
without tritonX-100 permeabilisation and PFA fixation and using a high-salt buffer. 
Scale bar = 100µm. 
Immunohistochemistry with high-salt buffer is compatible with the Zenon
®
 labelling 
kits. The staining from standard immunolabelling with secondary antibodies shows 
similar patterns to that using the Zenon
®
 labelling kit protocol and there is no reduction 
in fluorescent signal when not using triton X-100 or PFA fixation and with the use of 
high-salt buffer instead of standard PBS. 
The multiplex assay is capable of identification of type I and type II RRFs in the muscle 
tissue of patients with MERRF (Figure 6.19). 
 
MYH-Slow 
(Type I Fibres) 
Zenon
®
 Control High Salt 
A.  B.  
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Figure 6.19 Fibre type and RRF identification using Zenon
®
 IgG labelling kits. 
RRFs were identified by standard techniques such as (A) SDH histochemistry and (B) 
conventional immunohistochemistry using mitochondrial marker antibodies (MTC02). 
Zenon
®
 IgG labelling technology was used for multiplex immunohistochemistry of 
(C,F) MHC-Slow (Green) and (D,G) MTC02 (Red). Merged images demonstrate the 
appearance of type I RRF (E) and type II RRF (H). (A-E) Images of the same fibre in 
serial sections identified using (A) SDH, (B) conventional labelling or (D) using 
Zenon
®
 technology. Scale bar = 100µm. 
All successfully optimised components of the staining procedure were combined for the 
final protocol. An overview of the final protocol process can be found in Figure 6.20. 
Type I 
RRF 
Type II 
RRF 
MYH-Slow MTC02 Merge 
MTC02 SDH 
Zenon
®
 IgG labelling kit 
Conventional techniques 
A.  B.  
C.  D.  E.  
F.  G.  H.  
B.  
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Figure 6.20 An overview of the final experimental procedure. The optimised 
procedure for preparation, staining and dissection of muscle fibres and the extraction 
and quality control of RNA from the dissected tissue. 
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6.4 Results and Discussion 
6.4.1 Preparation of final samples 
The tissue samples were collected from the muscle biopsy of a 58 year old male 
diagnosed with MERRF and an age-matched control male who donated muscle whilst 
undergoing knee surgery.  
Muscle sections for both participants were dual-stained for MYH-Slow and MTC02 to 
simultaneously identify type I fibres and RRF (patient only) (Figure 6.21). Type I, 
normal fibres were dissected from the control (CON) and MERRF patient (NOR). Type 
I, RRFs were dissected from the MERRF patient (RRF).  
 
Figure 6.21 Isolating cell populations using laser microdissection. Muscle sections 
are visualised on x20 magnification with brightfield (A, D, G), a rhoadmine (red) filter 
set for MYH-Slow (B, E, H) and a FITC (green) filter set for MTC02. (A-C) Type I 
RRF stain strongly for both MYH-Slow and MTC02, (D-F) normal Type I fibres only 
stain strongly for MYH-Slow but not MTC02. (G-I) Any RRF which do not stain for 
MYH-Slow are Type II fibres and are not included in the study. 
 
MYH-Slow MTC02 
Type I 
RRF 
Brightfield 
Type I 
Normal  
Type II 
RRF  
A. B. C. 
D. E. F. 
I. H. G. 
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Each slide was processed within an hour, continuing with fresh sections until ~ 500 
fibres of each type were been dissected. After quality control assessment, cell lysates 
were pooled and the RNA extracted.  
RNA quality of final samples  
The expression of the three reference genes (GAPDH, B2M and ACTB) were assessed in 
the samples from sections remaining after laser-microdissection and in the dissected 
fibres. The gene expression does not change by more than 2-fold for either gene in any 
of the microdissected samples (Figure 6.22A). The 5’ to 3’ assay indicates ~50% 
reduction in 5’ signal in samples from the MERRF patient(RRF and NOR) (Figure 
6.22B).  
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Figure 6.22 mRNA transcript profile and integrity of final samples for microarray 
analysis. (A) The expression of the reference genes GAPDH and B2M relative to ACTB 
were measured from control and MERRF muscle sections before dissection and all 
laser-microdissected samples (B) Amplicons from the 5’ and 3’ region of both GAPDH 
and B2M were compared to assay for RNA quality. The ΔCt for these reference genes 
were normalised against a sample from fresh, untreated tissue to obtain fold changes 
(ΔΔCt). A fold change of 1 (dashed line) indicates no difference in gene expression 
profile from the control sample. 
The RNA concentration of the final samples could not be accurately determined by 
conventional methods, but was estimated as ~ 1 ng/ µL using the gene expression of the 
reference genes (Appendix F. ). 
6.4.2 Microarray results 
Quality assessment 
The RNA samples, and following cDNA samples were spiked with bacterial gene 
sequences to assess labelling and hybridisation efficiency. All genes were detected as 
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present at the correct ratios, indicating efficient microarray preparation for all samples 
(Appendix G.1). The raw probe cell intensity from CEL files and expression signal was 
calculated using Affymetrix
®
 Expression Console™. The probe cell intensity values are 
similar for each sample indicating a similar quantity of cDNA hybridised onto each 
microarray. After application of the MAS5 algorithm, the expression signal is 
normalised and the mean is the same for all samples (Appendix G.2). The RawQ, 
scaling factor (SF), background (BG), noise and percentage present calls (%P) values 
were calculated by the Affymetrix
®
 Expression Console™ and are similar across all 
samples, suggesting preparation and quality of samples are consistent. 
The expression values for the three reference genes, GAPDH, B2M and ACTB were 
normalised against that of the control (CON). Although there is a decrease of GAPDH 
(0.6) and B2M (0.8) in RRF, the ACTB level in RRF and all genes in NOR remained 
stable (1.0). The 5’ to 3’ ratio of GAPDH should ideally be above 0.8 (1.25 3’/5’); 
however, some of the final samples from the microarray fall below this range (CON, 
0.80; RRF, 0.71; NOR, 0.77) (Appendix G.4). 
Although the integrity of the RNA could be improved, the samples are similar enough 
to be comparable, allowing for analysis of gene expression between these samples. 
Gene dysregulation 
Genes were filtered following procedure set out in Figure 6.6 (Section 6.2.7), assigning 
dysregulated genes into three groups for up- and downregulation, based on a cut-off 
threshold of 3-fold. Where genes in RRF were up- or downregulated compared to 
normal fibres from both the MERRF and control individuals, these genes were 
considered ‘RRF-specific’. If genes were up- or downregulated in both fibre types from 
the MERRF patient compared to the control, these genes were considered ‘MERRF-
specific’. Genes were considered ‘exacerbated in RRF’ where some dysregulation 
observed in MERRF normal fibres was dysregulated to a greater extent in RRFs.  
A total of 12,512 genes were detected (present; P) in at least one of the samples. Of 
these, 1188 (9.5 %) have mitochondrial-related functions (based on gene ontology 
(Ashburner et al., 2000)). A total of 1770 (13.3 %) were classified as MERRF-specific, 
957 genes (7.3 %) were classified as exacerbated in RRF and 1636 genes (12.4 %) were 
classified as RRF-specific (Table 6.6).  
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The proportions of mitochondrial genes dysregulated in the sample groups are similar to 
the proportion in overall detected genes; though the highest increase is observed in 
those genes exacerbated in RRF (11.6 % compared to 9.5 % in total).  
Table 6.6 Statistics for gene dysregulation from microarray analysis. The total 
number of genes and the proportion of those that have mitochondrial-related function 
are given for all detected genes, and those that are dysregulated within RRFs or MERRF 
patient tissue.  
Group Total RRF-Specific 
Exacerbated 
in RRF 
MERRF-
Specific 
Detected genes 
Total  12512    
Mitochondrial  1188    
Mito % of Total 9.5 %    
      
Total 
dysregulated 
genes 
Upregulated  880 430 616 
Downregulated  756 527 1154 
Total 
dysregulated 
 1636 957 1770 
% of Total  12.4 % 7.3 % 13.4 % 
      
Mitochondrial 
genes 
Upregulated  79 61 63 
Downregulated  61 50 67 
Total 
mitochondrial 
 140 111 130 
% of 
Dysregulated 
 8.6 % 11.6 % 7.3 % 
 
There are more genes up- than downregulated specifically in RRF, but the opposite is 
true for genes ‘exacerbated in RRF’ and ‘MERRF-specific’ genes. Of the genes 
detected on this array, a similar number are dysregulated between the MERRF samples 
compared to the control samples, and the normal fibres of both individuals compared to 
RRF. This is more than was previously expected as both MERRF samples were 
extracted from the same sections of muscle, with the only difference being noticeable 
increase in mitochondrial biogenesis. 
The proportion of genes with mitochondrial-related function does not change depending 
on the classification. This is unexpected, considering the increased mitochondrial 
biogenesis observed in RRFs; however, it is plausible that some mitochondrial 
processes are downregulated as others are upregulated. 
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Comparison to previous skeletal muscle microarray analysis 
Gene expression profiling was performed from the skeletal muscle homogenates of 
patients with either MELAS or PEO caused by the m.3243A>G point mutation, or PEO 
caused by macrodeletions (Crimi et al., 2005). The genes found to be commonly 
dysregulated between these groups of patients were compared to the microarray results 
from laser-microdissected MERRF fibres (Table 6.7). Two genes were commonly 
regulated across all disease types (not specific to RRFs), these were CDKN1A and 
MAOA. A further four genes had similar dysregulation to one or two of the other disease 
groups. A total of six genes were dysregulated in the opposite direction to those 
observed in other patient groups, though disagreement was common between all groups 
within the study.  
Table 6.7 Gene dysregulation common to mitochondrial encephalomyopathies. The 
genes reported to be commonly dysregulated in either MELAS or PEO caused by 
m.3243A>G or the common deletion (ΔmtDNA) (Crimi et al., 2005) were compared to 
the microarray analysis results from laser-microdissected MERRF muscle fibres. 
 
Each gene between 
disease types 
MELAS 
m.3243A>G 
PEO 
m.3243A>G 
PEO 
ΔmtDNA 
MERRF 
m.8344A>G 
In agreement 
1 10 6 9 3 
2 5 5 6 1 
3 2 2 2 2 
Total agreements 26 22 27 11 
      
In 
disagreement 
1 2 6 9 5 
2 
 
3 
 
1 
3 - - - - 
 Total disagreements 2 12 9 7 
 
A higher degree of correlation in gene dysregulation would be expected in the patient 
groups studied by Crimi and colleagues (2005). Firstly, the samples are all tissue 
homogenates rather than laser-microdissected type I fibres; secondly, each group either 
shares the same genetic cause of disease (m.3243A>G) or same clinical phenotype 
(PEO). 
An additional study compared the muscle tissue of patients and carriers with 
m.3243A>G to controls and found dysregulation in genes related to the immune 
response, protein transport, programmed cell death (van Eijsden et al., 2008). Of note, 4 
of the 9 genes found dysregulated in relation to protein transport (ARHGEF2, RPL23, 
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RRBP1 and TRAM2) are also dysregulated specifically in RRF, or are exacerbated in 
RRF in this study.   
Enriched biological processes 
The genes which are classified as either ‘RRF-specific’, ‘exacerbated in RRFs’ or 
‘MERRF-specific’ can be grouped by whether they are up- or downregulated in 
MERRF tissues and subjected to functional annotation clustering by the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) v6.7 software (Dennis et 
al., 2003). This software assigns biological processes to known genes based on their 
ontology, and compares the proportion of genes for each process in the target list to a 
background (e.g. human expressed genes) and then groups them into functionally-
related clusters. 
To assess the biological processes dysregulated in MERRF tissue, genes exacerbated in 
RRF and specific to MERRF are combined to generate enriched biological processes for 
the up- and downregulated gene sets (Table 6.8). Each cluster is assigned an enrichment 
score (E), and each biological process within the cluster has an associated Bonferroni-
corrected p-value, to determine significance with multiple comparisons.  
The highest enrichment in upregulated genes was negative regulation of transcription 
(E=5.35; corrected p-value < 0.001 for most significant included process). Three of the 
top 10 enriched biological processes which are upregulated remain significant after 
Bonferroni correction. 
The highest enrichment in downregulated genes was in phosphorylation-related 
processes (E=4.7; corrected p-value < 0.01). Six of the top 10 enriched biological 
processes which are downregulated remain significant after Bonferroni correction. 
Chapter 6  
224 
 
Table 6.8 Enriched biological processes in MERRF patient tissues. Functional 
annotation clustering generates enriched biological processes and groups them by 
related function. Exacerbated in RRF and MERRF-specific categories have been pooled 
by up- or downregulation for an overall impression of dysfunction in MERRF. 
Enrichment score (E) represents the whole cluster, the total processes are the number of 
individual biological processes included in the cluster, and p-values given are for only 
the most significant process within the cluster, before and after Bonferroni correction.   
* p < 0.05, ** p < 0.01, *** p <0.001, **** p < 0.0001 Fisher Exact. 
 
Cluster Description 
Enrchment 
Score (E) 
Total 
processes 
p-value / 
corrected 
Upregulated 
1 
Negative regulation of cellular 
macromolecule biosynthetic 
process / transcription 
5.35 12 **** *** 
2 
Positive regulation of cellular 
macromolecule biosynthetic 
process / transcription 
3.89 16 **** ** 
3 Apoptosis 2.96 4 *** n.s. 
4 
Regulation of gene-specific 
transcription 
2.55 6 **** * 
5 
Proteolysis / macromolecule 
catabolic process 
2.26 9 *** n.s. 
6 Chromatin organisation 2.07 3 *** n.s. 
7 Stem-cell maintenance 2.03 3 *** n.s. 
8 
Intracellular receptor-mediated 
signalling pathway / steroid 
hormone signalling 
1.91 3 ** n.s. 
9 RNA splicing / mRNA processing 1.63 7 ** n.s. 
10 
Blood vessel/vasculature 
development 
1.44 4 ** n.s. 
       
Downregulated 
1 
Phosphorylation / Phosphate 
metabolism 
4.7 4 **** ** 
2 Skeletal muscle development 3.12 7 **** * 
3 
Cellular response to stress/DNA 
repair 
2.96 4 **** * 
4 
Blood vessel/vasculature 
development 
2.92 4 *** * 
5 
Intracellular transport/ cellular 
protein localisation 
2.8 7 **** ** 
6 
Regulation of transcription, DNA-
dependent 
2.66 4 *** * 
7 
Positive regulation of cellular 
macromolecule biosynthetic 
process / transcription 
2.46 12 ** n.s. 
8 Regulation of translation 2.22 3 ** n.s. 
9 Transcription, DNA-dependent 2.07 3 ** n.s. 
10 
Peptidyl-threonine/serine 
phosphorylation 
2.06 4 *** n.s. 
 
Biological processes related to regulation of transcription are enriched in in both up- 
and downregulated genes in MERRF patient tissue. Clusters of positive and negative 
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regulation of transcription were both upregulated, in addition to regulation of gene-
specific transcription, chromatin organisation and mRNA processing. However, only 
positive regulation of transcription and DNA-dependent transcripton were enriched in 
downregulated genes. Therefore, although certain transcriptional pathways may be 
upregulated, overall there is a decrease in transcriptional activity in MERRF tissue 
compared to that of an age-matched control individual, evidenced by higher numbers of 
downregulated MERRF-specific genes (Table 6.7). Since transcription is an energy-
demanding process, a decrease in transcription is an expected result of lowered energy 
production in the muscle of MERRF patients. 
Vasculature development is also enriched in both up- and downregulated genes. 
Vasculopathy is a common occurrence in mitochondrial disorders, as blood vessels have 
increased protein nitration causing a reduction in flow-mediated vasodilatation in 
mitochondrial diseases (Vattemi et al., 2011). 
Phosphorylation-related biological processes are downregulated, specifically peptidyl-
threonine/serine phosphorylation which might relate to the upregulation of genes in 
intracellular receptor-mediated signalling pathways. 
The biological processes dysregulated in MERRF patient tissue as a whole can be 
compared to those dysregulated specifically in RRFs. The genes classified as 
‘exacerbated in RRF’ and ‘RRF-specific’ were pooled and subjected to the same 
functional annotation clustering (Table 6.9). 
The most enriched cluster of biological processes observed in upregulated genes was 
negative regulation of transcription (E=3.45), though this did not remain statistically 
significant after Bonferonni correction. Only one cluster included a statistically 
significant biological process included after Bonferroni correction, which was 
regulation of intracellular protein localisation (E=3.41, p-value <0.05).  
Overall, enrichment of biological process clusters was much stronger in downregulated 
genes. The most enriched cluster of biological processes was mRNA splicing and 
processing (E=5.79; corrected p-value < 0.0001). All of the top 10 clusters contain 
statistically significant biological processes.  
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Table 6.9 Enriched biological processes in RRFs. Functional annotation clustering 
generates enriched biological processes and groups them by related function. RRF-
specific and exacerbated in RRF categories have been pooled by up- or downregulation 
for an overall impression of dysfunction in RRF. Enrichment score (E) represents the 
whole cluster, the total processes are the number of individual biological processes 
included in the cluster, and p-values given are for only the most significant process 
within the cluster, before and after Bonferroni correction. * p < 0.05, ** p < 0.01, *** p 
<0.001, **** p < 0.0001 Fisher Exact. 
 
Cluster Description 
Enrchment 
Score 
Total 
processes 
p-value / 
corrected 
Upregulated 
1 
Negative regulation of cellular 
macromolecule biosynthetic 
process / transcription 
3.45 12 **** n.s. 
2 Intracellular protein localisation 3.41 8 **** * 
3 
Cytoskeletal organisation/ 
protein binding 
2.73 4 *** n.s. 
4 
Intracellular receptor-mediated 
signalling pathway / steroid 
hormone signalling 
2.31 3 *** n.s. 
5 
Regulation of transcription, 
DNA-dependent 
2.15 4 ** n.s. 
6 
Positive regulation of cellular 
macromolecule biosynthetic 
process / transcription 
1.96 12 *** n.s. 
7 Phosphorylation 1.87 4 ** n.s. 
8 
Chromatin silencing / epigenetic 
negative regulation of gene 
expression 
1.82 6 *** n.s. 
9 
Cellular response to stress/ 
DNA repair 
1.73 4 ** n.s. 
10 mRNA splicing/processing 1.66 4 ** n.s. 
   
    
Downregulated 
1 mRNA splicing/processing 5.79 7 **** **** 
2 Intracellular protein localisation 5.36 15 **** **** 
3 
Positive regulation of cellular 
macromolecule biosynthetic 
process / transcription 
3.96 16 **** *** 
4 Transcription, DNA-dependent 3.94 3 **** * 
5 
Proteolysis / macromolecule 
catabolic process 
3.62 9 **** ** 
6 Chromatin organisation 3.36 3 *** * 
7 Phosphorylation 2.97 4 *** * 
8 mRNA localisation 2.94 8 *** * 
9 
Post-transcriptional regulation 
of gene expression / translation 
2.82 3 **** ** 
10 
Negative regulation of cellular 
macromolecule biosynthetic 
process / transcription 
2.76 11 *** * 
 
Many of the biological processes enriched in dysregulated genes specific to MERRF 
tissue were also dysregulated in RRFs. There was increased focus of regulation of 
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transcription, with upregulation of chromatin-silencing and epigenetic negative 
regulation of gene expression further corroborating decreased transcription observed in 
disease tissue. mRNA splicing processes were somewhat enriched in upregulated genes, 
but highly enriched in downregulated genes, along with chromatin organisation and 
DNA-dependent transcription.  
The controlled intracellular trafficking of macromolecules was also dysregulated in 
RRFs, with upregulation of cytoskeletal organisation and intracellular protein 
localisation. Biological processes for intracellular protein and mRNA localisation are 
also observed significantly enriched in downregulated genes.  
Enriched pathways and processes 
Using the same grouping system, functional annotation of each gene with the related 
KEGG pathways (Kanehisa and Goto, 2000) allowed identification of biochemical 
pathways which are dysregulated in both MERRF tissue in general and specifically in 
RRFs. The 15 most enriched pathways upregulated in MERRF and specifically in RRFs 
are listed in Table 6.10 (excluding disease pathways). The majority of listed pathways 
are signalling pathways, which are enriched in genes dysregulated in both MERRF and 
specifically in RRFs. There are three pathways only enriched in genes dysregulated in 
RRFs: the spliceosome (corrected p-value <0.01); ubiquitin-mediated proteolysis 
(corrected p-value <0.05); and the citric acid (TCA) cycle (corrected p-value <0.05).  
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Table 6.10 Enriched pathways. KEGG pathways found to be enriched by functional 
annotation analysis. RRF-specific and exacerbated in RRF categories have been pooled 
by up- or downregulation for an overall impression of dysfunction in RRF. Each 
pathway is ranked and the number of gene contributing to enrichment given. p-values 
given are for each pathway, before and after Bonferoni correction. * p < 0.05, ** p < 
0.01, *** p <0.001, **** p < 0.0001 Fisher Exact. 
 
RRF-specific MERRF-specific 
Term Rank Count 
P-Value / 
corrected 
Rank Count 
P-Value / 
Corrected 
Wnt signalling pathway 1 41 **** *** 5 35 *** * 
Spliceosome 2 32 **** ** - - - - 
Insulin signalling pathway 3 33 *** ** 2 40 **** **** 
Focal adhesion 4 43 *** * 6 43 *** * 
ErbB signalling pathway 5 23 *** * 4 25 *** ** 
Neurotrophin signalling pathway 6 29 *** * 1 38 **** **** 
Ubiquitin-mediated proteolysis 7 31 *** * - - - - 
mTOR signalling pathway 8 16 ** * 3 22 **** **** 
Apoptosis 9 22 ** * 13 21 ** n.s. 
MAPK signalling pathway 10 50 ** * 19 48 * n.s. 
Citrate cycle (TCA cycle) 11 11 ** * - - - - 
Adherens junction 12 19 ** n.s. 10 20 ** * 
Adipocytokine signalling pathway 13 17 ** n.s. 8 19 ** * 
Regulation of actin cytoskeleton 14 40 ** n.s. 15 41 * n.s. 
VEGF signalling pathway 15 17 * n.s. 12 19 ** n.s. 
Aldosterone-regulated sodium 
reabsorption 
- - - - 7 14 ** * 
GnRH signalling pathway - - - - 9 24 ** * 
TGF-beta signalling pathway 32 17 n.s. n.s. 23 19 * n.s. 
RNA degradation 16 14 * n.s. 11 16 ** n.s. 
Toll-like receptor signalling pathway 34 19 n.s. n.s. 14 23 ** n.s. 
 
When analysed on KEGG, the enriched pathways dysregulated in MERRF tissue form a 
complex, inter-connected network of signalling pathways, ultimately leading to the 
regulation of cytoskeletal remodelling and focal adhesions, ubiquitin-mediated 
proteolysis, apoptosis and regulation of autophagy (Appendix H.1). 
The spliceosome is the most significant pathway dysregulated specifically in RRFs. The 
spliceosome is typically comprised of five small nuclear ribonucleoproteins (snRNPs) 
and several spliceosome-associated proteins (SAPs) and is responsible for correct 
assembly of intronic sequence from the transcribed pre-mRNA. A total of 32 
spliceosome components or regulatory genes are dysregulated (18 downregulated and 
13 upregulated) specifically in RRFs. Spliceosome dysfunction has not been previously 
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reported in mitochondrial diseases and suggests the importance of expanding gene 
expression studies to include differential transcript expression.  
Dysregulated genes in these pathways can be seen on the adapted KEGG pathways in 
Appendix H.  
Regulation of mitochondrial biogenesis 
To gain insight into the regulation of mitochondrial biogenesis in RRFs, the expression 
changes for known regulators of mitochondrial biogenesis were collated from the 
microarray analysis (Table 6.11).  
Many gene expression changes are somewhat validated by two probe sets, or by two 
genes within the same protein complex showing similar dysregulation. Although gene 
expression changes have been classified as ‘MERRF-specific’, ‘Exacerbated in RRF’ or 
‘RRF-specific’ there is often an overlap when close to the threshold of ± three fold-
change.  
MERRF-specific changes include upregulation of FOXO1 and FOXO3 transcription 
factors and downregulation of the adenylate cyclase genes ADCY1, ADCY5 and ADCY9. 
A significant finding is the RRF-specific upregulation of PPARGC1A, encoding 
PGC1α, the core regulator of mitochondrial biogenesis (7.68-fold compared to normal 
fibres from the same patient, and 16.31-fold compared to the age-matched control). In 
addition, NRF1 is only upregulated in RRF compared to control (3.79). 
All three isoforms of the retinoid X receptor (RXRA, RXRB and RXRG) are 
downregulated either specifically in ragged-red fibres or not present in either sample 
from MERRF. 
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Table 6.11 Gene expression changes in mitochondrial biogenesis genes. The 
expression changes of known regulators of mitochondrial biogenesis from literature 
have been collated. Gene expression changes ≤ -3 or ≥ 3 are shown. 
Descriptive 
Gene 
Symbol 
Definition Present 
NOR to 
CON 
RRF to 
CON 
RRF to 
NOR 
AMPK 
Transcriptional 
stimulator 
PRKAA2 Exac. in RRF All  -4.13 
 
PRKAB2 RRF Specific All  -3.52 -3.53 
PRKAG3 
MERRF 
Specific 
All -6.96 -4.63 
 
       
CAMKs 
Transcriptional 
stimulator 
CAMK2A 
MERRF 
Specific 
All -4.11 -4.03  
CAMK2B 
Exac. in RRF All  -3.66  
Exac. in RRF All  -5.01  
CAMK2D 
RRF Specific All  3.01 8.85 
MERRF 
Specific 
All 3.91 4.05  
CAMK2G Exac. in RRF 
NOR/ 
CON 
 -3.34  
All  -3.92  
       
Cn 
(Calcineurin) 
Transcriptional 
stimulator 
PPP3CA RRF Specific All 
 
 
-3.98 
 -4.54 -3.81 
PPP3CB Exac. In RRF All  -3.07  
PPP3CC 
Exac. In RRF All  3.13  
MERRF 
Specific 
All 4.36 3.96  
       
Adenylate 
cyclase 
Transcriptional 
stimulator 
ADCY9 
MERRF 
Specific 
CON -3.29 -3.29 
 
ADCY5 
MERRF 
Specific 
CON -3.31 -3.31 
 
ADCY1 
MERRF 
Specific 
All -6.40 -6.42 
 
       
cAMP-
dependent 
protein kinase 
PRKACB 
RRF Specific 
NOR/ 
CON  
-3.27 -11.01 
Exac. in RRF 
RRF/ 
NOR  
3.54 
 
       
MAPK 
Transcriptional 
stimulator 
MAPK1 
RRF Specific 
NOR/ 
CON 
 
-12.85 -6.82 
 
-3.79 -7.08 
Exac. in RRF All 
 
-4.80 
 
MAPK8 
MERRF 
Specific 
NOR/ 
CON 
-3.02 -3.82 
 
MAPK12 
MERRF 
Specific 
NOR/ 
CON 
-5.42 -8.44 
 
       
RXR 
Transcription 
Factor 
RXRA 
RRF Specific All 
 
-3.57 -9.91 
RRF Specific 
NOR/ 
CON  
-21.51 -36.63 
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Descriptive 
Gene 
Symbol 
Definition Present 
NOR to 
CON 
RRF to 
CON 
RRF to 
NOR 
 
 
 
RXRB RRF Specific All 
 
-3.45 -5.00 
RXRG 
MERRF 
Specific 
CON -25.34 -25.34 
 
       
MEF2 
Transcription 
Factor 
MEF2A RRF Specific 
NOR/ 
CON  
-4.37 -11.04 
       
c/EBP 
Transcription 
Factor 
CEBPD 
MERRF 
Specific 
All 
5.26 3.93 
 
14.39 9.51 
 
CEBPG RRF Specific All 
 
-5.09 -4.37 
       
FOXO 
Transcription 
Factor 
FOXO1 
MERRF 
Specific 
All 
21.21 12.74 
 
7.09 5.15 
 
12.67 3.53 
 
FOXO3 
MERRF 
Specific 
All 
9.93 5.28 
 
5.69 3.19 
 
FOXO6 
MERRF 
Specific 
CON -11.72 -11.72 
 
       
MyoD 
Transcription 
Factor 
MYOD1 
MERRF 
Specific 
CON -3.21 -3.21 
 
       
E2A 
Transcription 
Factor 
TCF3 RRF Specific 
RRF/ 
NOR  
3.59 8.88 
       
AKT 
Transcription/ 
Post-
translational 
Repressor 
AKT2 
RRF Specific 
NOR/ 
CON  
-3.63 -3.86 
Exac. in RRF All 
 
-3.58 
 
AKT3 
Exac. in RRF 
NOR/ 
CON  
-3.70 
 
MERRF 
Specific 
All -3.90 -3.63 
 
       
GCN5 
Post-
translational 
Repressor 
KAT2A RRF Specific All   -4.08 
       
MYBBP1A 
Post-
translational 
Repressor 
MYBBP1A 
MERRF 
Specific 
NOR/ 
CON 
-4.68 -6.56 
 
       
PRMT1 
Post-
translational 
activator 
PRMT1 Exac. in RRF All 
 
-3.19 
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Descriptive 
Gene 
Symbol 
Definition Present 
NOR to 
CON 
RRF to 
CON 
RRF to 
NOR 
GSK-3β 
Post-
translational 
activator 
GSK3B Exac. in RRF All 
 
-3.27 
 
       
PGC-1α 
Core regulator 
PPARGC1A RRF Specific 
RRF/ 
NOR  
16.31 7.68 
       
PPARδ 
Transcriptional 
response 
initiator 
PPARD Exac. in RRF 
NOR/ 
CON 
-3.70 -19.27 -5.21 
       
PPARα 
Transcriptional 
response 
initiator 
PPARA 
RRF Specific All 
 
4.60 6.21 
Exac. in RRF 
NOR/ 
CON  
-4.17 
 
MERRF 
Specific 
All 
4.34 4.97 
 
8.13 3.60 
 
       
ERRγ 
Transcriptional 
response 
initiator 
ESRRG 
MERRF 
Specific 
RRF/ 
NOR 
8.02 
  
CON -3.05 -3.05 
 
       
NRF2 
Transcriptional 
response 
initiator 
GABPB1 
MERRF 
Specific 
CON -3.32 -3.32 
 
       
NRF1 
Transcriptional 
response 
initiator 
NRF1 Exac. in RRF All 
 
3.79 
 
       
YY1 
Transcriptional 
response 
initiator 
 
 
YY1 Exac. in RRF All 
 
-4.24 
 
YY1AP1 RRF Specific All 
 
-3.33 -4.23 
 
The increased expression of PPARGC1A (PGC1α) and NRF1 in RRFs is unsurprising 
considering the massive mitochondrial proliferation observed in these fibres.  
RXR proteins, downregulated specifically in RRFs, form heterodimers with PPARγ and 
bind peroxisome proliferator response elements (PPREs) with PGC1α functioning as a 
transcriptional coactivator (Delerive et al., 2002). The transcriptional responses induced 
by RXR/PPARγ binding include lipid metabolism, insulin sensitisation and 
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inflammatory response. One action of RXR/PPARγ is inhibition of NF-κB and mitogen-
activated protein (MAP) kinase cascades (Desreumaux et al., 2001, Dubuquoy et al., 
2002). RXR is already proving a potential therapeutic target for the treatment of 
inflammatory disease, cancer and even metabolic conditions such as diabetes and 
obesity (Perez et al., 2012). 
6.5 Concluding Remarks 
The study of gene expression in mitochondrial diseases has previously been restricted to 
cell culture models or tissue homogenates. By optimising a multiplex assay for the 
simultaneous identification of fibre type and “ragged-red” status, whilst maintaining 
high-quality RNA, it has been possible to analyse the gene expression differences 
between normal and ‘ragged-red’ fibres from the same individual.  
Several previous reports of gene expression changes and dysregulated biochemical 
processes in mitochondrial diseases, and in particular MERRF, have been corroborated 
by microarray analysis of laser-microdissected tissue. In addition, three pathways have 
been identified as being enriched in genes specifically dysregulated in RRFs, including 
components of the spliceosome machinery. No previous reports of wide-spread 
spliceosomal dysfunction in mitochondrial diseases have been reported and present an 
interesting potential direction for future study.  
The retinoid X receptor (RXR) family of proteins are downregulated specifically in 
RRFs. As these have proved potential therapeutic targets other diseases, further study of 
this family of proteins in mitochondrial disease is warranted.   
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7.1 Overview 
The research described in this thesis was undertaken to further understand how mtDNA 
replication and mitochondrial biogenesis are regulated and investigate the importance of 
these biological processes to human health. 
The aim was to address the following questions: 
1. How does the mtDNA bottleneck influence the inheritance of pathogenic 
mutations? 
2. How are mtDNA replication and biogenesis regulated throughout formation of 
the mtDNA bottleneck in mice?  
3. Can the mtDNA bottleneck be modelled in a cell culture system to assess gene 
expression critical to regulation of the mtDNA replication? 
4. Can disease tissue, where mitochondrial biogenesis is observed (such as RRFs in 
muscle tissue), be used to study how mtDNA replication is regulated in a 
biologically relevant situation? 
7.2 Investigating Inheritance of Pathogenic mtDNA Mutations  
The studies of mtDNA heteroplasmy transmission have often included only one 
particular mutation or are limited to a small number of pedigrees (Howell et al., 1994, 
Wong et al., 2002). Analysis of heteroplasmy in 82 single primary oocytes from a 
woman carrying m.3243A>G suggested a random genetic drift mechanism of 
inheritance (Brown et al., 2001). A similar study for m.8993T>G reported skewed 
segregation; however, only seven oocytes from this patient were assayed (Blok et al., 
1997). 
Meta-analysis of the published data in the past has suggested that pathogenic mtDNA 
mutations may behave differently (Chinnery et al., 2000b), but the techniques used to 
assay heteroplasmy levels can vary greatly, potentially causing bias between studies. 
Many early studies relied on counting the proportion of mutant and control sequences in 
bacterial clones, giving only a rough estimation of true mtDNA heteroplasmy, with 
recent techniques having greater accuracy and sensitivity.  
This study was undertaken to: firstly, determine the most accurate, appropriate method 
for measuring the heteroplasmy levels of numerous mtDNA mutations; secondly, assay 
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the heteroplasmy level of numerous mutations in a large number of mother-child pairs 
to determine whether inheritance patterns are truly different for some mutations; thirdly, 
to compare these results to that of published studies to determine whether the results 
from meta-analysis can be validated experimentally. 
Pyrosequencing out-performed fluorescent-based RFLP and has the advantage of being 
applicable to any mutation, not requiring the addition or removal of a specific restriction 
site. Heteroplasmy level measurements were made for three mutations, m.3243A>G, 
m.8344A>G and m.8993T>G and were used to calculate the O-M values. Frequency 
distributions for these mutations corroborated previously published data suggesting a 
random genetic drift model of inheritance for the tRNA mutations, m.3243A>G and 
m.8344A>G but skewed segregation for m.8993T>G. In addition, the mutations 
m.11778G>A and m.3460G>A also showed a positive increase in heteroplasmy level 
between generations. The reliability of the m.3460G>A finding is called into question 
because of the apparent decrease of heteroplasmy level observed in blood with age, 
similar to that of m.3243A>G (Kaplanova et al., 2004). Why some mutations are 
selected against in blood precursor cells has still not been established. If severity of 
mutation alone was the cause, m.3460G>A should not be selected against, as it has low 
penetrance and is frequently observed as homoplasmic in individuals (Black et al., 
1996).  
Samples from non-mitotic tissues, such as muscle, would have been more suitable for 
this study; however, muscle biopsies are often only sampled for proband cases, with 
DNA samples from family members only available from peripheral tissues such as 
blood, saliva or urine. 
Further confounding factors still remain which give caution to interpretation of such 
data. It is unavoidable that the only pedigrees in any study have been brought to the 
attention of clinical services by a proband case, and even upon exclusion of the proband 
could still introduce bias. There was variable tolerance for high mutation load observed 
for different mutations, with a reduced frequency of cases with >80 % heteroplasmy 
level for m.3243A>G and m.8344A>G; however, the other mutations m.8993T>G, 
m.11778G>A and m.3460G>A are commonly homoplasmic. Many individuals in 
m.8344A>G and m.8993T>G pedigrees are homoplasmic for wild-type molecules, 
suggesting either complete loss of the mutation in these individuals or de novo mutation 
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upon another branch of the pedigree. Fixation to wild-type homoplasmy from a 
heteroplasmic individual is evident at relatively high proportions in m.8344A>G 
pedigrees (17.3 %) but low in m.8993T>G pedigrees (3.4 %), suggesting a higher 
proportion of pedigrees containing de novo occurrence of the m.8993T>G mutation. 
Determining whether selection is occurring for particular mutations is of critical 
importance when genetic counselling is given to women known to carry pathogenic 
mtDNA molecules. If mtDNA mutations undergo positive selection with tendency to 
increase mutation load with subsequent generations, there would be greater probability 
of earlier onset of a more severe phenotype. In contrast, a tendency to decrease mutation 
load by negative selection might simply lead to the loss of the mutation without the 
child presenting any clinical phenotype. Mutation-specific advice is of particular 
importance with pre-implantation genetic diagnosis (PGD) becoming a common service 
offered to women with known mtDNA mutations and the potential future prospect of 
pronuclear transfer to prevent transmission of mitochondrial disease (Craven et al., 
2010).  
7.3 Gene Expression during Murine Embryogenesis 
The existence of a mtDNA bottleneck, responsible for the shifts in heteroplasmy 
observed between generations has been long-established (Hauswirth and Laipis, 1982, 
Laipis et al., 1988, Olivo et al., 1983). Since then, many studies have attempted to 
elucidate the mechanism and timing of the mtDNA bottleneck (Cao et al., 2007, Cree et 
al., 2008, Jenuth et al., 1996, Wai et al., 2008). Due to differences in techniques for 
identifying PGCs and subsequently isolating them from somatic tissue, several 
mechanisms for the mtDNA bottleneck have been proposed and there is a clear need for 
validation with an independent technique.  
Recently, Freyer and colleagues (2012) assayed the heteroplasmy levels of a pathogenic 
mtDNA mutation in PGCs at 13.5 d.p.c. during mouse embryonic development. They 
observed substantial variance between PGCs already established by 13.5 d.p.c., 
supporting a prenatal mtDNA bottleneck. 
Critical to formation of the mtDNA bottleneck is the regulation of mtDNA replication. 
Since establishing that the mtDNA bottleneck occurs before 13.5 d.p.c. it has become 
more essential to study mtDNA replication in PGCs before this point. 
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This study sought to investigate the expression of genes critical to regulation of mtDNA 
replication during embryonic development in mice. A panel of 32 appropriate genes was 
established and their expression studied during five stages of pre-implantation 
development. This corroborated previous research into the turnover and replication rate 
of mtDNA during pre-implantation (McConnell and Petrie, 2004), and identified Lrpprc 
as having a similar gene expression profile to other transcription genes. Further study is 
required to determine the significance of this finding. Technical limitations prevented 
assessing expression in PGCs during post-implantation. Assessing the expression of key 
replication genes during pre-implantation development alone cannot bring any further 
insight into mtDNA replication in PGCs during formation of the mtDNA bottleneck. 
The number of PGCs per embryo at the early stages of development is exponentially 
lower than at later stages. Whilst microarray analysis is feasible from gender-specific 
embryos at 12.5 d.p.c. onwards, it remains challenging to obtain sufficient material from 
any earlier time-points (Sabour et al., 2011). A technique is required for pooling PGCs 
from many female embryos, often spaced days to weeks apart, while maintaining high-
quality RNA and without compromising the integrity of the results.  
Preliminary assessment of new RNA extraction techniques with somatic cells, obtained 
through FACS, suggests that sufficient material could be obtained from 100-250 cells 
extracted from either a single embryo or pooled from many. Utilising Prdm as a PGC-
specific reporter in addition to Dppa3 (Stella) would allow identification of PGCs from 
as early as 6.5 d.p.c. (Ohinata et al., 2008).  
If mtDNA replication can be assessed during formation of the mtDNA bottleneck, it 
would be possible to assess whether manipulation of the involved genes could affect 
how mtDNA mutations are inherited. The availability of mice with stable, 
heteroplasmic, pathogenic mtDNA mutations make this a feasible possibility for the 
near-future. 
7.4 Identification of Factors Affecting mtDNA Copy Number Regulation 
The majority of research investigating regulation of mtDNA content has relied upon 
hypothesis-driven selection of a gene of interest, which is subsequently knocked-down, 
knocked-out or overexpressed (Ekstrand et al., 2004, Spelbrink et al., 2000, Tyynismaa 
et al., 2004). However, changes in mtDNA content upon gene manipulation are not 
necessarily relevant to biological situations where mtDNA replication is regulated. 
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The mtDNA repopulation assay was successfully employed by this research group to 
demonstrate reduced mtDNA replication capacity in the fibroblasts of patients with 
mutations in POLG (Stewart et al., 2011). This study sought to adapt this assay to 
model the reduction and subsequent increase in mtDNA copy number observed during 
formation of the mtDNA bottleneck, and identify which genes are regulated in order to 
modify mtDNA content.  
The mtDNA repopulation assay was adapted for use with myoblasts using ddC as a 
depletion agent. Although myoblasts survived the duration of the experiment and were 
successfully depleted and repopulated, the mtDNA copy number in untreated myoblasts 
increased as cells were passaged. Since the gene expression of TFAM, POLG, POLG2 
and NRF1 was not considerably dysregulated during depletion/repopulation, reliance on 
oxidative phosphorylation was induced by culture in glucose-free galactose media.  
mtDNA-depleted fibroblasts failed to thrive in pure galactose media, and media 
containing both glucose and galactose failed to induce substantial gene expression 
changes. No other analysed genes from other biological processes were dysregulated; 
therefore the mtDNA repopulation assay is not a suitable model to study gene 
expression changes responsible for regulation of mtDNA replication. 
It is possible that the increase in mtDNA content in fibroblasts after removal of the drug 
is instead due to lower turnover rate, rather than increased replication rate. The lack of 
any substantial gene expression changes during mtDNA repopulation contradicts the 
concept that increased expression of replication genes such as POLG, TFAM, NRF1 and 
C10orf2 (Twinkle/PEO1) is essential for an increase in mtDNA content. 
Contrary to previous reports (Davis et al., 1996), the expression of POLG protein was 
decreased during depletion and later recovered as fibroblasts repopulated their mtDNA. 
This suggests that perhaps more than just TFAM and POLRMT are downregulated 
(Seidel-Rogol and Shadel, 2002) and the stability of more components of the nucleoid 
complexes are also affected by the absence of mtDNA. 
The levels of mtDNA-encoded proteins recover much slower than that of mtDNA or 
mitochondrial transcripts. Since nucleoids and translational machinery form a linked 
series of protein complexes, it is possible that perturbation of nucleoids also disrupts 
correct assembly or function of the mitochondrial translation machinery. 
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7.5 Gene Expression Analysis in MERRF Muscle Fibres 
RRFs commonly appear in the muscle biopsies from patients with mitochondrial 
disease, defined by the massive upregulation of mitochondria in the subsarcolemmal 
region between fibres. This study sought to determine the plausibility of studying the 
gene expression changes induced by the mitochondrial biogenesis upregulated 
specifically in these fibres, alongside any other RRF-specific biological pathways.  
Previously, the study of RRF-specific gene or protein expression has been under taken 
in a hypothesis-driven manner by in situ hybridisation or immunohistochemistry for a 
pre-selected target of interest (Kunishige et al., 2003, Sparaco et al., 1993). Large-scale 
gene expression analyses to study mitochondrial diseases, such as MERRF, have either 
relied on tissue homogenates or cell culture models (Crimi et al., 2005, Ma et al., 2005). 
Although useful, cell culture models are not as biologically relevant as primary tissue, 
and homogenates often introduce variability through tissue heterogeneity and inter-
individual changes. 
Type I (oxidative) fibre predominance, a common compensatory mechanism for 
patients with mitochondrial diseases, was observed in the muscle of the MERRF patient 
used for this study (Enns et al., 2005). This finding highlights the need for fibre-specific 
gene expression analysis. Many gene expression differences observed between the 
homogenates of this patient and a healthy control would relate to fibre type 
composition, and not necessarily due to biochemical differences in the fibres. 
A multiplex assay for the simultaneous identification of fibre type and “ragged-red” 
status, whilst maintaining high-quality RNA, was successfully established. This is of 
critical importance, as utilising pre-stained serial sections can be time-consuming and 
unreliable. In addition to the technical difficulty of locating specific fibres from serial 
sections, the biochemical properties of muscle fibres have been shown to alter 
longitudinally (Durham et al., 2007). Therefore, even upon correct identification of the 
fibres from serial sections, there is no guarantee of the same biochemical property in the 
unstained tissue. 
Importantly, our study analyses differences not only between a MERRF patient and an 
age-matched control, but also between the normal and ‘ragged-red’ fibres of an 
individual patient. This not only allows a unique study of this pathological 
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phenomenon, but also eliminates variation introduced by tissue heterogeneity and 
comparisons between different individuals.  
Crimi and colleagues (2005) performed microarray analysis on skeletal muscle 
homogenates of 12 patients with either MELAS (m.3243A>G), PEO (m.3243A>G) or 
PEO (deletions). Four of the gene expression changes identified in two or more of these 
patient groups were validated in our microarray study of MERRF dissected fibres 
(m.8344A>G). 
As this study was a pilot to test the plausibility of the technique, the greatest limitation 
was the comparison of just one patient (both ragged-red and normal fibres) to one 
control. The microarray analysis would be strengthened by inclusion of further 
mitochondrial disease patients; however, sourcing an appropriate patient with high 
numbers of RRFs and sufficient available material prevented extension of the project. 
Due to this limitation, individual probe data is not reliable until validated by q-PCR, in 
situ hybridisation or immunohistochemistry. However, utilising gene ontology terms 
assigned to each gene allows clustering of dysregulated targets by enriched biological 
processes or pathways. Many of the enriched biological processes and pathways either 
up- or downregulated in MERRF tissue as a whole have been reported as altered in 
previous studies (Alemi et al., 2007, Crimi et al., 2005, Kadowaki and Kanazawa, 2003, 
Ma et al., 2005). 
Ubiquitin-mediated proteolysis and the spliceosome were found dysregulated 
specifically in RRF and not MERRF tissue in general. Ubiquitin-mediated proteolysis 
has been observed as being dysregulated in mitochondrial patients with mtDNA 
deletions (Alemi et al., 2007), and importantly ubiquitin has already been observed as 
being specifically upregulated in RRFs visualised by immunohistochemistry (Sparaco et 
al., 1993). However, there are currently no reports of specific spliceosome 
downregulation in mitochondrial disease patients.  
Future development of these results would require assembling a suitable cohort of 
patients to allow more reliable microarray analysis. Since the spliceosome is strongly 
dysregulated, specifically in RRFs, a more suitable technique for RNA analysis would 
be an Exon Array or RNASeq to also identify splicing variants. Further analysis of the 
downregulation RXR receptors specifically in RRFs is warranted as, as they are 
promising therapeutic targets for metabolic conditions, such as diabetes and obesity. 
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7.6 Concluding remarks 
This thesis has explored the complex regulation of mtDNA replication and 
mitochondrial biogenesis and its implications to mitochondrial disease. Attempting to 
accurately model situations of increased mtDNA replication and biogenesis has proved 
challenging, highlighting the importance of studying the regulation of these processes in 
biologically relevant tissues.  
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Appendix A.  Column statistics for measured mtDNA heteroplasmy 
frequency histograms. 
This appendix contains the descriptive statistics, normality test results and t-test results 
for m.3243A>G, m.8344A>G and m.8893T>G heteroplasmy results measured by 
pyrosequencing.  
Appendix A.1 Descriptive statistics for measured transmissions. Descriptive 
statistics for O-M variance distributions include: median and mean, minimum (min) and 
maximum (max) values, interquartile ranges (25 %, 75 %), standard deviation (Std. Dev) 
and standard error of the mean (SEM).  
Mutation 
Descriptive Statistics 
n Min. 25% Median 75% Max. Mean Std. Dev. SEM 
m.3243A>G 60 -84.3 -13.73 5.65 26.65 79.2 5.77 31.34 4.05 
m.8344A>G 19 -57 -23.7 -4.70 20 55.3 -3.15 26.64 6.11 
m.8993T>G 12 -50.3 2.69 48.83 72.33 89.33 33.03 46.87 13.53 
Appendix A.2 Normality statistics for measured transmissions. Each distribution 
was subjected to the D’Agostino-Pearson omnibus normality test and the skewness and 
kurtosis calculated.  
Mutation 
D'Agostino & Pearson omnibus normality test 
Skewness Kurtosis 
K2 p-value Passed?  Significant? 
m.3243A>G 1.695 0.4286 Yes ns -0.31 0.39 
m.8344A>G 0.2964 0.8623 Yes ns 0.18 0.18 
m.8993T>G 1.896 0.3875 Yes ns -0.86 -0.31 
Appendix A.3 One-sample t-test results for measured transmissions. Each 
distribution was subjected to a one-sample t-test against a theoretical mean of 0 and an 
alpha of 0.005. The discrepancy, 95 % confidence interval (CI) and p-value are given. 
Mutation 
One-sample t test 
Mean Discrepancy 
95% CI of 
discrepancy 
t, df p-value  Significant? 
m.3243A>G 5.767 -5.767 -2.33 to 13.86 t=1.425 df=59 0.16 No 
m.8344A>G -3.147 3.147 -15.99 to 9.69 t=0.5150 df=18 0.61 No 
m.8993T>G 33.03 -33.03 3.25 to 62.81 t=2.441 df=11 0.03 Yes 
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Appendix A.4 Descriptive statistics for m.3243A>G with potential sources of bias 
removed. Descriptive statistics for O-M variance distributions include: median and 
mean, minimum (min) and maximum (max) values, interquartile ranges (25 %, 75 %), 
standard deviation (Std. Dev) and standard error of the mean (SEM).  
 
Sample 
Descriptive Statistics 
n Min. 25% Median 75% Max. Mean Std. Dev. SEM 
m.3243A>G Total 60 -84.30 -13.73 5.65 26.65 79.20 5.77 31.34 4.05 
Without Probands 15 -36.30 -10.20 16.60 45.80 79.20 16.71 31.95 8.25 
Excluding MHet Bias 36 -46.79 -12.87 2.63 20.01 34.72 1.99 20.80 3.47 
<15 % Het 29 -52.4 -15.25 5.1 23.05 50.7 3.85 25.47 4.73 
Appendix A.5 Normality statistics for m.3243A>G with potential sources of bias 
removed. Each distribution was subjected to the D’Agostino-Pearson omnibus 
normality test and the skewness and kurtosis calculated.  
Sample 
D'Agostino & Pearson omnibus normality test 
Skewness Kurtosis 
K2 p-value Normal?  Significant? 
m.3243A>G Total 1.70 0.43 Yes ns -0.31 0.39 
Without Probands 0.3235 0.8507 Yes ns 0.26 -0.50 
Excluding MHet Bias 1.514 0.4691 Yes ns -0.36 -0.58 
<15 % Het 0.9386 0.6255 Yes ns -0.39 -0.36 
Appendix A.6 One-sample t-test results for m.3243A>G with potential sources of 
bias removed. Each distribution was subjected to a one-sample t-test against a 
theoretical mean of 0 and an alpha of 0.005. The discrepancy, 95 % confidence interval 
(CI) and p-value are given. 
Sample 
One sample t test 
Mean Discrepancy 
95% CI of 
discrepancy 
t, df p-value  Significant? 
m.3243A>G Total 5.77 -5.77 -2.33 to 13.86 t=1.425 df=59 0.16 ns 
Excl. Probands 16.71 -16.71 -15.99 to 9.69 t=2.026 df=14 0.06 ns 
Excl. Bias 1.99 -1.99 3.25 to 62.81 t=0.5727 df=35 0.57 ns 
Excl. <15 % Het 3.852 -3.852 -5.83 to 13.54 t=0w8144 df=28 0.42 ns 
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Appendix B.  Meta analysis 
This appendix contains the sources of published studies used to collate data for the meta 
analysis and the descriptive statistics, normality test results and t-test results for the 5 
mutations: m.3243A>G; m.8344A>G; m.8993T>G; m.11778G>A and m.3460G>A. 
Appendix B.1 Publications contributing heteroplasmy values for meta analysis. 
Heteroplasmy values were collated for m.3243A>G; m.8344A>G; m.8993T>G; 
m.11778G>A and m.3460G>A. The number of pedigrees and total O-M transmissions 
contributed by each publication have been given. 
Mutation Pedigrees Transmissions Reference 
m.3243A>G 
3 8 Ciafaloni et al. (1992) 
2 8 Martinuzzi et al. (1992) 
1 5 Huang et al. (1994) 
1 4 Liou et al. (1994) 
6 15 Hammans et al. (1995) 
3 8 Iwanishi et al. (1995) 
1 2 Rusanen et al. (1995) 
1 1 Fabrizi et al. (1996) 
1 3 Huang et al. (1996) 
2 8 Jansen et al. (1997) 
1 2 Vilarinho et al. (1997) 
1 1 Wilichowski et al. (1998) 
3 12 Olsson et al. (1998) 
2 2 Onishi et al. (1998) 
1 2 Chinnery et al. (1999) 
1 8 Dubeau et al. (2000) 
1 1 Hotta et al. (2001) 
1 2 Ko et al. (2001) 
1 5 Lien et al. (2001) 
1 2 Morovvati et al. (2002) 
1 3 Cervin et al. (2004) 
1 1 Chou et al. (2004) 
1 1 Lu et al. (2002) 
    
m.8344A>G 
2 28 Larsson et al. (1992) 
3 7 Hammans et al. (1993) 
2 4 Hammans et al. (1995) 
1 7 Piccolo et al. (1993) 
2 4 Silvestri et al. (1993) 
1 8 Campos et al. (1994) 
1 6 Seibel et al. (1994) 
1 5 Traff et al. (1995) 
1 2 Howell et al. (1996) 
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Mutation Pedigrees Transmissions Reference 
1 3 Gamez et al. (1998) 
1 22 Munoz-Malaga et al. (2000) 
1 9 Wong et al. (2002) 
1 7 van de Glind et al. (2007) 
   
m.8993T>G 
1 3 Holt et al. (1990) 
1 1 Sakuta et al. (1992) 
1 2 Puddu et al. (1993) 
1 4 Shoffner et al. (1992) 
1 5 Tatuch et al. (1992) 
1 2 Ciafaloni et al. (1993) 
4 6 Santorelli et al. (1993) 
1 5 Fryer et al. (1994) 
1 1 Lodi et al. (1994) 
1 1 Pastores et al. (1994) 
1 6 Degoul et al. (1995) 
1 3 Houstek et al. (1995) 
1 8 Makela-Bengs et al. (1995) 
1 2 Tulinius et al. (1995) 
1 3 Bartley et al. (1996) 
1 3 Mak et al. (1996) 
1 4 Ferlin et al. (1997) 
4 9 Uziel et al. (1997) 
4 16 White et al. (1999b) 
1 2 Porto et al. (2001) 
1 2 Wong et al. (2002) 
1 3 Enns et al. (2006) 
1 3 Steffann et al. (2007) 
2 5 Mkaouar-Rebai et al. (2009) 
    
m.11778G>A 
1 3 Holt et al. (1989) 
1 5 Sweeney et al. (1992) 
4 16 Zhu et al. (1992) 
1 15 Howell et al. (1994) 
3 6 Harding et al. (1995) 
3 7 Carelli et al. (1997) 
2 8 Juvonen et al. (1997) 
1 10 Tanaka et al. (1998) 
1 7 Simon et al. (1999) 
1 5 Chuenkongkaew et al. (2005) 
3 30 Phasukkijwatana et al. (2006) 
    
m.3460G>A 
1 4 Howell et al. (1991) 
1 5 Howell et al. (1992b) 
1 3 Sweeney et al. (1992) 
2 8 Harding et al. (1995) 
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Mutation Pedigrees Transmissions Reference 
1 23 Black et al. (1996) 
1 7 Ghosh et al. (1996) 
2 5 Carelli et al. (1997) 
1 11 Kaplanova et al. (2004) 
1 7 Volod'ko et al. (2006) 
 
Appendix B.2 Descriptive statistics for five mutations from published data. 
Descriptive statistics for O-M variance distributions include: median and mean, 
minimum (min) and maximum (max) values, interquartile ranges (25 %, 75 %), standard 
deviation (Std. Dev) and standard error of the mean (SEM).  
Sample 
Descriptive Statistics 
n Min. 25% Median 75% Max. Mean Std. Dev. SEM 
m.3243A>G 111 -59.52 -12.08 0 18.53 80.07 3.32 27.01 2.56 
m.8344A>G 96 -84 -18.5 -2.5 10 63 -4.96 26.72 2.73 
m.8993T>G 118 -54 10 32 53.25 100 32.67 33.07 3.04 
m.11778G>A 118 -54 -2 10.26 36 82 15.4 27 2.49 
m.3460G>A 74 -40 -3.21 17.5 51.25 91.8 22.02 32.13 3.735 
Appendix B.3 Normality statistics for five mutations from published data. Each 
distribution was subjected to the D’Agostino-Pearson omnibus normality test and the 
skewness and kurtosis calculated.  
Sample 
D'Agostino & Pearson omnibus normality test 
  
K2 p-value Normal?  Significant? Skewness Kurtosis 
m.3243A>G 5.06 0.0797 Yes ns 0.4696 0.4005 
m.8344A>G 3.712 0.1563 Yes ns -0.245 0.8995 
m.8993T>G 1.592 0.4512 Yes ns -0.2182 0.2781 
m.11778G>A 1.521 0.4673 Yes ns 0.2563 -0.2179 
m.3460G>A 8.55 0.0139 No * 0.3268 -0.9184 
Appendix B.4 One-sample t-test results for five mutations from published data. 
 Each distribution was subjected to a one-sample t-test against a theoretical mean of 0 
and an alpha of 0.005. The discrepancy, 95 % confidence interval (CI) and p-value are 
given. 
Sample 
One sample t test 
Mean Discrepancy t, df p-value  Significant? Mean 
m.3243A>G 3.32 -3.32 -1.762 to 8.407 t=1.296 df=110 0.1977 No 
m.8344A>G -4.96 4.961 -10.38 to 0.4612 t=1.819 df=95 0.072 No 
m.8993T>G 32.67 -32.67 26.64 to 38.70 t=10.73 df=117 < 0.0001 Yes 
m.11778G>A 15.4 -15.4 10.48 to 20.33 t=6.196 df=117 < 0.0001 Yes 
m.3460G>A 22.02 -22.02 14.57 to 29.47 t=5.896 df=73 < 0.0001 Yes 
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Appendix C.  Mouse gene expression BestKeeper analysis.  
Appendix C.1 Descriptive statics for ‘reference gene’ Ct values. BestKeeper 
software calculates the geometric and arithmetic mean, the minimum and maximum Ct 
values, standard deviation and the coefficient of variance (CV) for all the ‘reference 
genes’. 
Statistic 18S rRNA B2m Gapdh Hist2a 
n 15 14 15 12 
geo Mean [Ct] 19.638 30.832 26.092 30.327 
ar Mean [Ct] 19.705 30.955 26.287 30.534 
min [Ct] 16.655 27.477 20.814 24.837 
max [Ct] 22.354 36.547 31.413 35.297 
std dev [± Ct] 1.301 2.353 2.749 2.984 
CV [% C] 6.600 7.602 10.457 9.772 
Appendix C.2 Pearson correlation coefficient calculations. First, the BestKeeper 
software generates coefficients of correlation between all reference genes; those with 
high correlation are used to generate a BestKeeper Index value, which is in turn 
compared to each gene.  
BestKeeper vs. 18S rRNA B2m Gapdh Hist2a 
coeff. of corr. [r] 0.866 0.736 0.845 0.865 
p-value 0.001 0.003 0.001 0.001 
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Appendix C.3 Average Ct values for reference genes. The bar chart shows the 
average Ct values for all reference genes for the different pre-implantation samples. 18S 
has much higher expression than the other reference genes and is also more stable. The 
Ct values for 16-32-cell and Blastocyst (Blasto) are generally lower than the 2-cell, 4-
cell and 8-cell samples.  
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Appendix D.  Mouse microarray expression profiles 
Microarray data from Sabour and colleagues (2011) was analysed using GEO2R 
through the NCBI’s Gene Expression Omnibus (Edgar et al., 2002). Duplicate RNA 
samples were extracted from PGCs between 11.5 and 18.5 d.p.c. PGCs at 11.5 d.p.c. 
were not gender typed; however all other stages selected for analysis are collected from 
female embryos only. 
 
Appendix D.1 Microarray analysis of mitochondrial replication genes. The bar 
charts represent the raw gene expression signal of mitochondrial replication genes (A) 
Peo1, (B) Polg, (C) Polg2 and (D) Rnaseh1 taken from published microarray data 
during post-implantation embryonic development.  
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Appendix D.2 Microarray analysis of mitochondrial transcription genes. The bar 
charts represent the raw gene expression signal of mitochondrial transcription genes (A) 
Tfam, (B) Tfb2m, (C) Polrmt, (D) Nrf1, (E) Lrpprc and (F) Sp1 taken from published 
microarray data during post-implantation embryonic development. 
 
Appendix D.3 Microarray analysis of mitochondrial dynamics genes. The bar charts 
represent the raw gene expression signal of mitochondrial transcription genes (A) 
Dmn1l, (B) Fis1, (C) Mfn1, (D) Mfn2 and (E) Opa1 taken from published microarray 
data during post-implantation embryonic development. 
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Appendix D.4 Microarray analysis of mitochondrial biogenesis genes. The bar 
charts represent the raw gene expression signal of mitochondrial transcription genes (A) 
Pparg, (B) Ppargc1a and (C) Ppargc1b taken from published microarray data during 
post-implantation embryonic development. 
Appendix E.  Repopulation 
This appendix contains the BestKeeper analysis, performed on RNA samples for a 
variety of different conditions to establish the most stable housekeeping gene.  
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Appendix E.1 The stability of Ct values for ‘reference genes’ across variable 
biological conditions. The bar chart shows the average Ct values for all reference genes 
for fibroblast under different experimental conditions.  
 
A. Pparg B. Ppargc1a C. Ppargc1b 
1
1
.5
 
1
2
.5
 
1
3
.5
 
1
4
.5
  
1
5
.5
 
1
6
.5
  
1
7
.5
 
1
8
.5
 d
.p
.c
 
Chapter 8  
255 
 
Appendix E.2 Descriptive statics for ‘reference gene’ Ct values and Pearson 
correlation coefficients. BestKeeper software calculates the geometric and arthithmetic 
mean, the minimum and maximum Ct values, standard deviation and the coefficient of 
variance (CV) for all the ‘reference genes’. BestKeeper software generates coefficients 
of correlation between all reference genes, those with high correlation are used to 
generate a BestKeeper Index value, which is in turn compared to each gene. 
Statistic ACTB B2M GAPDH 
n 14 14 14 
geo Mean [Ct] 16.22 18.96 16.41 
ar Mean [Ct] 16.23 18.98 16.42 
min [Ct] 15.32 18.04 15.83 
max [Ct] 17.16 21.15 17.84 
std dev [± Ct] 0.47 0.63 0.37 
CV [% Ct] 2.9 3.31 2.23 
coeff. of corr. [r] 0.921 0.957 0.909 
p-value 0.001 0.001 0.001 
 
Appendix F.  Quality control microarray RNA samples. 
This appendix contains the standard curves generated for quantification of RNA 
concentration from dilute samples, and the calculations made for the final microarray 
samples. 
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Appendix F.1 Generation of standard curves from Ct values for estimation of RNA 
concentration. (A) Standard curves are generated for the reference genes GAPDH, 
B2M and ACTB using RNA samples where concentration has also be assessed by 
Agilent Bioanalyzer. (B) Using the standard curve equations for each gene, the 
concentration for each sample was calculated and compared to the measured 
concentration. Each sample falls within a 50% range of the measured concentration. 
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Appendix F.2 Quantification of final sample concentration. The Ct values measured 
in the final samples for GAPDH, B2M, ACTB are used to estimate the concentration of 
RNA from the previously calculated standard curves. 
Sample 
Concentration (pg/µL) 
GAPDH B2M ACTB Min Max Average StdDev 
CON 1094.5 791.2 511.2 253.6 1636.0 799.0 291.7 
RRF 969.9 1412.8 782.1 365.5 2068.2 1054.9 323.8 
NOR 511.1 938.7 592.2 226.8 1361.6 680.6 227.1 
Appendix G.  Quality control of microarray data. 
This appendix contains details of quality control measures to ensure preparation of the 
microarray was sufficient and gene expression signals were reliable.  
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Appendix G.1 Microarray labelling and hybdrisation efficiency. (A) RNA samples 
were spiked with unlabelled B.subtilis genes lys, phe, thr and dap at increasing 
concentrations to assess labelling efficiency. (B) cDNA samples were spiked with 
prelabelled E.coli genes bioB, bioC, bioD and Cre at increasing concentrations to assess 
hybridisation efficiency. Labelling and hybridisation was successful in all samples.  
 
Appendix G.2 Signal intensity from microarray. Box-plots calculated by the 
Affymetrix
®
 Expression Console™. The (A) raw probe cell intensity from CEL files 
and (B) MAS5 calculated expression signal was similar for all samples. 
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Appendix G.3 Statistics for microarray samples. RawQ, scaling factor (SF), 
background (BG), noise and percentage present calls (%P) values calculated by the 
Affymetrix
®
 Expression Console™ are similar across all samples for microarray 
analysis. 
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Appendix G.4 Reference gene profile integrity from microarray analysis. (A) The 
gene expression profile of GAPDH, B2M and ACTB relative to that in CON. RRF has 
lower GAPDH expression than CON or NOR. (B) 5’ to 3’ ratio for GAPDH in CON, 
RRF and NOR shows a similar amount of loss of 5’ signal for all samples.  
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Appendix H.  Regulated pathways 
This appendix contains pathway information modified from the KEGG database 
(Kanehisa and Goto, 2000). 
 
 
Appendix H.1 An overview of inter-connected enriched biological pathways in 
MERRF patient tissue. Signalling pathways are labelled blue and functional pathways 
are labelled green. Pathways not enriched are labelled in light colours, those enriched in 
all MERRF tissue are labelled in medium colours. The only pathway enriched 
specifically in RRF, ubiquitin-mediated proteolysis is labelled in dark green.  
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Appendix H.6 PPAR Signalling Pathway. Pathway maps are adapted from KEGG. 
Red annotations indicate upregulated genes, blue annotations indicate downregulated 
genes. If there are both up and downregulated genes within each term, the annotation is 
purple. Light colours indicate MERRF-specificity, medium colours indicate 
‘exacerbated in RRF’ and dark colours indicate RRF-specificity. 
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